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Abstract 
Leukaemia is the most common form of haematological malignancy and includes a group of 
diseases characterised by an uncontrolled growth of malignant haematopoietic cells. It accounts 
for about 33% and 3% of cancer cases in children and adults, respectively. Worldwide, 
approximately 350,000 new cases of leukaemia are diagnosed each year, with more than 
250,000 deaths. Acute myeloid leukaemia (AML) is the most common form of acute 
leukaemia, accounting for around 85% of adult cases, and a leading cause of cancer death in 
young adults. Although chemotherapy is often effective in the treatment of AML, at least in 
the short term, the agents currently in use are associated with a wide range of side effects 
including increasing the risk of developing therapy-related cancers. Therefore, there is 
considerable interest in the anti-cancer potential of natural agents with lower toxicities. 
Fucoidan is a fucose-rich sulphated polysaccharide that exists in the cell wall matrix of brown 
seaweeds. This component has shown immunomodulatory and anti-tumour activities. 
However, the underlying mechanisms of these activities remain largely unknown. 
Herein, the anti-tumour activities of fucoidan were examined in in vitro and in vivo models of 
AML, and its activity as a potential adjunct therapy was investigated. Investigation of the 
effects of fucoidan on leukaemic cells (NB4; a t(15;17) positive acute promyelocytic 
leukaemia, KG-1a; a minimally differentiated AML, HL60; a t(15;17) negative acute 
promyelocytic leukaemia and K562; an acute erythroleukaemia cell line) revealed evidence 
that fucoidan has a selective inhibitory effect on acute promyelocytic leukaemia (APL) and not 
other types of AML cells, initiating apoptosis. Examination of the pathways mediating the 
observed apoptotic mechanisms revealed the observed effect was caspase-dependent as it was 
significantly attenuated by pre-treatment with a pan-caspase inhibitor. P21/WAF1/CIP1 was 
significantly up-regulated leading to cell cycle arrest. Fucoidan decreased the activation of 
ERK1/2, and down-regulated the activation of AKT through hypo-phosphorylation of Thr(308) 
residue but not Ser(473). 
The anti-tumour activity of fucoidan was supported by in-vivo evidence which demonstrated 
that oral doses of fucoidan significantly delayed tumour growth in the APL xenograft model in 
athymic Balb/c nude mice, potentially by increasing the cytolytic activity of NK cells. This is 
the first study to reveal the anti-tumour activity of fucoidan on leukaemia in vivo. The selective 
inhibitory effect of fucoidan on APL cells and its protective effect against APL development 
in mice may prove that fucoidan may be useful in treatment of certain types of leukaemias. 
APL is one of the most aggressive types of AML characterised by differentiation arrest and 
accumulation of abnormal promyelocytes. Current APL therapies are associated with various 
side effects such as hyper-leucocytosis and differentiation syndrome which occurs in a quarter 
of the patients and is a serious and potentially fatal complication. There is therefore interest in 
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the possibility of reducing the incidence of these morbidities through the use of adjunctive 
therapies which permit lower doses of toxic therapies to be used whilst maintaining efficacy. 
Herein, the synergistic effects of fucoidan on current APL therapy, arsenic trioxide (ATO) and 
all-trans retinoic acid (ATRA), were investigated. In vitro, the effect of fucoidan combined 
with both therapeutic and lower doses of these drugs was examined in APL cells. Fucoidan in 
combination with ATO enhanced apoptosis in APL cells at both therapeutic and lower doses 
of ATO as indicated by an increased sub G0/G1 population, DNA fragmentation and annexin 
V positive apoptotic cells. Furthermore, the combination of fucoidan with low doses of ATRA 
and ATO significantly enhanced cell differentiation as indicated by G0/G1 arrest and increased 
CD11b expression. The triple combination of these agents resulted in the greatest myeloid 
differentiation in APL cells compared to single or double combinations. 
The efficacy of fucoidan as an adjuvant to the anti-leukaemic activity of ATO or ATRA was 
identified in vivo in athymic Balb/c nu/nu mice bearing APL. Tumour growth was monitored 
by measurement of tumour size and survival. When fucoidan and sub-therapeutic doses of ATO 
were administered in APL-bearing mice, the median survival and tumour volume doubling 
time significantly increased in mice treated with fucoidan alone and combined with ATO but 
not ATO alone compared to the control group. 
When fucoidan plus low dose ATRA were administered as the therapy regimen in APL-bearing 
mice, the median survival and tumour volume doubling time significantly increased in all 
treated groups compared to the control group. Moreover, the differentiation of APL cells 
obtained from animal’s tumour mass significantly increased in mice treated with fucoidan 
alone and fucoidan+ATRA but not ATRA alone compared to the control group. A further novel 
finding was that the differentiated APL cells derived from the excised tumour mass exhibited 
a down regulation of CD44 in fucoidan+ATRA treated mice. The presence of differentiated 
leukaemic cells with low or no expression of CD44 may be associated with decreased migration 
of these cells in APL.  
Taken together these findings  provide important evidence that fucoidan may prove an effective 
adjuvant therapeutic agent in the treatment of selected leukaemia sub-type APL and may permit 
lower doses of ATO and ATRA to be employed to achieve better efficacy of treatment 
accompanied by lower toxicity. 
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1.1 Haematological Malignancies 
Haematological malignancies (HMs) are tumours of the haematopoietic or lymphoid tissues, 
accounting for nearly 9% of all cancers (excluding non-melanoma skin cancers). Although 
there is no identifiable cause for most patients, factors such as exposure to ionising radiation, 
certain chemicals, genetic predisposition, viral infection and Down’s syndrome are associated 
with increased risk of these diseases (1). 
Haematological malignancies are classified into three major types; 1. leukaemia; cancer of 
immature or abnormal white blood cells, 2. lymphoma; cancer of the lymphoid tissues leading 
to accumulation of abnormal lymphocytes in lymph nodes and other tissues; and 3. multiple 
myeloma which is cancer of plasma cells originating in bone marrow. Figure 1.1 represents the 
amount of estimated new cases of leukaemia, lymphoma and myeloma in 2015 in Australia 
(2).  
 
 
 
Figure 1.1. Estimated new cases (%) of leukaemia, lymphoma, and myeloma in 
Australia, 2015*. Source: Australian Institute of Health and Welfare; 2014 (2). 
* Total percentage does not add up to 100% due to rounding in the calculation of individual percentages. 
 
 
1.1.1 Leukaemia 
Leukaemias are a group of malignancies involving the uncontrolled proliferation of immature 
or abnormal white blood cells in bone marrow and peripheral blood (3). Leukaemias are the 
leading cause of cancer deaths in males younger than 40 and females younger than 20 years 
Chapter 1                                                                                                         Literature Review 
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(4). Worldwide, approximately 350,000 new cases of leukaemia are diagnosed each year. There 
are more than 250,000 deaths. According to a report by Australian Institute of Health and 
Welfare, 2774 people were diagnosed with different types of leukaemias in 2011, and there 
were 1368 deaths due to this cancer in 2012 (5). 
Haematopoietic cells contain two major lineages; myeloid which gives rise to granulocytes, 
monocytes/macrophages, megakaryocytes and erythrocytes; and lymphoid which produces 
different types of lymphocytes (Figure 1.2). Leukaemia may derive from either of these two 
lineages (6). Leukaemias are also categorised into acute and chronic types depending on the 
rate of the progression and whether mature or immature WBCs are involved. In acute 
leukaemias, the number of non-functional immature WBCs increases rapidly without 
differentiating into mature cells. Acute leukaemias develop quickly and have a poor prognosis 
if untreated. In contrast, chronic leukaemias mostly involve proliferation of mature WBCs and 
tends to progress slowly (6).  
There are four major types of leukaemias:  acute lymphoblastic leukaemia (ALL), acute 
myeloid leukaemia (AML), chronic lymphocytic leukaemia (CLL) and chronic myeloid 
leukaemia (CML). Among all types of leukaemia, AML causes the most deaths in Australia 
and worldwide (1, 7). 
 
1.1.2 Acute Myeloid Leukaemia 
Acute myeloid leukaemia (AML) is characterised by rapid production and accumulation of 
immature myeloid cells. It is the most common form of acute leukaemia accounting for 25% 
of all adult leukaemias in USA, Australia and Europe (8, 9). AML is regarded as a highly 
malignant neoplasm and has the lowest survival rate of all leukaemias (8). The age of onset of 
AML has two peaks (Figure 1.3). It is the most common form of acute leukaemia during the 
first few months of life and also becomes the most frequent form of acute leukaemia in the 
middle and later years of life, with median age of 60. The increase in incidence of AML could 
be secondary due to the progression of the very common myelodysplastic syndrome (MDS) in 
elderly patients to AML. More than 80% of patients with MDS are over the age of 60 (10), and 
it has been reported that 30% of MDS cases evolve into AML (11). 
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Figure 1.2. Overview of normal haematopoiesis (12)   
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Various etiological factors have been associated with AML occurrence, such as exposure to 
radiation, viruses, chemical agents such as benzene and previous treatment with 
chemotherapeutic agents (6). However, most of the AML cases are not known to be linked with 
these factors.  
 
 
Figure 1.3. Age-specific incidence rates for AML (all races), 2007-2011 (13). 
 
Different subtypes of AML have been categorised. The French-American-British (FAB) 
classification and the newer World Health Organisation (WHO) classification are two of the 
main systems that have been used to classify AML. In 1976, the FAB group classified AMLs 
into 8 different subtypes according to morphology (maturity of the leukaemic cells) and 
cytochemical reactions of the cells’ enzymes (Table 1.1). In 2001, a new classification of AML 
was introduced by WHO, in which the genetic changes, and biologic and clinical features of 
the disease were incorporated into the FAB scheme (3). The 2008 revision of the WHO 
classification of AML is outlined in Table 1.2. 
The treatment of AML varies and depends on age, AML subtype and clinical history of 
patients. The main treatment for AML includes intensive chemotherapy which is composed of 
two stages: remission induction therapy to eradicate the leukaemic cells and induce remission; 
and consolidation therapy which begins after remission induction therapy (14). The goal of the 
latter stage is to destroy any remaining leukaemic cell and to prevent relapse. Other treatment 
strategies include radiation therapy and stem cell transplantation. 
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Table 1.1. The FAB classification of acute myeloid leukaemia (6) 
 
 
 
 
 
 
 
 
 
 
 
Subtypes Name Cytogenetics 
AML-M0 Undifferentiated acute myeloblastic leukaemia  
AML-M1 Acute myeloblastic leukaemia with minimal maturation  
AML-M2 Acute myeloblastic leukaemia with maturation t(8;21)(q22;q22), 
t(6;9) 
AML-M3 Acute promyelocytic leukaemia (APL) t(15;17) 
AML-M4 Acute myelomonocytic leukaemia Inv(16)(p13q22), 
del(16q) 
AML-M5 Acute monocytic leukaemia Del (11q), t(9;11), 
t(11;19) 
AML-M6 Acute erythroid leukaemia  
AML-M7 Acute megakaryoblastic leukaemia t(1;22) 
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Table 1.2. 2008 WHO classification of acute myeloid leukaemia (3) 
 
 
 
 
AML with recurrent genetic abnormalities 
 
AML with t(8;21)(q22;q22); RUNX1-RUNX1T1;  
AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22) CBFB-MYH11 
APL with t(15;17)(q22;q12); PML-RARA 
AML with t(9;11)(p22;q23); MLLT3-MLL 
AML with t(6;9)(p23;q34); DEK-NUP214 
AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 
AML (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1 
Provisional entity: AML with mutated NPM1 
Provisional entity: AML with mutated CEBPA 
 
Acute myeloid leukaemia with myelodysplasia-related changes 
 
Therapy-related myeloid neoplasms 
 
Acute myeloid leukaemia, not otherwise specified 
 
AML with minimal differentiation  
AML without maturation 
AML with maturation 
Acute myelomonocytic leukaemia 
Acute monoblastic/monocytic leukaemia 
Acute erythroid leukaemia 
Pure erythroid leukaemia 
Erythroleukaemia, erythroid/myeloid 
Acute megakaryoblastic leukaemia 
Acute basophilic leukaemia  
Acute panmyelosis with myelofibrosis 
Myeloid Sarcoma 
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1.1.3 Acute Promyelocytic Leukaemia 
Acute promyelocytic leukaemia (APL) or AML-M3 is one of the most aggressive subtypes of 
AML, characterised by accumulation of abnormal promyelocytes in bone marrow. It accounts 
for around 10-12% of all AML cases (15) with the unusual average age of 30-40 years, which 
is remarkably lower than that of other subtypes (60-70 year) (16). 
Due to its unique biologic characteristics compared to the other subtypes of AML, APL is 
characterised by distinct clinical features, associated with an apparent bleeding tendency (6). 
In the late 1950s, APL was first described as a hyper-acute fatal illness associated with a 
haemorrhagic syndrome based on this distinctive clinical symptom (17, 18).  
Morphologically, abundant amount of azurophilic granules are present within the malignant 
cells. The clumps of these granules form structures known as Auer rods which are found in 
most cases of APL (Figure 1.4). The frequently-observed haemorrhagic complications such as 
disseminated intravascular coagulation (DIC) occur due to presence of pro-coagulant materials 
in APL cell granules (6).  
 
1.1.3.1 APL Pathophysiology 
The chromosomal translocation t(15;17)(q22;q21) is the characteristic chromosomal 
abnormality in more than 95% of APL cases (19). The t(15;17) translocation involves fusion 
of segment of the PML gene on the long arm of chromosome 15 with segment of the retinoic 
acid receptor alpha (RARα) gene on the long arm of chromosome 17 (Figure 1.5) (20). The 
PML gene encodes the promyelocytic leukaemia protein PML which functions as a nuclear 
transcription factor and tumour suppressor. The RARα gene encodes transcription factor 
retinoic acid receptor alpha which is mainly expressed in haematopoietic cells. The RARα 
protein regulates the expression of a wide range of genes involved in proliferation, 
differentiation and maturation of WBCs, in particular from the promyelocyte stage (21).  
The fusion of PML and RARα genes encodes a hybrid protein, PML-RARα, with altered 
functions. It attaches to the genes involved in maturation with high affinity, resulting in 
transcriptional repression of those genes. The affected promyelocytes lose their differentiation 
capability and cannot give rise to mature cells (22) (Figure 1.6).  
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Figure 1.4. Acute promyelocytic leukaemia blood smear. APL with t(15;17) shows 
predominantly abnormal promyelocytes (×500). Inset (top right): Abnormal promyelocytes 
with bundles of Auer rods. (6) 
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Figure 1.5. Chromosomal translocation between PML and RARα genes (23) 
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Figure 1.6. The mutant PML-RARα blocks promyelocytes differentiation (23) 
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1.1.3.2 APL Treatment 
At the time of the first description of APL in the late 1950s, the front-line treatment for APL 
was similar to other subtypes of AML including chemotherapeutic drugs such as daunorubicin. 
In 1973, due to relatively low rate of complete remission in patients, the remission induction 
therapy phase was changed to chemotherapy composed of an anthracycline (daunorubicin, 
idarubicin, or others) and cytosine arabinoside (Ara-C), which led to an increased rate of 
complete remission from 55% to 75-80% in newly diagnosed patients (24-26). However, due 
to the unique clinical features of APL and the high likelihood of haemorrhagic complications 
the death rate was still high and the median duration of complete remission remained low. 
Since it was discovered that the accumulation of malignant promyelocytes in APL occurs as a 
result of differentiation arrest, in the early 1970s new insight into developing differentiation-
based therapy rather than cell death-based therapy was offered (26). All-trans retinoic acid 
(ATRA) and arsenic trioxide (ATO) were further introduced as potential molecules targeting 
differentiation in APL cells. In a newly published clinical trial, the combination of ATO with 
ATRA and idarubicin was used in induction therapy, and ATO with ATRA were used as 
consolidation therapy (27).  
 
1.1.3.2.1 All-Trans Retinoic Acid (ATRA) 
Retinoids are a family of molecules that are chemically and structurally related to vitamin A 
(retinol). Retinol, presents in the diet, is stored in the liver and can be converted to various 
derivatives such as ATRA, 9-cis-RA, 13-cis-RA, and retinal (28). These chemical compounds 
are present in human plasma and exert diverse physiological functions such as regulation of 
cell proliferation and differentiation (29).  
In 1980s, following introduction of the differentiation-based therapies, the synthetic form of 
retinoic acid (RA) was shown to trigger morphological and functional maturation in APL cell 
lines (28). In the first clinical trial, all patients who received ATRA underwent clinical 
remission, with a gradual differentiation of malignant promyelocytes in bone marrow and 
peripheral blood. This success was further confirmed by several clinical trials which reported 
complete remission of 85-90% in patients treated with ATRA (30, 31). However, continuous 
ATRA therapy led to progressive resistance to the drug leading to relapse within 3-6 months 
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in almost all patients (32). Subsequently it was found that the combination of ATRA and 
chemotherapy such as anthracyclines was more beneficial than each alone. This not only 
resulted in higher overall complete remission rates up to 95%, but also decreased the incidence 
of differentiation syndrome (DS) in newly diagnosed patients (26). DS is a life-threatening 
complication which is postulated to be caused by therapy-induced cytokine release from 
myeloid cells as they undergo differentiation. Clinical features may include fevers, dyspnoea 
with pulmonary infiltrates, effusions and renal failure (33). 
Today, the combination of ATRA and anthracycline-based chemotherapy is the first line of 
APL treatment in newly-diagnosed patients (22), resulting in 12-year progression-free survival 
rate of about 70%. However, relapse and death occur in 30% of patients within five years (28). 
 
1.1.3.2.2 Arsenic Trioxide (ATO) 
Arsenic trioxide (ATO) or white arsenic is an inorganic form of arsenic derived from minerals 
such as realgar or orpiment (34). ATO has been used in traditional Chinese medicine for 
thousands of years. In the late 18th and early 19th centuries, ATO was introduced for treating 
periodic fever and chronic myelogenous leukaemia. Although its usage was limited as it was 
highly poisonous and induced severe toxicities in patients (34, 35). 
In early 1990s, intravenous injection of crude solutions of ATO containing 1% of the 
component induced complete remission in 65% of APL patients with 30% survival rate after 
10 years (36). Impressively, ATO was shown to be more effective in relapsed APL patients or 
in patients who developed resistance to chemotherapy or ATRA than newly diagnosed patients 
(26). In 2000, the Food and Drug Administration (FDA) approved administration of ATO for 
the treatment of induction of remission and consolidation in patients with APL who are 
refractory to, or relapsed from, retinoid and anthracycline chemotherapy, and whose APL is 
characterised by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression 
(37, 38). Recently, oral formulations of ATO have been developed and are entering clinical 
practice (39). 
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1.1.3.2.3 Combination of ATRA and ATO 
New insights provided by research using combined treatment of ATO and ATRA led to this 
chemotherapy being offered in 1998 (26). Subsequently, cell culture and animal studies 
revealed a significantly increased cell death in acute promyelocytic leukaemia NB4 cell line 
and a marked increase in survival of APL-bearing animals (40, 41). In the first phase of initial 
clinical trials it was revealed that even though the complete remission rates in ATRA single, 
ATO single and combined groups were similar, the time to achieve the complete remission was 
significantly shorter in the combination group (42). After 18 months follow up, 100% of the 
cases in the combination group remained in complete remission, while APL relapsed in nearly 
20% of the single therapy groups. The combination of oral ATRA and intravenous ATO is now 
considered as the standard treatment for relapsed APL (39). ATRA plus ATO is also used as 
induction therapy in elderly patients and in patients who cannot tolerate the anthracycline-
based therapy (43). However, despite the promising results from various clinical trials, the 
efficacy and safety of ATO+ATRA or ATO+ATRA+chemotherapy are still unclear and 
several pilot studies investigating their use for remission induction in newly diagnosed patients 
and other stages are ongoing (44, 45). In a recent multi-central randomized clinical trial, Zhu 
et al. tested the efficacy and safety of an oral formula of ATO and compared with intravenous 
ATO in newly diagnosed APL patients (46). Their findings showed that the oral formula of 
ATO plus ATRA was not inferior to intravenous ATO plus ATRA as first-line treatment of 
APL as the disease free survival was 98.1% and 95.5% in oral and intravenous ATO 
respectively. These results suggest that oral ATO plus ATRA could be considered as first-line 
treatment option for APL treatment. 
Although there have been advances in APL treatment, the early death rate related to 
hemorrhagic complications is still high. Besides, relapses, drug resistance and significant side-
effects of current treatments still remain clinical challenges. Therefore, new APL treatment 
strategies are needed to increase the disease free survival rate and improve the clinical outcome.  
 
1.2 Cellular Processes in Tumourigenesis 
During tumour development, various crucial cellular pathways are disrupted. Over the last 
decades, the major hallmarks of cancers have been identified as follows; 1. Self-sufficiency in 
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growth signals, 2. Insensitivity to death signals, 3. Apoptosis evasion, 4. Unlimited replicative 
potential and immortality, 5. Angiogenesis, 6. Invasion and metastasis to other tissue, (47) 7. 
Reprogramming energy metabolism and 7. Immune response destruction (48). These acquired 
capabilities are shared between almost all types of cancers. 
Unlike the traditional cancer therapies that kill rapidly proliferating cells and affect both tumour 
and normal cells, novel therapeutic agents are designed to target the molecules which are 
abnormally expressed only in tumour cells. These tumour-specific structures could be either 
surface antigens; such as polymorphic epithelial mucin (PEM) which is aberrantly glycosylated 
and overexpressed in a variety of epithelial cancers (49), or intracellular molecules; such as 
phosphatase of regenerating liver-3 (PRL-3) which is overexpressed in gastric carcinoma (50). 
In this regard, our understanding from the cancer hallmarks and involved pathways has 
enormously advanced anti-cancer treatments. In this section, the main involved cellular and 
molecular pathways, the role of their defects in cancer development, and their therapeutic 
implication in cancer will be reviewed.  
 
1.2.1 Apoptosis 
Until recently, accelerated or deregulated cell proliferation was believed to be the only 
causative factor for cancer. Kerr et al. however hypothesised that hyperplasia and malignant 
neoplasms can result from reduced programmed cell death known as apoptosis rather than 
increased unlimited proliferation only (51). Apoptosis is an active multi-step cell self-destruct 
program that can potentially occur in each cell in the body, leading to the removal of unwanted 
cell. 
During apoptosis, the chromosomal DNA is fragmented as a consequence of cleavage between 
nucleosomes. These DNA fragments can then be broken into small pieces of around 50 
nucleotides. Eventually, cleavage of proteins that are responsible for integrity of cytoplasm and 
organelles leads to cell self-shrinkage and formation of fragments known as                        
aapoptotic bodies (Figure 1.7). The apoptotic bodies can be recognised and phagocytosed by 
macrophages (52). 
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Due to the crucial role of apoptosis in abnormal cell removal, the molecules involved in 
apoptosis are broadly recruited for anti-cancer drug development. Therefore, understanding the 
apoptotic pathway and involved molecules as well as the role of relevant impairments causing 
cancers would help in designing therapeutic agents. 
 
 
 
 
Figure 1.7 Apoptotic bodies (53) 
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1.2.1.1 Apoptosis Initiation 
A variety of exogenous and endogenous agents initiate the apoptosis process including the 
agents that cause DNA damage (e.g. ionising radiation and cytotoxic drugs such as alkylating 
agents), the factors that activates the death receptors (e.g. some hormones), the biochemical 
agents which enhance the downstream components of apoptotic system such as phosphates and 
kinase inhibitors (e.g. perylenequinone antibiotic calphostin C), and the factors which mediate 
the apoptosis process by direct cell membrane damage (e.g. heat and other stressors) (54). 
 
1.2.1.2 Apoptosis Pathways 
Apoptosis initiation by stimuli results in activation of a number of molecules and proteolytic 
enzymes, causing the progression of the apoptosis cascade (Figure 1.8). Caspases or cysteine-
aspartic proteases known as the executioner proteins in apoptosis cascade are a family of 
cysteine proteases and have a pivotal role in this process (55). Caspases are divided into initial 
caspases which trigger the initial steps of the apoptosis; and effector caspases which function 
at the later stages of apoptosis leading to the cleavage of crucial molecules. The initial phase 
of apoptosis can be carried out either through activation of the cell death receptors (extrinsic 
pathway) or via the mitochondrial signalling (intrinsic pathway). In the extrinsic pathway, 
transmembrane death receptors transmit the death signals to the apoptotic machinery, while the 
intrinsic pathway is activated in response to death signals derived from inside the cell such as 
DNA damage. These signals cause permeabilisation of mitochondria and subsequently release 
of cytochrome C. Both pathways trigger the activation of effector caspases. 
 
1.2.1.2.1 Extrinsic Pathway 
A large number of death signals trigger the extrinsic pathway through attachment to death 
receptors located on cell surface. Different cell-surface death receptors have been characterised 
so far, which belong to the tumour necrosis factor (TNF) receptor gene superfamily. The Fas 
receptor, TNF-α receptor-1 and TRAIL receptors DR-4 and DR-5 are 
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Figure 1.8. Apoptosis related molecules (56) 
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the main death receptors (Table 1.3). UV radiation is an example of a stimulus which induces 
the extrinsic pathway of apoptosis through Fas clustering on the surface of keratinocytes.  
All death receptors contain a homologous cytoplasmic domain named Death Domain (DD) 
which includes approximately 80 amino acids and is responsible for transmitting the death 
signal into the intracellular signalling pathways. The DDs of activated death receptors recruit 
the DDs in adapter molecules such as FADD and TRADD and cause formation of death 
inducing signalling complex (DISC) (Figure 1.9). The DISC contains a multi-protein complex 
such as several caspase 8 molecules. The activated caspase 8 then directly cleaves and activates 
the downstream effector caspases.  
 
 
Table 1.3 Death receptors and their ligands 
 
 
 
 
 
 
 
 
 
 
 
 
Death receptors Ligands for death receptors 
Fas (CD95) CD95L (FasL) 
TNFR1 (p55, CD120a) TNF and Lymphotoxin alpha 
DR3 (Apo3) Apo3L 
DR4 TRAIL (Apo2L) 
DR5 (Apo2) TRAIL (Apo2L) 
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Figure 1.9. Apoptosis extrinsic pathway (57) 
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1.2.1.2.2 Intrinsic Pathway 
Intracellular stimuli and non-receptor mediated signals such as DNA damage, viral infection, 
hypoxia and high level of Ca2+ are responsible for the intrinsic apoptosis pathway. These 
stimuli induce changes in the inner membrane of mitochondria and lead to mitochondria 
transmembrane potential loss. Upon this, the mitochondrial membrane permeability increases 
and pro-apoptotic molecules such as cytochrome C are released into the cytosol. The released 
cytochrome C accompanied by dATP bind to a protein named Apoptotic Protease Activating 
Factor 1 (Apaf-1) which is the core of caspase-activating signal complex (Figure 1.10). In the 
absence of cytosolic cytochrome C, Apaf-1 is in monomeric form, but upon presence and 
binding to the cytochrome C, Apaf-1 forms an oligomeric holoenzyme complex called 
apoptosome which triggers the cleavage of procaspase 9 to caspase 9. The activated caspase 9 
then activates the downstream executive caspases and promotes the caspase cascade in the later 
stage of the apoptosis. 
Intrinsic and extrinsic pathways can be cross-linked together through a BH3 only family protein 
named BH3 interacting-domain death agonist (BID). Following the cleavage and activation of 
BID by caspase 8, the truncated BID is translocated to mitochondria and triggers release of 
cytochrome C (Figure 1.10). 
 
1.2.1.2.3 Common Pathway 
Activation of either caspase 8 through the extrinsic pathway or caspase 9 through the intrinsic 
pathway results in the activation of effector or executive caspases including caspases 3, 6 and 
7. It is believed that caspase 3 is the main executive caspase. In nuclei, caspase 3 cleaves and 
activates endonucleases such as Caspase-Activated DNase (CAD) which causes DNA 
fragmentation, degradation and chromatin condensation (52). Another role of caspase 3 is the 
proteolytic cleavage of poly(ADP-ribose)polymerase-1 (PARP-1), a nuclear enzyme involved 
in DNA repair and DNA stability. In addition, it mediates the disruption of cytoskeletal 
molecules such as gelsolin which is the core of actin polymerisation. The cleavage of gelsolin 
then results in actin filaments depolymerisation and cytoskeletal disruption (58).  
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Figure 1.10. Apoptosis intrinsic pathway (57) 
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1.2.1.3 Apoptosis Regulatory Proteins 
Cell survival is regulated by a balance between pro-apoptotic and anti-apoptotic signals. A 
large group of apoptosis regulatory proteins including oncogenes and tumour suppressor 
proteins have been characterised (59).  
Members of a protein family named Bcl-2 family (B-cell lymphoma 2) play pivotal roles in the 
regulation of the intrinsic apoptosis pathway. Bcl-2 family includes 25 either pro-apoptotic 
(such as Bax, Bak, BAD) or anti-apoptotic (such as Bcl-2 and Bcl-xL) proteins that reside in 
outer membrane of mitochondria and contribute to the regulation of apoptosis pathway. The 
anti-apoptotic proteins block the release of cytochrome C from mitochondria and inhibit 
apoptosis cascade permitting cell survival. In contrast, the pro-apoptotic proteins alter the 
mitochondrial membrane permeability, induce cytochrome C release and promote cell death 
(60). 
Inhibitors of apoptosis proteins (IAPs) are other anti-apoptotic proteins which interact with 
caspases and inhibit their activation. X-linked inhibitor of apoptosis (XIAP) is one of the IAP 
members which binds to and inhibits three caspases 3, 7 and 9 (61). 
 
1.2.1.4 Apoptosis Deregulation and Leukaemogenesis 
A well-known mechanism for tumourigenesis is disrupted balance between pro and anti-
apoptotic proteins. Characterisation and cloning of the protein Bcl-2, one of the main anti-
apoptotic proteins in the Bcl-2 family, opened new insight into understanding the impact of 
apoptosis in tumour development as its mutation and overexpression enhanced cell survival. 
Bcl-2 derives its name from its original discovery in B-cell lymphomas. The chromosomal 
translocation t(14;18) involving Bcl-2 gene on chromosome 18 and immunoglobulin heavy-
chain locus (IgH) on chromosome 14 is associated with human B-cell follicular lymphoma. 
The juxtaposition of these genes results in enhanced transcription and overexpression of the 
Bcl-2 protein in the cells (62), thereby promoting long-lived follicular precursor and memory 
B-cells (63). 
There are some pro-apoptotic Bcl-2 family proteins whose defect can also cause HM. Many 
frame-shift mutations in the Bax gene have been identified in T-cell acute lymphoblastic 
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leukaemia cell lines (64). These mutations lead to a decreased level of proteins or dysfunctional 
ones and cause impaired apoptosis within the tumour cells. 
Another mechanism by which apoptosis contributes to cancer formation is reduced caspase 
level or function. In 2002, Devarajan et al. reported undetectable caspase-3 mRNA levels in 
breast and cervical cancers and substantially decreased levels of caspase 3 mRNA in ovarian 
tumour cells (65). The irregular caspase expression has also been shown in HM pathogenesis. 
In 2003, Takeuchi et al. reported frame-shift mutations within the coding repeats of caspase 5 
gene in lymphoid leukaemia/lymphoma cell lines (66).  
The third mechanism for contribution of apoptosis in tumourigenesis is abnormal death 
receptor signalling. Several impairments related to death signalling have been clarified so far. 
Loss of expression of death receptors, non-functional receptors and lack of proper death signals 
are examples of death receptor signalling defects (67). Fas receptor also known as CD95 or 
APO1, is a death receptor on the membrane of target cell. Fas ligand or CD95L is a soluble 
protein which binds to the Fas receptor and causes trimerisation of the Fas receptor. Alterations 
in Fas receptor or Fas ligand level or function can cause interaction failure or excessive use of 
these proteins leading to neoplastic transformation. For instance, to balance peripheral 
lymphocyte homeostasis, Fas is widely expressed on activated T and B-cells. Disruption of the 
Fas/Fas L pathway has been reported to be highly associated with lympho-proliferation and 
increased risk of lymphoid neoplasms. For instance, several somatic mutations in Fas gene 
have been identified in non-Hodgkin lymphoma (68).  
 
1.2.1.5 Apoptosis: Therapeutic Implications 
In 1975, Searle et al. proposed that the chemotherapeutic agents induce apoptosis in the tumour 
cell (69). Since then, a large number of drugs have been designed, which either inhibit the anti-
apoptotic molecules or enhance the expression and function of pro-apoptotic molecules. Here, 
the anti-cancer agents are classified into drugs which target 1. extrinsic pathway molecules, 2. 
intrinsic pathway molecules or 3. caspases. 
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1.2.1.5.1 Therapies Targeting Extrinsic Pathway Molecules 
Activation of death receptors by anti-cancer agents such as death receptor agonists has shown 
promising results in different malignant cells. MegaFasL as an example is a novel Fas agonist 
and its usage as an effective regimen in haematological malignancy cells has been shown in 
the last decade (70, 71). However, despite the potential anti-tumour activity of Fas agonists and 
also TNF agonists, when they were used in vivo in murine models, they induced severe toxicity 
in hepatocytes and also caused haemorrhagic necrosis (72, 73). 
TRAIL (TNF-related apoptosis-inducing ligand) is another TNF family molecule which 
induces cell death through binding to the death receptors DR4 and DR5. TRAIL agonists 
including recombinant TRAIL natural ligand or monoclonal antibodies also trigger the 
apoptosis during cancer therapy. It has been shown that TRAIL agonists act more selectively 
than the other death receptor agonists and their systemic administration to animal models is 
associated with less toxicity. Also, some pre-clinical studies have demonstrated that 
recombinant TRAIL or antibodies against DR4 and DR5 enhance the efficacy of radiotherapy. 
Administration of TRAIL agonists in combination with chemotherapeutic agents such as 
doxorubicin has brought about profound apoptosis progression in animal models (74). 
 
1.2.1.5.2 Therapies Targeting Mitochondrial Pathway Molecules 
This group includes the agents that perform their activities on the inner membrane of 
mitochondria. The potential anticancer drugs in this group mostly target the Bcl-2 family. Some 
of these agents inhibit activity of anti-apoptotic proteins such as Bcl-2 and Bcl-xl or down-
regulate their expression. Others increase the activity of pro-apoptotic molecules such as Bax 
and Bad to promote the mitochondrial apoptosis pathway.  
“Oblimersen Sodium” is an antisense oligonucleotide which targets the inhibition of Bcl2 
protein. At the molecular level, it binds to and degrade the Bcl-2 mRNA, leading to decreased 
Bcl-2 protein translation. Pre-clinical and clinical studies have indicated that administration of 
oblimersen sodium combined with chemotherapeutic agents increases their anti-cancer effects. 
In a clinical trial, administration of oblimersen sodium to CLL patients who had previously 
received chemotherapy resulted in reduction of hepatosplenomegaly, lymph node size and 
lymphocyte count (75). 
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Another strategy includes designing small molecules which inhibit anti-apoptotic proteins. For 
instance, ABT-737 and ABT-263 bind to anti-apoptotic protein such as Bcl-2 and Bcl-X(L) 
with high affinity leading to their inhibition (76). ABT-199 is another small molecule Bcl-2 
inhibitor, which has recently received breakthrough designation by FDA for certain types of 
chronic lymphoma leukaemia (77). Findings from a phase I clinical trial showed an overall 
response rate of 84% in 56 patients with high risk relapsed or refractory CLL, including 20% 
complete remission (78). 
 
1.2.1.5.3 Therapies Targeting Caspases 
Due to the importance of caspases in the apoptosis pathway, targeting the initial and effector 
caspases is a potential anti-tumour therapeutic strategy. In this regard, some small molecule 
caspase activators have been developed to activate the effector caspases directly. Procaspase-
Activating Compound-1 (PAC-1) is the first-developed procaspase activating agent which 
promotes apoptosis through triggering caspase 3 activation (79). 
Caspase-based gene therapy is another strategy which recruits caspases for promotion of 
apoptosis. Caspase 8 expression is frequently silenced by transcription factors such as SP1 and 
ETS-like which are responsible for caspase 8 promoter hypermethylation and inactivation. 5-
aza-2’deoxycytidine (5-AZA) is a specific inhibitor of DNA methylation which demethylates 
the caspase 8 regulatory sequences, enhances the activity of caspase 8 promoter and therefore 
the expression of caspase 8 leading to apoptosis progress (80). 
 
 
1.2.2 Cell Cycle 
The cell division process is an ordered series of events within cells which lead to cell replication 
and production of two daughter cells. The processes from one cell division to the another is 
named “cell cycle” which is characterised by distinct biochemical steps (81). The whole cell 
cycle takes different amounts of time depending on the organism. For instance, cell division in 
bacteria like Escherichia coli takes around 20-30 minutes, and unicellular yeast divide every 
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90-120 minutes (82, 83). One complete cell cycle takes around 24 hours in most mammalian 
cells (81). 
 
1.2.2.1 Cell Cycle Stages 
The cell cycle events are classified into four main phases (Figure 1.11). The step where the 
division of the cell occurs and two daughter cells are formed is known as mitotic phase (M 
phase). Since each daughter cell needs to receive the same amount of genetic complement from 
the mother cell, the parent cell needs to duplicate its DNA prior to cell division. The DNA 
synthesis process is carried out during a stage named synthesis phase (S phase). Furthermore, 
there are two gaps during the cell cycle; the first gap is located between the end of M phase 
and onset of DNA synthesis, known as gap 1 phase (G1 phase) and the second gap is between 
the end of DNA synthesis and onset of M phase (G2 phase). At G1 phase, the cell grows and 
new organelles in addition to many proteins and RNAs are synthesised. These molecules are 
required for cell growth and DNA synthesis prior to division.  At G2 phase, the repair systems 
are activated to correct any DNA damage that may have occurred during S phase. Total G1, S 
and G2 phases are known as a single phase called interphase (84). The majority of the cell 
cycle process takes place in interphase. In a proliferating human cell, interphase typically needs 
20 hours to be completed while mitosis phase takes only less than an hour  (81) . 
Before cell entry to the S phase, cells might pause in the G1 phase and enter to a state of 
quiescency called G0 phase. In G0 phase, the cell is neither dividing nor preparing to divide. 
At any one time, most of the cells in the mammalians body are in G0 phase. Some cell types 
such as neuronal cells and heart muscle cells remain in G0 phase during the life span of the 
whole organism, whereas some specialised cells such as haematopoietic, gut epithelium and 
skin cells are always proliferating (85).  
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Figure 1.11. Average time spent in each phase of the cell cycle in a human cell  
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It is important to know that there is a small difference between a G0 cell and a quiescent cell. 
Quiescent cells are those which have reached a state of terminal differentiation and never re-
enter the G1 phase, whereas G0 cells may enter the cell cycle if needed.  
 
1.2.2.2 Cell Cycle Regulation 
There are several checkpoints within the cells that prevent them from entering the next step 
while they have not completed the previous step. Also, there should be certain checkpoints 
which allow G cells or newly divided cells to re-enter the cell cycle. 
The central molecules which positively regulate the cell cycle are called cyclin-dependent 
kinases (CDKs). CDKs are small serine/threonine protein kinases that have low enzymatic 
activity. CDKs have regulatory subunits referred as “cyclins” whose attachment to CDKs leads 
to CDK activation. CDKs 1, 2, 4 and 6 and cyclins A, B, D and E are the main CDKs and 
cyclins that function in specific phases of the cell cycle (81). CDKs 2, 4 and 6 are G1-specific 
CDKs. Cyclin D-CDK 4-6 complexes help the cell to progress toward late G1 phase. CDK2 
however functions in late G1 phase and is responsible for G1 phase completion and cell entry 
to S phase (81). Progression from either S to G2 or from G2 to M phase is dependent on cyclin 
A expression  (85) whereas cyclin B-CDK1 complex promotes M phase progression (86). 
A different group of proteins have been identified as negative regulators of the cell cycle. These 
proteins are referred as cyclin-dependent kinase inhibitor protein (CDKIs or CKIs). CDKIs 
which function as tumour suppressor genes normally inhibit G1-specific CDKs and lead to cell 
cycle arrest at G1 phase. p16, p19, p21/WAF1 and p27 are examples of CDKIs which inhibit 
CDK2, CDK4, CDK6 or G1 related cyclin-CDK complexes (81). 
Cell cycle progression is also regulated by a variety of external signals such as growth factors 
and stress stimuli. These stimuli affect cell cycle through different signal transduction 
pathways. The Ras/Raf/MAPK pathway is one of the main signalling pathways which controls 
the cell cycle mainly through the activation of G1 cyclin-CDK complexes (87). 
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1.2.2.3 Cell Cycle Deregulation and Leukaemogenesis 
The final aim of the cell cycle is to replicate exactly one copy of DNA, not more and not less, 
to produce two identical chromosomes during synthesis phase and then to segregate the 
chromosomes equally between two daughter cells. Defects in the process can lead to serious 
abnormalities. 
The role of deregulation of the cell cycle components in haematological malignancy 
development and progression has been well established. Due to the high rate of haematopoietic 
cell turn over, maintaining the balance between cell death and cell proliferation is an essential 
element for normal haematopoiesis. B-cell chronic lymphocytic leukaemia (B-CLL) is a well-
identified example of haematological malignancies in which tumour cells accumulate through 
reduction of cell death process rather than high proliferation. In contrast, Burkitt lymphoma is 
a type of haematological malignancies which is characterised by high proliferation index and 
increased activity of cell cycle promoters. 
In 2010, Gladkikh et al. examined the expression of cyclin D1 in different types of lymphomas 
compared with normal mature B-cells and showed a four-fold increase in cyclin D1 expression 
in mantle cell lymphoma (MCL) compared to normal lymphocytes (88). Cyclin E is also a 
proto-oncogene whose amplification and overexpression have been reported in ALL and AML 
(89, 90). 
As discussed above, CDK inhibitors negatively regulate cell cycle. The deregulation of CDKI 
gene has been reported in leukaemia development. p16INK4 for instance is a critical regulator 
of CDK activity, which specifically binds to CDK4 or CDK6 and inhibits cell cycle progression 
(91). The homozygous deletion of chromosome 9 (del9p21) containing p16INK4 gene resulting 
in its complete or partial loss has been documented in different types of haematological 
malignancies (92). 
 
1.2.2.4 Cell Cycle: Therapeutic Implications 
Over the last several years, our understanding about the role of genetic alterations in CDKs, 
CDKIs and other cell cycle molecules in carcinogenesis have opened new insights into 
designing anti-cancer agents which target these molecules. CDKs, which are the key motor of 
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cell cycle progression are known to be upregulated in malignancies. Many novel synthetic 
CDK inhibitors have been developed to inhibit CDKs expression and induce cell cycle arrest 
in the tumour cells. These anti-cancer agents can either directly target the catalytic activity of 
CDKs or target the regulatory mechanisms that contribute to CDK activity. 
Flavopiridol is a pan CDK inhibitor, which binds to, and inhibits CDKs 1, 2, 4, 6 and 7 and 
leads to cell cycle arrest at the G1 to S as well as G2 to M points. Several clinical trials have 
assessed the proliferation inhibitory effect of flavopiridol on a variety of human malignancies. 
In a clinical trial, a novel schedule with specific doses of flavopiridol was employed in patients 
with refractory CLL who had high-risk cytogenetic abnormalities. It was reported that 45% of 
patients attained a high response with durable remissions (93). 
Seliciclib or CYC202 is another CDK inhibitor, which inhibits multiple CDKs. This agent 
selectively blocks CDK2–cyclin E, CDK2–cyclin A, CDK7–cyclin H and CDK9–cyclin T1. 
CYC202 has been shown to increase the sub G0/G1 population and down-regulates cyclins D1 
and H in mantle cell lymphoma cell lines (94). 
 
1.2.3 Signal Transduction Pathways 
The signals created by extracellular stimuli are transmitted to the downstream effector cells by 
a series of phosphorylation steps through pathways known as signal transduction pathways. 
The transduced signal into nuclei up-regulates or down-regulates certain genes on DNA, which 
are associated with various cellular processes such as proliferation, growth, apoptosis and 
differentiation (95). Ras/Raf/MEK/MAPK, PI3K/Akt, JAK/STAT and Wnt signalling 
pathways are examples of signal transduction pathways which play key roles in cell 
proliferation and apoptosis. 
The Ras/Raf/MEK/MAPK pathway is one of the best categorised signal transduction pathways 
in cell biology (96). The external stimuli such as growth factors first activate Ras protein by 
GDP-GTP exchange (Figure 1.12). Activated Ras phosphorylates and activates different 
transduction molecules like serine-threonine kinase Raf. Activated Raf then phosphorylates 
MEK (MAPK/ERK kinase), which subsequently phosphorylates MAPK (Mitogen-Activated 
Protein Kinase) molecules such as ERK1 and ERK2. Upon phosphorylation, the activated 
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ERK1 and ERK2 translocate into nuclei where they activate their substrates; transcription 
factors which can further change gene expression (97). 
PI3K/Akt/mTOR is another important signalling pathway that regulates numerous cellular 
functions such as angiogenesis, metabolism, survival and apoptosis. The proto-oncogene AKT 
is the main enzyme in this pathway, which mainly inhibits apoptosis (98). Upon the pathway 
activation, phosphatidylinositol tri phosphate (PIP3) is produced by phosphoinositide 3-kinase. 
PIP3 acts as plasma membrane docking site for proteins such as AKT (Figure 1.12). Akt is then 
phosphorylated and activated by kinase activity of another molecule and transduces the signals 
into nuclei through phosphorylation and activation of downstream molecules (99).  
 
1.2.3.1 Signal Transduction Pathway Deregulation and Leukaemogenesis 
Defects in signal transduction pathways are highly linked with oncogenic transformations. The 
ERK pathway is the best-studied mammalian cell signalling pathway and its deregulation has 
been associated with one-third of all human cancers (96). The ERK pathway is mostly 
associated with cell proliferation, thus its overexpression contributes to tumourigenesis. As 
explained above, Raf and Ras groups are the initiator molecules of this pathway. The mutations 
occurring on these early stage molecules are the leading causes of consecutive activation of 
ERK pathway resulting in cancer development. For instance, B-Raf mutation alone is found in 
66% of malignant melanomas and is seen in various other malignancies such as colon and 
pancreatic cancers at lower frequencies (100). The ERK pathway deregulation has been 
reported in haematological malignancies as well. Okuda et al. showed that 
hyperphosphorylation and activation of proto-oncogene Raf-1 is highly associated with clonal 
evolution of myeloid leukaemic cells. Ras mutations are also seen in nearly 40% of patients 
with MM and in about 30% of myelodysplastic syndromes and AMLs (101, 102). 
PI3K/Akt/mTOR contains various oncoproteins and tumour suppressors, and deregulation of 
these components can mediate tumour development. Constitutive activation of PI3k/AKT 
pathway has been reported in half of AML cases (103). As AKT is a survival factor, its 
overactivation is highly associated with tumour survival and drug resistance. Blackburn et al. 
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Figure 1.12. Overview of main signal transduction pathways involved in cell 
proliferation and apoptosis 
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reported that at least 50% of relapse-driving leukaemic cells evolved genetic lesions and 
epigenetic modifications that acquired AKT activation (104). They showed that inhibition of 
AKT pathway in acute lymphoblastic leukaemia restored the malignant cell responses to 
chemotherapy. 
 
1.2.3.2 Signal Transduction: Therapeutic Implications 
Signalling pathway molecules have high potential to be exploited as targets for cancer 
treatment. As mentioned, mutant up-regulated B-Raf is commonly seen in various cancers and 
therefore B-Raf inhibitors are amongst the best potential therapeutic candidates. Two B-Raf 
inhibitors namely BAY43-9006 (Sorafenib) and PLX4032 (Vemurafenib) have obtained FDA 
approval and are in clinical use in advanced renal cell and hepatocellular carcinomas and in 
late-stage melanoma, respectively (105). 
RAS genes are the most commonly mutated oncogenes in human cancers and thus designing 
therapeutic agents inhibiting Ras activity is of considerable interest. Enzyme Farnesyl 
transferase (FTase) is responsible for activating the inactive cytosolic Ras. Synthetic inhibitors 
of FTase (FTIs) have shown promising activities in treating haematological cancers in clinical 
trials (106).  
Inhibitors of PI3k/AKT/mTOR pathway are other examples of anti-cancer agents. 
Administration of these agents caused partial response in patients with gynaecological and 
breast cancer (107). It is also well established that inhibition of PI3k/AKT/mTOR pathway can 
restore the tumour cells sensitivity to chemotherapy and radiotherapy. Therefore, their 
combination with chemotherapy can increase the efficacy of standard treatments (108). 
Amongst the PI3k inhibitors in development, idelalisib is the most studied compound in 
haematological malignancies, and was recently granted a full FDA approval to treat patients 
with relapsed CLL (109, 110). 
 
1.2.4 The Role of Immune System in Tumourigenesis 
Immuno-oncology research has provided strong evidence that tumour cells can be recognised 
by the immune system and destroyed or controlled by complex immune pathways. Cancer 
development has been shown to be accompanied by immune suppression in many types of 
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cancers, leading tumour cells to escape from immune system. The mechanism of this escape 
varies. Loss of tumour antigens, which normally make them recognisable to immune cells, and 
loss of tumour cell sensitivity to T-cells or natural killer (NK) cells are examples. Moreover, 
alterations in cytokine production by tumour cells or immune cells can provide a beneficial 
tumour microenvironment for cancer cells, as those can inhibit the immune cell activity (111). 
Our understanding from the mechanisms by which immune cells and molecules lose their 
immunosurveillance ability has opened new insights into developing immunotherapy 
approaches for cancer treatment. Designing these strategies has helped us to boost immune 
system responses against cancers. These strategies, for instance, can suppress the unfavourable 
tumour microenvironment which is caused by suppressive cytokines produced by tumour cells 
and immune cells. Specific anti-tumour immunity has been achieved by using antibodies 
designed for certain tumours or using agents which induce T-cell expansion (112). 
 
1.2.4.1 Immune Response: Therapeutic Implications 
Over the last two decades cancer immunotherapy (exploiting immune system mechanisms to 
treat cancers) has become a main focus of anti-neoplastic agent research. One of these 
approaches is to administer cancer vaccines by which the immune system would be able to 
recognise tumour cells. Another method is the use of passive immunotherapy by administration 
of monoclonal antibodies. The designed antibodies are specific for tumour specific antigens 
and therefore their binding to the tumour cell surface helps the immune system to recognise 
and kill the tumour cells. This approach promotes antibody-dependent cellular cytotoxicity 
(ADCC), whereby immune cells such as NK cells recognise the antibody-coated tumour cells, 
bind to them and destroy the cancer cells by cytolytic activity. 
Rituximab, a monoclonal anti-CD20 antibody, is one of the best categorised chimeric 
monoclonal antibodies, which is widely used in patients with certain types of leukaemias and 
lymphomas. CD20 is highly expressed on neoplastic B-lymphocytes and using anti-CD20 
along with chemotherapeutic agents has improved the outcome of patients with B-cell 
neoplasms. It has been identified that binding of rituximab and CD20 triggers NK-cells to 
mediate ADCC (113).  
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Targeting immune checkpoints that maintain physiologic self-tolerance has been a focus of 
cancer immunotherapy in recent years. Cytotoxic T-lymphocyte antigen-4 (CTLA-4) is a 
protein receptor that regulates the immune system and tolerance through inhibition of T-cells. 
Clinical and pre-clinical data have shown that blockade of CTLA-4 using anti-CTLA-4 
monoclonal antibody therapy is a promising approach for a number of cancers, particularly 
advanced melanoma (114). It is believed that suppression of inhibitory signals leads to the 
generation of an antitumor T-cell response, and therefore CTLA-4 blockade results in direct 
activation of CD4+ and CD8+ effector cells (115). Programmed cell death protein 1 (PD-1) is 
another immune checkpoint, that down-regulates immune system by preventing the activation 
of T-cells, and its blockade by monoclonal anti-PD-1 antibodies restores the immune function 
in the tumour microenvironment in melanoma, renal and non-small cell lung cancers (116).  
Another approach of cancer immunotherapy is use of immune cells such as NK cells and 
cytotoxic T-cells. To increase the cytotoxic activity of  immune cells in patients, these cells are 
isolated from the patient’s body, activated in vitro, enriched and then transfused back to patient 
(117). Another method is to administer therapeutic cytokines such as alpha/beta interferons to 
stimulate and activate the immune cells in vivo (118). 
 
1.2.5 Cancer Therapy Complications  
Despite promising tumour growth-inhibitory effects in pre-clinical tests, many potential 
therapies fail in clinical trials when adverse unexpected side effects become apparent. 
Traditionally anti-cancer chemotherapy targets rapidly dividing cells. Therefore, normal cells 
which have high-proliferating potential are also affected. Novel therapeutic agents are designed 
to target specific molecules (targeted therapy). However, these targeted therapies are not 
always completely free of side effects either. For instance, usage of the B-Raf enzyme inhibitor 
vemurafenib, the first targeted molecular therapy, is highly associated with a rapid emergence 
of acquired resistance and adverse dermatological effects. It also stimulates B-Raf expression 
in V600E B-Raf negative patients, promoting melanoma growth (105, 119). Monoclonal 
antibodies are another example of targeted therapy as they specifically target the cancer 
antigens located on tumour cells. Monoclonal antibodies are generally safer than chemotherapy 
and the side effects mainly include mild allergic reactions such as urticaria. However, they can 
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also cause severe reactions such as infusion reactions and serum sickness. Rituximab (anti-
CD20), as an example, generally causes only mild toxicities. However, severe complications 
such as anaphylactic reactions, high risk of tumour lysis syndrome in patients who have high 
burden of circulatory tumour cells, and myocardial infarction have been reported (120).  
 
1.2.6 A Role for Natural Products for Cancer Treatment 
Toxicity, drug resistance and increased risk of developing secondary cancers from 
chemotherapeutic chemicals often limit their efficacy in cancer treatment. Concerns over these 
complications have generated interest in exploiting natural products, as they are generally safer 
and have multi-functional mechanism of action for cancer treatment. In the last decades, 
organic substances derived naturally from microbes and plants; either in their unmodified 
(naturally occurring) or synthetically modified analogues, have provided a number of useful 
cancer chemotherapeutic drugs (121). Taxol is an examples of these molecules, which is used 
to treat a number of cancers such as breast and colon cancers. It was first isolated from bark of 
the Pacific yew, Taxus brevifolia (122). 
Due to the multi-functional properties, natural products are also being tested as adjuvants for 
use in synergy with chemotherapeutic agents. For example those with immunomodulatory 
effects can reduce immune suppression and the associated increased risk of infection. In 
George et al. (123) study, Indukantha Ghritha, a polyherbal preparation consisting of 17 plant 
components, was used as an adjuvant to cyclophosphamide cancer chemotherapy and shown 
to stimulate the haematopoietic system and induce leucopoiesis in tumour-bearing mice. When 
administrated in combination with cyclophosphamide, it reversed myelosuppression induced 
by cyclophosphamide suggesting its potential to minimise or reverse chemotherapy-induced 
leucopenia. 
Polysaccharides include a large family of diverse biopolymers constituted by monosaccharide 
residues linked together by O-glycosidic linkage and can be seen in both natural and semi-
synthetic forms (124). Due to structural diversity, polysaccharides display the highest 
biological properties among macromolecules. Many natural polysaccharides obtained from 
natural sources such as plants and algae have demonstrated anti-cancer properties. The 
multifunctional structure of natural polysaccharides also allows them to be used in conjugation 
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with anti-cancer agents which lack physiochemical and biopharmaceutical properties (124, 
125). Among those, fucoidan derived from brown seaweeds has gained significance in the 
treatment of cancer. 
 
1.3 Fucoidan 
(This section has been substantially published in Atashrazm et al. 2015 (126)) 
Seaweeds have been a part of diets in China, Japan, and Korea since ancient civilization. 
Approximately, 400 different types of seaweeds are consumed by humans as food and for 
medical purposes (127). In the 11th century, in “The Canon of Medicine” -an encyclopaedia of 
medicine compiled by Persian polymath Avicenna (Bu-Ali Sina)-, the medical values of algae 
of different species were described. Among those, the usage of marine algae in treatment of 
tumours, vesicles, and joint pain has been proposed (128). 
Polysaccharides are of the main functional components in the structure of seaweeds. Fucoidan 
is a sulphated polysaccharide that exists in cell wall matrix of different species of brown 
seaweeds such as mozuku, limumoui, bladderwrack and wakame. Variant forms of fucoidan 
have been also recognised in some marine invertebrates (129) such as sea urchins (130) and 
sea cucumbers (131). The first isolation of fucoidan was carried out by Professor Kylin from a 
slimy ingredient of Kombu in 1913 (132). Research studies based on fucoidan functional 
activities and biological properties started to gain importance in early 1970’s. These studies 
have reported the potent physiological and biochemical properties of fucoidan such as its 
cytotoxic activities (133-135).  
Due to its heterogeneity and natural source, fucoidan remains unexploited as a basis of 
therapeutics. It is believed that pharmaceutical companies prefer “druggable” small molecules 
rather than larger and polydisperse compounds (136). In recent decade, few companies have 
attempted to produce fucoidan for research use. In limited studies, commercially available 
heterogeneous fucoidans have been examined in several clinical trials mainly for their anti-
coagulant and anti-viral properties. It is suggested that reproducibly defined fucoidan fractions 
could be created from controlled sources of seaweed, using modern extraction and 
characterization methods. As suggested by Fitton (136), high quality defined fucoidan could 
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be produced to standards suitable as ingredients in medical devices and even cross the threshold 
into drug development route”. 
 
1.3.1 Fucoidan Structure 
Fucoidan is a heterogeneous sulphated polysaccharide and its chemical composition differs 
based on the seaweeds source, harvesting time, and local climate conditions (137, 138). 
Fucoidan mainly consists of sulphated L-fucose with a fucose content of 34-44% (139) and 
can contain a large quantity of other monosaccharaides such as galactose, mannose, xylose and 
uronic acid all of which make up less than 10% of the total fucoidan structure. The degree of 
sulphation varies between 4-8% based on the harvesting location and season (138). The 
molecular weight (MW) of fucoidan also differs mainly according to the type of the seaweed 
from which it is isolated (132). 
 
1.3.2 Fucoidan Sources 
Fucoidan is widely extracted from different sources of seaweeds such as Fucus vesiculosus, 
Cladosiphon okamuranus and Sargassum muticum. Among those, Undaria pinnatifida and 
Fucus vesiculosus are two major sources of fucoidan that have been shown to have powerful 
biological activities in vitro and in vivo.  
 
1.3.2.1 Undaria pinnatifida  
Undaria pinnatifida also called wakame or Japanese kelp can reach an overall length of about 
0.5-3 metres (Figure 1.13). Wakame is edible seaweed and is widely consumed in Asian 
countries. The extracted fucoidan from this alga has been classified by the United States FDA 
as GRAS (Generally Regarded as Safe).  
This seaweed is native to Japan, Korea and China, however, it has been spread out from its 
origin to other sites of the world such as the Atlantic and Mediterranean coasts of Europe (140-
142) and shores of New Zealand (143), Argentina (144) and Australia (145, 146). 
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1.3.2.2 Fucus vesiculosus  
Fucus vesiculosus is the scientific name for brown macro algae named bladderwrack. It 
contains a main midrib while paired spherical vesicles surround it (Figure 1.14). Its colour 
varies from light yellow to brownish-green and its maximum length reaches to around 2-3 feet. 
Bladderwrack is found on the coasts of the North Sea and the Atlantic and Pacific Oceans. 
 
 
Figure 1.13. Undaria pinnatifida 
 
 
 
Figure 1.14. Fucus vesiculosus 
Chapter 1                                                                                                                       Literature Review 
 
 
Page 43 
 
1.3.3 Fucoidan Metabolism 
Fucoidanase, the enzyme responsible for fucoidan hydrolysis, has only been found in brown 
seaweed and marine microorganisms such as some marine bacteria and fungi (147) and not in 
humans. It is possible that the acidic conditions in the stomach could degrade fucoidan, 
however it has been reported that the low gastric pH has restricted effects on fucoidan (148). 
Transport across Gut 
Investigations over fucoidan transportation across the gut have shown that small amounts of 
dietary fucoidan can be endocytosed and cross the intestinal wall directly without breaking 
down (148). In Tokita et al. study, 10 volunteers were given oral fucoidan and the 
concentrations of fucoidan in the serum and urine were analysed. Fucoidan was detectable 3 
hours after administration and increased to 100 ng/mL in serum and 1000 ng/mL in urine.  
Although, the rate of absorption in the small intestine was highly variable among the 
participants. The MW of fucoidan in serum was similar to administered fucoidan indicating 
that fucoidan was not hydrolysed by digestive enzymes (149). However, the MW of the 
fucoidan detected in urine was significantly smaller than the ingested fucoidan suggesting that 
fucoidan is degraded in the excretory system and possibly the kidney and not by intestinal 
enzymes or normal flora. 
Transport across Cell Membrane 
To evaluate the fucoidan uptake process by cells, the internalisation of low molecular weight 
(LMW) fucoidan into rabbit smooth muscle cells (SMCs) was analysed. Fucoidan was shown 
to be internalised by endocytosis at 6 hours. The number of vesicles containing fucoidan 
increased in the peri-nuclear region at 24 hours, but nuclear internalisation was not observed 
at any time during the study (150). However, examining the transport of a native fucoidan from 
Cladosiphon okamuranus with MW of 80 KDa revealed a poor permeation of fucoidan across 
the human colon adenocarcinoma Caco-2 cell monolayer (151). 
Regarding the specific ligands by which fucoidan binds to the cell surface, several molecules 
have been proposed including class A macrophage scavenger receptors for fucoidan attachment 
to macrophages (152) as well as adhesion molecules such as integrins (153), L-selectin and P-
selectin (154). However, Aisa et al. reported the anti-tumour activity of fucoidan on human 
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HS-Sultan lymphoma cells while these cells lack selectin on their surface indicating that 
fucoidan exerted its activity through selectin-independent mechanisms (155). Two main 
pathways have been described for receptor-mediated endocytosis including the clathrin-
dependent and the caveolae/lipid raft-dependent endocytic pathways. In recent studies, it has 
been revealed that endocytosis of fucoidan is performed by caveolae-dependent pathway (156). 
 
1.3.4 Fucoidan Biological Properties 
A century after discovery of fucoidan, only recently, the biomedical potentials of fucoidans 
have been elucidated. It has been reported that this agent has effect on the immune system and 
can enhance rapid haematopoietic stem cell mobilization (134). Kim et al. studied the 
immunomodulatory effects of fucoidan on dendritic cells and indicated that viability of 
dendritic cells and production of some important immune system proteins such as TNF-α and 
IL-12 increased in the presence of fucoidan (157). Additionally, fucoidan has been reported as 
an antiviral (135)  and antioxidant (158) agent. All research conducted on fucoidan have proved 
it to be non-allergenic with no significant toxicological effects in human and animals. Human 
trials involving orally administration of fucoidan to healthy volunteers showed no adverse 
effect on liver, renal and haematopoietic function over a period of three months (128). 
 
1.3.5 Fucoidan’s Anti-Cancer Potential 
The anti-cancer property of fucoidan has been demonstrated in vivo and in vitro in different 
types of cancers. Nevertheless, it has been rarely used for its anti-cancer activity in clinical 
trials. Fucoidan mediates its activity through various mechanisms such as induction of cell 
cycle arrest, apoptosis and immune system activation. Additional activities of fucoidan have 
been reported that may be linked to the observed anti-cancer properties and these include 
induction of inflammation through immune system, oxidative stresses  and stem cell 
mobilisation (159). 
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1.3.5.1 Fucoidan and Cell Cycle 
Fucoidan induces cell death through modulation of cell cycle and results in accumulation of 
sub-G0/G1 cells (dead cells/apoptotic cells) in a variety of cell types (155, 160). It can also 
induce cell cycle arrest in other phases; Riou et al. (161) and Mourea et al. (162) reported arrest 
in G1 phase in a chemo-resistant non-small-cell bronchopulmonary carcinoma line by fucoidan 
from Ascophyllum nodosum and Bifurcaria bifurcate, respectively. 
In an investigation of its mechanism of action, fucoidan demonstrated significant down 
regulation of cyclin D1, cyclin D2 and CDK4 in cancer cells (163-165). The crude fucoidan 
from Fucus vesiculosus increased the level of p21/WAF1/CIP1 in human prostate cancer PC3 
cells and down-regulated E2F; a transcription factor that controls progression of cells from G1 
to S phase (163). 
In a recent study, fucoidan down-regulated cyclin E, CDK2, CDK4 resulting in G0/G1 arrest 
in human bladder cancer 5637 cells. Furthermore, immunoprecipitation assays revealed a 
significant increase in the binding of p21/WAF1/CIP1 to CDK2 and CDK4 in cells treated with 
fucoidan, suggesting that the induced G0/G1 arrest is due to suppression of CDK activity 
following direct binding of this CDK inhibitor to CDKs 2 and 4 (166). Table 1.4 summarises 
findings of studies examining the effects of fucoidan on cell cycle. 
 
1.3.5.2 Fucoidan and the Apoptosis Pathway 
Several studies examining a variety of cancers such as haematopoietic, lung, breast and colon 
cancers have shown that fucoidan-mediated cell death occurs through triggering apoptosis 
(Table 1.4) (160, 167, 168). A very low dose of fucoidan from F. vesiculosus (20 µg/mL) 
activated common caspases 3 and 7 in human colon cancer cells (167), whereas it induced the 
same activity in T-cell leukaemia at a much higher concentration (3 mg/mL) (165). Caspase 8 
and 9 are also activated by fucoidan (167). Yamasaki-Miyamoto et al. showed that pre-
treatment with caspase 8 inhibitor completely blocked fucoidan mediated apoptosis in MCF-7 
breast cancer cell line (168). In contrast, in Zhang et al. study (160), the mediated apoptosis by 
fucoidan from Cladosiphon okamuranus in MCF-7 human breast cancer cell line was shown 
to be caspase independent. As cytochrome C and apoptosis inducing factor (AIF) increased in  
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Table 1.4. Effects of fucoidan on cell cycle and apoptosis molecules 
Ref Cell Type Fucoidan 
Source 
Dose 
(µg/mL) 
Effects on Cell Cycle Effects on Apoptosis Pathways 
  Extrinsic                                     Intrinsic                                                                  Common   
(155) lymphoma HS-
sultan cells 
F. 
vesiculosus 
100 • ↑ sub G0/G1 
• No G0/G1 or G2/M arrest 
    - • ↓ MMP  • Caspase 3 activation 
(165) HTLV-1 infected 
T-cell HUT-102-  
cells 
C. 
okamurans 
3000 • G1 arrest 
• ↓ cyclin D2, c-myc 
• No changes in p21,p53 
Apoptosis was reversed by 
caspase 8 inhibitor 
• Caspase 9 activation 
• No changes in Bcl-2 and Bcl-XL 
• ↓survivin, cIAP-2 
• Apoptosis was reversed by 
caspase 3 inhibitor 
(169) Hepatocellular 
carcinoma  
Okinawa 
mozuku 
22.5 • ↑ G2/M phase in HAK-1A, KYN-2, KYN-3 cell lines - • No clear caspase 9 activation in HAK-1B cell 
line 
• No clear caspase 3 activation in 
HAK-1B cells 
(168) Breast cancer 
MCF7 cells 
Not 
mentioned 
1000 • ↑ sub-G1 fraction • Caspase 8 activation 
 
• Caspase 9 activation 
• ↓ Bid, cytosolic Bax, ↑ Bax, cytochrome C  
• Caspase 7 activation 
• PARP cleavage 
(170) Acute leukaemia 
NB4 and HL-60 
cells 
F. 
vesiculosus 
150 • ↑ sub-G1 fraction • Caspase 8 activation • caspase 9 activation 
• No changes in Bcl-2 or Bax. 
• ↓  Mcl-1, ↑ cytochrome C 
• PARP cleavage  
• Caspase 3 activation 
(167) Colon cancer HT-
29 and HCT116 
cells 
F. 
vesiculosus 
20 - • Caspase 8 activation 
• ↑ Fas, DR5, TRAIL 
• No significant effects on 
FasL and DR4 
• Caspase 9 activation 
• ↑ cytochrome C,  Smac/Diablo, Bak, t-Bid 
• No changes in Bcl-2, Bcl-xL, Bax, Bad, Bim, 
Bik,   ↓  XIAP, survivin 
• PARP cleavage  
• Caspase 3 and 7 activation 
(171) Lung cancer A549 
cells 
U. 
pinnatifida 
50, 100, 
200 
• ↑ Sub‐G1frction - • Caspase‐9 activation 
• ↓ Bcl‐2 ,  ↑ Bax 
• ↓ procaspase‐3  
• PARP cleavage 
(160) Human breast 
cancer MCF-7 
cells 
Cladosiphon 
novae-
caledoniae 
82, 410, 
820 
• ↑Sub-G1  
• No significant changes in cell cycle distribution 
• No changes in caspase-8 • Mitochondrial dysfunction 
• AIF and cytochrome C release 
• No cleavage of caspase-9 and Bid. 
• ↓ Bcl-2, Bcl-xl ,↑ Bax, Bad 
• No activation of PARP and 
caspase-7 
• All caspase inhibitors failed to 
attenuate FE-induced apoptosis 
(172) Hela cells Sargassum 
filipendula 
1500 - - • No effect on caspase 9 activation 
• ↑  cytosol AIF 
• No effect on caspase 3 (Caspase 
independent)   
(164) Breast cancer 
MCF-7 cells 
F. 
vesiculosus 
400, 800, 
1000 
• G1 phase arrest 
• ↑ Sub G0/G1 ↓ cyclin D1 and CDK-4 gene expression 
• Caspase-8 activation • ↓  Bcl-2, ↑ Bax 
• Release of cytochrome C and APAf-1  
• Caspase-dependent pathway  
(163) Prostate cancer 
PC-3 cells 
U. 
pinnatifida 
100 • G0/G1 phase arrest 
• ↓ E2F-1, ↑ p21Cip1/Waf  
• DR5, caspase-8 
activation 
• ↓ Bcl-2 , ↑ Bax, 
• Caspase 9 activation 
• Caspase-3 activation 
• PARP cleavage 
(173) Hepatocellular 
Carcinoma 
SMMC-7721 cells 
U. 
pinnatifida 
1000 • Non-significant accumulation in S-phase • Caspase-8 activation 
 
• Caspase-9 activation 
• MMP dissipation, Cytochrome C release 
• ↓ Bcl-2, ↑ Bax 
• ↓ XIAP, livin mRNA expression  
• Caspase-3 activation 
 
(166) Human bladder 
carcinoma 5637 
and T-24 cells 
F. 
vesiculosus 
100 • ↑ G1-phase, p21WAF1           
• ↓ Cyclin E, D1, DK2, CDK4                                                                           -                                                 -                                                                                - 
• No change in p27KIP,p53 
• ↑ p21WAF1 and CDK4 binding 
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the cytosol, it was concluded that fucoidan performed its activity through mechanisms altering 
mitochondrial function. 
Fucoidan also affects other components of extrinsic and intrinsic pathways. Analysing the 
extrinsic pathway, 20 µg/mL crude fucoidan from F. vesiculosus increased the levels of the 
death receptors Fas, DR5 and TRAIL but not FasL and DR4 in human colon cancer cell lines 
(167). Contradictory results have been described in the expression of Bcl-2 family members in 
response to fucoidan (Table 1.4). Treatment of MDA-MB231 breast cancer cells with 820 
µg/mL of low molecular weight (LMW) fucoidan resulted in a significant decrease in anti-
apoptotic proteins Bcl-2, Bcl-xl and Mcl-1 (174). In contrast, no changes in expression of Bcl-
2, Bcl-xl, Bad, Bim and Bik were observed in colon cancer cells when they were treated with 
20 µg/mL fucoidan from Fucus vesiculosus (167). Taken together, these findings suggest that 
fucoidan may interact with several components of the apoptosis pathway. 
 
1.3.5.3 Fucoidan and Angiogenesis 
Fucoidan inhibits the formation of new vessels by which tumour cells receive their oxygen and 
required nutrients. Fucoidan inhibited the binding of VEGF, a key angiogenesis promoting 
molecule, to its cell membrane receptor (175).  Xue et al. examined the anti-angiogenic 
properties of fucoidan in 4T1 mouse breast cancer cells both in vitro and in vivo and observed 
a significant dose-dependent decrease in VEGF expression in cells treated with fucoidan (176). 
Further, in a mouse breast cancer model using 4T1 cells, intraperitoneal injections of 10 mg/kg 
body weight fucoidan from F. vesiculosus markedly reduced the number of microvessels.  
 
1.3.5.4 Fucoidan and Metastasis 
Fucoidan significantly decreased tumour cell metastasis to the lungs in animals that were 
intravenously injected with rat mammary adenocarcinoma 13762 MAT cells (177). It was first 
reported that fucoidan inhibits cell invasion through competing with tumour cell binding with 
laminin in the basement membrane (178). Subsequent studies then revealed that fucoidan binds 
to fibronectin with high affinity and prevents attachment of tumour cells (179). 
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Tumour invasion requires the secretion of proteolytic enzymes by tumour cells to break down 
the extracellular matrix (ECM) proteins (e.g. collagen, fibronectin and laminin), with the 
matrix metalloproteinases (MMPs) MMP-2 and MMP-9 playing a major role. Fucoidan 
attenuates both expression and activity of these enzymes (180). 
Selectin inhibition by fucoidan interferes with tumour cell–platelet interaction. When highly 
metastatic MDA-MB-231 breast cancer cells were plated in platelet-coated plates in the 
presence or absence of 100 µg/mL fucoidan the number of cells attached to the platelets 
decreased by 80% in the presence of fucoidan (181). Interaction of tumour cells with platelets 
is one of the key factors in facilitating the early steps of tumour cell migration. During tumour 
cell migration, most circulating tumour cells do not survive attack from immune cells or the 
shear forces of the blood stream. However, they can attach to platelets to induce platelet 
aggregation allowing the tumour cell cluster to survive in the micro-vascular system. It was 
concluded that fucoidan inhibited P-selectin residing on the platelet surface and led to reduced 
number of attached tumour cells. Fucoidan can also inhibit other adhesion molecules such as 
integrins residing on the tumour cell surface and can modify distribution of their subunits. 
 
1.3.5.5 Fucoidan and Signalling Pathways 
The Ras/Raf/MAPK pathway is often hyperphosphorylated in a variety of human cancers. 
Various studies have shown that fucoidan inhibits tumour cell proliferation by decreasing 
ERKs activity through reduction of its phosphorylation (155, 182). 
JNK and p38 are other MAPK superfamily members whose activity is altered by fucoidan. 
Fucoidan induced cell death in breast cancer cells through phosphorylation and of JNK and 
p38 after 30 minutes. The fucoidan-induced apoptosis significantly annulled in the presence of 
JNK inhibitor, indicating critical role of JNK in fucoidan-mediated apoptosis (160). 
Similarly, the PI3K/Akt, GSK and Wnt pathways have been shown to be triggered by fucoidan. 
Akt over-activation is linked with drug resistance and tumour cell survival. Most of the studies 
have reported inactivation of Akt by fucoidan. PI3k, an upstream molecule of Akt, is also 
inhibited by fucoidan (180). Upregulation of the Wnt signalling pathway is believed to have a 
critical role in prostate cancer development, survival and progression. Fucoidan from F. 
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vesiculosus activated GSK-3β in PC3 human prostate cancer cells resulting in hypo-
phosphorylation and inactivation of β-catenin (163).  
1.3.5.6 Fucoidan and the Immune System 
The effects of fucoidan on molecules of the immune system have been studied both in-vitro 
and in-vivo and effects on both cellular and humoral elements have been described. Fucoidan 
increases both activity and number of NK cells in vivo (183, 184). Increase in the number of 
cytotoxic T-cells (CTLs) has also been reported. A high-molecular-weight (HMW) fucoidan 
from Cladosiphon okamuranus (200–300 KDa) induced a large increase in the proportion of 
murine cytotoxic T cells (185). Investigation of the role of fucoidan on dendritic cell (DC)-
mediated T-cell cytotoxicity has revealed that the stimulation of CTLs was more effective in 
fucoidan-treated DCs as CTLs co-cultured with fucoidan-treated DCs exerted a high level of 
specific lysis of breast cancer cells (186). 
In a recent study, the role of fucoidan in DCs function and its adjuvant effect have been 
examined in vivo. Fucoidan was systemically administrated to mice by intraperitoneal 
injection. Examination of the spleen DCs revealed up-regulation of maturation markers as well 
as production of IL-6, IL-12 and TNF-α. Fucoidan was then used as an adjuvant in vivo with 
ovalbumin antigen and induced Th1 mediated immune response and CTL activation (187). 
 
1.3.5.7 Fucoidan and Malignant Transformation in Vitro and in Vivo 
Few studies have reported the potential of fucoidan to inhibit neoplastic transformation. Teas 
et al. fed rats with dietary seaweed (Laminira) for 55 days and administrated the carcinogen 
7,12-dimethylbenz(a) anthracene intragastrically. Following 26 weeks monitoring, 
experimental rats showed a significant delay in the median time for tumour appearance (19 vs 
11 weeks in the control group) (188). 
Transforming growth factor β1 (TGFβ1) is believed to promote tumour development and 
metastasis through epithelial to mesenchymal transition (EMT), a process that enables 
epithelial cells migrate to distant areas during late stages of breast cancer development (189). 
To trigger tumour progression, TGFβ1 recruits TGF receptors (TGFR) residing on the cell 
surface. The investigations of effects of fucoidan on TGFβ1-promoted carcinogenesis in MDA-
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MB-231 breast cancer cells have indicated that fucoidan decreased the expression of TGFRs 
and affected the downstream signalling molecules which are involved in TGFβ1-mediated 
EMT (190). 
Epidermal growth factor (EGF) is another carcinogenesis promoter, which induces tumour 
transformation through overexpression and activation of EGF receptor (EGFR). EGFR has a 
key role in cell proliferation and differentiation and many carcinomas arise from its mutations 
(191). Lee et al. examined the role of fucoidan on the activation of EGFR and EGF-mediated 
neoplastic transformation (192). They utilised murine JB6 Cl41 epidermal cells and induced 
cell transformation by EGF in the presence of fucoidan from L. guryanovae. Fucoidan 
markedly reduced the EGFR activation through hypo-phosphorylation. It also inhibited EGF-
tumourigenic activity through inhibition of AP-1, a transcription factor responsible for cell 
proliferation regulation. 
 
1.3.5.8 Fucoidan as a Synergistic Anti-Cancer Agent 
The ability of fucoidan to synergise with standard anti-cancer agents and/or reduce toxicity has 
recently been investigated. Ikeguchi et al. examined the synergistic effect of a HMW fucoidan 
with colorectal cancer chemotherapy agents; oxaliplatin plus 5-fluorouracil/leucovorin 
(FOLFOX) or irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI). The test patients received 
150 mL/day for 6 months of liquid that contained 4.05 g fucoidan. From the commencement 
of chemotherapy, toxicities and chemotherapy efficiency were compared. Fucoidan showed no 
side effects such as allergic dermatitis. Diarrhoea, neurotoxicity and myelo-suppression were 
not suppressed by fucoidan, whereas general fatigue was significantly decreased from 60% to 
10%. The patients were followed for approximately 15 months and the survival rate of the 
patients who received fucoidan was longer than that of the control participants; however the 
difference was not significant, probably due to the small numbers (193).  
Fucoidan affects the migration and invasion of multiple myeloma (MM) cells treated with 
chemotherapy drug cytarabine. The human myeloma cell lines RPMI8226 and U266 were 
treated with crude fucoidan from F. vesiculosus for 72 hours and then cytarabine for 6 hours. 
Fucoidan reduced cell migration and down-regulated expression of CXCR4 and MMP-9 (194). 
Fucoidan from Saccharina cichorioides has been reported to synergise with the anti-tumour 
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activity of low dose resveratrol on invasive and highly motile HCT 116 colon cancer cell line 
(195). In the colony formation assay, fucoidan plus resveratrol reduced the colony number by 
60% compared to 34% and 27% in resveratrol alone or fucoidan alone, respectively.  
Zhang et al. studied the combinatory effect of fucoidan and three commonly used anti-cancer 
agents; cis-platin (CDDP), tamoxifen (TAM) and paclitaxel (Taxol) on signal transduction 
pathways. Fucoidan from Cladosiphon navae-caledoniae plus anti-cancer agents reduced the 
ERK phosphorylation in MDA-MB-231 breast cancer cells compared to untreated control or 
fucoidan alone (196). Dietary fucoidan synergistically reduced cell growth in the OE33 cell 
line when it was combined with lapatinib, a targeted therapy that acts as a tyrosine kinase 
inhibitor in advanced HER2-positive breast cancer cells (197).  
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1.4 Research Aims 
The focus of this PhD project was to investigate the biological anti-tumour activities of the alga 
derived polysaccharide, fucoidan, on acute myeloid leukaemia cells. It was hypothesised that 
fucoidan exerts anti-tumour activity in AML cells and augments the efficacy of standard AML 
therapy.  
This study aimed to assess the inhibitory role of fucoidan on AML cell proliferation in vitro 
and in vivo, and to investigate the effect of fucoidan when combined with standard 
chemotherapeutic regimens in inhibition of AML cell growth in vitro and in vivo. The specific 
aims of this project were to: 
 
1. Determine if fucoidan has cytotoxic activity against AML cell lines, in vitro 
 
2. Characterise the mechanisms by which fucoidan induces cell death in AML cells  
 
3. Identify if fucoidan has anti-tumour property as a prophylactic agent during AML 
development, in vivo, and to characterise the underlying mechanisms 
 
4. Determine the synergistic effects of fucoidan with standard chemotherapy regimens for 
AML, both in vitro and in vivo 
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2.1 Cell Culture 
2.1.1 Cell Line Characteristics 
2.1.1.1 HL60 Cell Line 
HL60 is a human acute promyelocytic leukaemia (APL) cell line (198). Morphologically, these 
cells display a myeloblastic/promyelocytic feature; large, basophilic cytoplasm containing 
azurophilic granules and rounded nuclei with 2-4 distinct nucleoli. The HL60 cells are negative 
for translocation t(15;17) which is the karyotypic marker of most cases of APL in humans. In 
immunophenotyping analysis, the majority of HL60 cells are positive for CD13 (the pan-
myeloid marker), CD15 (granulocytes-associated antigen), CD11a (Integrin) and CD44 
(hyaluronic acid receptor). These cells are non-adherent and grow in a suspension culture with 
a doubling time varying between 24 to 40 hours.  
 
2.1.1.2 NB4 Cell Line 
NB4 is a human APL cell line which unlike HL60 carries the specific chromosomal 
translocation t(15;17) (199). Morphologically, NB4 cells are abnormal large promyelocytes 
with hyper-granular cytoplasm and prominent nuclei. In analysis of surface markers, NB4 cells 
are positive for CD13, CD15, and CD44 and also show low expression of CD11b. The NB4 
cells grow in a suspension culture with a doubling time of 24-36 hours.  
 
2.1.1.3 K562 Cell Line 
K562 is an erythroleukaemia type cell line derived from a patient with chronic myelogenous 
leukaemia in blastic crisis (200). Morphologically, K562 cells are lymphoblastic; round small 
cells with large round nuclei and high nuclear to cytoplasm (N/C) ratio. These cells are non-
adherent and their doubling time is around 24 hours. 
 
2.1.1.4 KG-1a Cell Line 
KG-1a is a human undifferentiated myeloblastic leukaemia and is a sub-clone of the KG-1 cell 
line (201). KG-1a represents an early or primitive stage of development and is generally 
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irresponsive to colony stimulating factor and is unable to differentiate into further mature cells. 
Morphologically, KG-1a cells are small round cells with presence of 1-2% giant myeloblasts. 
These cells are leukaemia stem cell-like cells and highly express CD34 while are negative for 
CD38. KG-1a grows slowly with doubling time of approximately 50 hours. 
 
2.1.1.5 Kasumi-1 Cell Line 
Kasumi-1 cells are human acute myeloblastic leukaemia cells containing translocation t(8;21) 
representative of AML-M2 in the FAB classification (202). Morphologically, these cells show 
myeloid maturation; the myeloblasts are the major cells with variation in size and N/C ratio. 
Kasumi cells express CD13, CD33 and are negative for CD34. The doubling time is around 
40-45 hours.  
 
2.1.1.6 Yac-1 Cell Line 
Yac-1 cell line is a mouse T-cell lymphoma which was induced by inoculation of Moloney 
leukaemia virus into a new-born mouse (203). Morphologically, Yac-1 cells are small round to 
oval lymphoblasts and can form clusters in suspension. The most important feature of these 
cells is their sensitivity to the cytolytic function of NK-cells. The non-adherent Yac-1 cells 
grow rapidly and their doubling time is around 20 hours. 
 
2.1.2 Cell Culture 
The K562 cell line was purchased from Sigma-Aldrich. The other cell lines were stored in 
liquid nitrogen at Menzies Institute for Medical Research. The cells were thawed and used for 
experiments when they reached log phase. The cells were cultured in RPMI-1640 
supplemented with 10% heat inactivated fetal calf serum (JRH Biosciences, Australia), 2 mM 
L-glutamine and 1% penicillin/streptomycin solution (5000 U/mL penicillin G and 5000 
µg/mL streptomycin, Sigma Aldrich, U.S.A). For the Kasumi-1 cell line, the RPMI-1640 
medium was supplemented with 20% heat inactivated fetal calf serum. 
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2.1.2.1 Thawing Cell Lines 
Cell line vials were removed from either the -80°C freezer or vapour phase of liquid nitrogen 
and thawed in a water bath at 37°C. The thawed cells were transferred to a 15 mL BD Falcon™ 
conical tube (Becton, Dickinson and Company Biosciences, U.S.A) and 10 mL media was 
gradually added to cells. After centrifugation (500 g for 5 minutes), 10 mL of fresh medium 
was added and the cells were transferred to cell culture flasks (Becton, Dickinson and Company 
Biosciences, U.S.A) and incubated at 37°C with 5% CO2. 
 
2.1.2.2 Culturing Cell Lines 
Cells were cultured in either 25 cm2 or 75 cm2 BD Falcon™ cell culture flasks. Cells were 
counted using a haemocytometer using trypan blue exclusion to assay viability. Cells were 
maintained at a concentration between 1 × 105 and 1 × 106 cells/ mL by sub-culturing the cells 
every 2-3 days.  
 
2.1.2.3 Cryopreservation of Cell Lines 
Cells were collected by centrifugation at 500 g for 5 minutes and resuspended in media at 1 × 
107 cells/ mL. Equal volume of media containing 20% DMSO was gradually added to the cell 
suspension. Aliquots (1 mL) were transferred to CryoTubes. Tubes were placed in a -80 °C 
freezer in a box insulated with cotton wool to slow freezing, and then transferred to the vapour-
phase of liquid nitrogen for storage. 
 
2.2 Cell Treatments 
Cell lines were treated with the following reagents for variable doses and times as indicated in 
Table 2.1. 
 
 
Chapter 2                                                                                                               Materials and Methods 
 
 
Page 57 
 
Table 2.1 Cell treatments 
Reagents Stock Preparation Treatment 
Purified fucoidan from Undaria 
pinnatifida (Marinova Pty Ltd) 
10 mg/mL in PBS (filtered through 
a 0.21-µm syringe filter (Millipore) 
Variable doses for variable 
times as indicated. 
Purified fucoidan from Fucus 
vesiculosus (Marinova Pty Ltd) 
10 mg/mL in PBS (filtered through 
a 0.21-µm syringe filter (Millipore) 
Variable doses for variable 
times as indicated. 
Fucoidan from Fucus 
vesiculosus (Sigma-Aldrich)* 
10 mg/mL in PBS (filtered through 
a 0.21-µm syringe filter (Millipore) 
Variable doses for variable 
times as indicated. 
Phorbol Myristate Acetate 
(PMA, Boehringer Mannheim, 
Australia) 
1 mg/mL in DMSO 20 ng/mL for 48 hours. 
Pan-Caspase Inhibitor Z-VAD-
FMK (Abcam) 
10 mM in DMSO 40 µM for 1 hour. 
Arsenic Trioxide  
(ATO, Sigma-Aldrich) 
Stock: 10 mM in 1.65 M NaOH. 
Working solution: 100 µM in PBS. 
0.25, 0.5 and 1 µM for 
variable times as indicated. 
All-Trans Retinoic Acid 
(ATRA, Sigma-Aldrich) 
Stock: 10 mM in absolute ethanol. 
Working solution: 100 µM in PBS. 
0.25, 0.5 and 1 µM for 
variable times as indicated. 
* The endotoxin level of the crude fucoidan solution (Sigma-Aldrich) was detected using 
chromogenic LAL endpoint assay (GenScript, U.S.A). 
 
2.3 DNA Content Analysis (Cell Cycle Assay) 
2.3.1 Reagents 
2.3.1.1 Propidium Iodide (PI) Solution 
PI powder was purchased from Sigma-Aldrich, U.S.A (Cat. No. P4170). The powder was 
dissolved in PBS to a concentration of 1 mg/mL and stored at 4 °C, protected from light. 
 
2.3.1.2 RNase A solution 
DNAase-free RNase A solution (100 mg/mL; 7000 units/mL) was purchased from Qiagen (Cat. 
No. 194101). A 10 mg/mL RNase A working solution was freshly prepared by diluting the 
RNase A solution in PBS. 
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2.3.1.3 DNA Content Staining Solution 
The DNA content staining solution was made freshly. For each sample, 40 µL of PI solution 
(see 2.3.1.1) and 10 µL of prepared RNase A (see 2.3.1.2) were added to 950 µL of PBS. 
 
2.3.2 DNA Content Analysis (Cell Cycle Assay) 
Evaluation of the cell cycle phase distribution and sub-G0/G1 population was performed using 
propidium iodide staining as described previously (204). In brief, approximately 1-2 × 106 cells 
were harvested following treatment as indicated, pelleted (500 g for 5 minutes) and washed in 
cold PBS. Cells were resuspended in 500 µL cold PBS and put on ice. To fix the cells, 4 mL 
of ice-cold 70% ethanol was added to cells drop wise with mixing. Cells were stored at -20°C 
overnight. 
The ethanol was aspirated after centrifugation (500 g for 10 minutes) and cells were washed 
once in PBS (500 g for 5 minutes). The cells were resuspended in 1 mL DNA content staining 
solution, transferred into 12×75 mm Polystyrene test tubes (BD Company, Cat. No. 352052) 
and incubated at room temperature for 30 minutes in the dark. Cell cycle was analysed using 
the FACSCantoTMII flow cytometer (BD Biosciences, U.S.A). The data was analysed by 
Kaluza Software (BD Biosciences, U.S.A). 
 
2.4 WST-8 Cell Proliferation Assay 
Cell proliferation was assessed using water-soluble tetrazolium salt WST-8 (Sigma-Aldrich). 
The assay is based on the extracellular reduction of WST-8 (205) by the glycolytic NAD(P)H 
production of viable cells. The WST-8 reduction produces yellow-colour formazan dye and 
generates colour which is directly proportional to the number of the living cells. According to 
the manufacturer’s instructions, 10 µL of WST-8 solution was added to 100 µL treated cells in 
a 96-well Corning® cell culture micro-culture plate for the last 4 hours of incubation. Finally, 
the absorbance was determined at 450 nm by spectrophotometry (SpectraMax® Plus384, 
Molecular Devices, U.S.A). 
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2.5 DNA Fragmentation TUNEL Assay 
The presence of fragmented DNA was detected using the Apo-BrdU TUNEL apoptosis assay 
kit (Invitrogen Ltd) according to the manufacturer’s protocol. In brief, 1-2 × 106 cells were 
harvested following treatment as indicated, pelleted (500 g for 5 minutes) and washed with 
PBS and resuspended in 0.5 mL PBS. Paraformaldehyde (5 mL at 1%) was added to the 
suspension and tubes were put on ice for 15 minutes. To remove the paraformaldehyde, cells 
were centrifuged (500 g for 5 minutes) and washed twice with 5 mL PBS.  The cell pellet was 
resuspended in 0.5 mL PBS. Five mL of 70% ethanol was added and cells were stored for 18 
hours in a -20°C freezer. After 18 hours, the experimental samples in addition to a 1 mL aliquot 
of manufacturer-supplied positive and negative control cells (containing approximately 1 × 106 
cells) were centrifuged at 500 g for 5 minutes and the ethanol was removed by aspiration. Cells 
were washed twice with wash buffer provided by the kit. The cell pellet was resuspended in 50 
µL of DNA-labelling solution (10 µL of reaction buffer, 0.75 µL of terminal deoxynucleotidyl 
transferase, 8.0 µL of 5-Bromo-2’-deoxyuridine 5’-triphosphate (BrdUTP) and 31.25 µL of 
Milli-Q water) and incubated at 37°C on heat-block for 60 minutes. 
Following the incubation time, 1 mL of provided rinse buffer was added to each tube and cells 
were centrifuged (500 g for 5 minutes). This step was repeated and then 100 µL antibody 
staining solution containing Alexa Fluor® 488 dye-labeled anti-BrdU antibody was added to 
the cell pellet and cells were incubated at room temperature for 30 minutes. Finally, 500 µL 
PBS was added to the tubes and the presence of DNA fragmentation was analysed by 
FACSCantoTMII flow cytometer (BD Biosciences). 
Note 1. The peak emission of Alexa Fluor® 488 is 519 nm and was measured in the FL-1 
channel. 
 
2.6 Annexin V/PI Apoptosis Detection Assay 
2.6.1 Reagents 
Annexin V binding buffer and annexin V-FITC antibody were purchased from Abcam. To 
prepare the 1X annexin V binding buffer, the 10X annexin V binding buffer was diluted in 
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PBS. To prepare the 1X annexin V-FITC antibody, the 5X annexin V-FITC antibody was 
diluted in 1X annexin V binding buffer. 
 
2.6.2 Annexin V/PI Apoptosis Detection Assay 
The presence of early and late apoptosis was detected using annexin V/PI apoptosis assay as 
described previously (206). Briefly, 1 × 105 cells were harvested following treatment as 
indicated, pelleted (500 g for 5 minutes) and washed with PBS and resuspended in 500 µL of 
1X annexin V binding buffer. Five µL of 1X annexin V-FITC antibody was added to the cell 
suspension and tubes were incubated at room temperature for 10 minutes. Propidium iodide 
solution (2.3.1.1) was added to each sample (1 µL) and cells were incubated at room 
temperature for an extra 5 minutes. The presence of different stages of apoptosis was analysed 
by FACSCantoTMII flow cytometer (BD Biosciences) and data was analysed using Kaluza 
Software (BD Biosciences, U.S.A)  
 
2.7 Western Blot Analysis of Cytoplasmic and Nuclear Proteins 
2.7.1 Preparation of Cytoplasmic and Nuclear Protein Extracts 
For this protocol, 25 mL cells at 5 × 105 cells/mL (i.e. 1.25 × 107 cells total) were used. 
Additional sample tubes and buffers were pre-cooled for over an hour prior to extraction. 
Nuclear and cytoplasmic extracts were prepared from a modified method (207). Briefly, cells 
were harvested following treatment as indicated, pelleted (500 g for 5 minutes at 4 °C) and 
washed twice in 10 mL of ice-cold PBS. The resulting cell pellet was resuspended in 750 µL 
of lysis buffer (containing 10 mM NaCl, 10 mM Tris (pH 7.4), 3 mM MgCl2, 0.1 mM EDTA 
(pH 8.0), 0.5% Igepal) and incubated on ice for 5 minutes to lyse the cells. Following 
centrifugation (500 g for 5 minutes at 4 ºC) the supernatant containing the cytoplasmic protein 
fraction was transferred to a fresh tube and placed on ice. The remaining nuclei pellet was 
washed in 750 µL of lysis buffer without Igepal (containing 10 mM NaCl, 10 mM Tris (pH 
7.4), 3 mM MgCl2, 0.2 mM EDTA (pH 8.0)) and centrifuged at 500 g for 5 minutes and 4 ºC. 
The nuclei were then resuspended in 25 µL of nuclei lysis buffer (containing 400 mM NaCl, 
7.5 mM MgCl2, 0.1 mM EDTA (pH 8.0), 1 mM DTT) and 1 µL of protease inhibitor 
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(containing aprotinin, leupeptin, complete EDTA-Free Protease Inhibitor Cocktail (Roche 
Applied Science, Switzerland)) to be incubated for 15 minutes on ice with shaking ensuring 
nuclear lysis. The suspension was centrifuged at 15,000 g for 5 minutes and 4 ºC and 
supernatant containing the nuclear proteins was transferred to a fresh tube. Protein 
concentration was measured using Bradford assay (208) (see Appendix B). 
 
2.7.2 SDS-PAGE and Western Blotting 
To separate proteins according to their molecular weight, SDS-PAGE (sodium dodecyl 
sulphate-poly-acrylamide gel electrophoresis) was performed. Briefly, protein extracts (10-20 
µg) were combined with an equal volume of 2X sample loading buffer (10 µL containing: 120 
mM Tris HCl (pH 6.8), 20% glycerol, 4% SDS, 0.04% Bromophenol blue, 5% β-
mercaptoethanol) and heated at 95 ºC for 5 minutes on a heat block. Spectra™ Multicolor 
Broad Range Protein ladder (10-260 kDa) (ThermoScientific, U.S.A) and 20 µL of samples 
were carefully loaded on the 12% Mini-PROTEAN® TGX™ pre-cast gel (Bio-Rad, U.S.A) 
with sufficient SDS-PAGE running buffer (192 mM glycine, 25 mM Tris (pH 8.0), 0.1% 
sodium dodecyl sulphate). Samples were initially electrophoresed for 15 minutes at 100 V and 
were subsequently subjected to 150 V until completion. 
The separated proteins were transferred from gel onto a 0.45 µM nitrocellulose membrane 
(Bio-Rad, U.S.A) using a wet transfer. The transfer assembly (consisted of the gel and membrane 
in direct contact surrounded by two layers of filter paper (Whatman, U.S.A) and a support pad on 
either side pressed together by the support grid) was placed in the transfer apparatus, immersed 
in western transfer buffer (20mM Tris (pH 8.3, 150 mM glycine, 20% methanol) and transfer 
was facilitated by 100 V for 90 minutes at 4 °C. 
 
2.7.3 Protein Detection 
The membrane was placed in blocking reagent (Blocking reagent (Roche Applied Sciences, 
Switzerland) diluted 1:10 in 1X TNT (10 mM Tris (pH 8.0), 150 mM NaCl, 0.05% Tween) 
and incubated at room temperature for 1 hour with shaking. The membrane was incubated with 
a specific dilution of primary antibody (see Appendix A) overnight at 4 ºC followed by three 
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10-minute washes with 1X TNT at room temperature with shaking. The membrane was 
incubated in 5 mL of secondary antibody (see Appendix A) for 45 minutes at room temperature 
followed by three 10-minute washes with 1X TNT at room temperature with shaking. 
To visualise the membrane, it was incubated with a mixture of 1 mL of SuperSignal® West 
Pico Stable Peroxide Solution and 1 mL of Pico Luminol/Enhancer solution (ThermoScientific, 
U.S.A) for 5-10 minutes with shaking in minimal light. Excess chemiluminescent complex was 
removed and the membrane was exposed for adequate lengths of time up to 10 minutes using 
the Chemi-Smart 5000 (Vilber Lourmat, France). 
 
2.8 Analysis of Fucoidan  
The constituents of fucoidan was determined in the laboratory of Marinova Pty Ltd. These 
experiments were performed by spectrophotometric analysis of fucoidan as follows: Total 
carbohydrate content was determined by spectrophotometric analysis of the hydrolysed 
compound in the presence of phenol, based on a method described by Dubois et al. (209). 
Sulphate content was analysed spectrophotometrically using a BaSO4 precipitation method 
(BaCl2 in gelatin), based on the work of Dodgson (210, 211). Analysis of polyphenol content 
was also determined spectrophotometrically, using a method based on the Folin-Ciocalteu 
reagent (phosphomolybdate/phosphotungstate) (212-214). The carbohydrate profile was 
determined using a GC-based method for the accurate determination of individual 
monosaccharide ratios in a sample. This method relies on the preparation of acetylated alditol 
derivatives of the hydrolysed samples (215). Molecular weight profiles were determined by 
Gel Permeation Chromatography, with the aid of a Size-Exclusion Column, and were reported 
relative to Dextran standards. 
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2.9 In Vivo Experiments 
2.9.1 Animals 
A total number of 120 athymic Balb/c nude mice (nu/nu) were obtained from the Cambridge 
Facility Farm (CFF) and housed at the animal facility, Medical Sciences Building 2, Menzies 
Institute for Medical Research. All animal studies were approved by the University of 
Tasmania Animal Ethics Committee (reference number: A13940) and were performed in 
accordance with the institutional guidelines.  
 
2.9.2 Mice Identification System 
The ear punch system was used for mice identification (Table 2.2) and a maximum of 5 mice 
with different ear punches were placed in one cage. A unique identification code was also 
prepared by the CFF for each mouse. To identify different cages, cage cards were used. The 
following information was included on each card: species, strain, mice identification code, ear 
punch category, date of birth, sex, date of arrival and names and contact details of responsible 
investigators. 
 
Table 2.2 Mice identification by ear punch 
 
 
 
 
 
 
 
Ear Punch Category Description 
1R 1 punch in right ear 
1L 1 punch in left ear 
1R1L 1 punch in right ear and 1 punch in left ear 
2R 2 punches in right ear 
2L 2 punches in left ear 
NM Non-marked 
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2.9.3 Mice Health Monitoring 
A monitoring sheet was prepared for each experiment (see Appendix C) and all animals were 
checked daily. Changes in behaviour, food or water consumption, aggression, muscular rigidity 
and reaction to handling were recorded. Mice were weighed daily and the weight was recorded. 
 
2.9.4 Animal Treatment 
Mice were treated with different substances as indicated in Table 2.3. As shown, various 
injection routes including intraperitoneal (IP), Sub-cutaneous (SC) and intravenous (IV) were 
used in the experiments. The following general requirements were applied: 1. the pH of 
solutions injected was verified to be 7.3 to 7.45; 2. isotonic sterilised solutions were warmed 
to body temperature when injecting either IV or IP; 3. where different substances were to be 
injected, both chemicals were combined in a single solution. 
 
Table 2.3 Animal treatments 
Substance Route Stock Preparation* 
Fucoidan (Sigma-Aldrich) Oral 70 mg/mL fucoidan in Milli-Q water 
Fucoidan (Sigma-Aldrich) IP 20 mg/mL fucoidan in sterile PBS 
Fucoidan (Sigma-Aldrich) IV 2 mg/mL fucoidan in sterile PBS 
All-Trans Retinoic Acid 
(ATRA) (Sigma-Aldrich) 
IP A stock of 100 mM ATRA (30 mg/mL) was prepared by 
dissolving ATRA powder in DMSO. 
Arsenic trioxide (ATO)  
(Sigma-Aldrich)  
IP A stock of 300 mM (59.34 mg/mL) ATO was prepared 
by dissolving ATO powder in 1.65 M NaOH. 
*All stock solutions were filtered through a 0.21-µm syringe filter (Millipore). To prepare the solutions for 
injection, stock solutions were diluted in sterile PBS. 
 
For S.C injection, the animal was restrained with the non-dominant hand. The syringe was held 
with the dominant hand with the bevel of the needle facing upwards. The needle was inserted 
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and the skin was gently tented upwards with the needle to confirm that the needle was in the 
subcutaneous space. The solution was injected and the plunger was depressed until the solution 
was fully administered. The animal was placed back into its cage and observed for any 
complications. For S.C injections, a needle of 26 gauge × 1/2 in. 0.45 mm × 13 mm 
(Becton Dickinson) was used. If the injection was successful, a small swelling under the skin 
was seen.  
For IP injections, the animal was restrained with the non-dominant. The syringe was held with 
the dominant hand with the bevel of the needle facing upwards. The substance was injected 
into the lower right quadrant of the abdomen towards the head at a 30‐40ᵒ angle. The solution 
was injected and the plunger was depressed until the solution was fully administered. The 
animal was placed back into the cage and observed for any complications. For IP injection, a 
needle of 30 gauge × 1/2 in. (Becton Dickinson) was used. 
For IV injection, the two lateral tail veins were used. The animal was restrained in a rodent 
cone-shaped restrainer. The tail was swabbed with 70% alcohol and rotated ¼ turn to place the 
tail veins dorsally for easier injection. The needle was approached at a 15-20° angle at the distal 
portion of the tail and inserted parallel to the tail vein penetrating 2-4 mm into the lumen while 
keeping the bevel of the needle face upwards and the material was injected slowly. A successful 
injection resulted in the material entering the vein with no resistance and blanching of the tail 
vein for the duration of the injection. 
 
2.9.4.1 Oral Administration of Fucoidan 
150 µg/g body weight (b.w.) fucoidan was orally administered. Mouse weight was measured 
daily and the required amount of fucoidan was mixed with peanut butter and a paste was 
prepared. For each mouse the peanut butter paste was prepared freshly just before feeding 
(Figure 2.1). The prepared fucoidan-peanut butter paste was put on a wooden applicator stick 
and put in the cage with a single mouse. Each mouse was not returned to its own cage until the 
entire paste was eaten. The control group was fed with peanut butter mixed with Milli-Q water 
in the same manner. 
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Figure 2.1. Preparation of fucoidan for oral administration. 1) The required amount of 
fucoidan was added to peanut butter. 2) Fucoidan was mixed with peanut butter. 3) The 
prepared paste was put on a wooden applicator stick. 4) The fucoidan paste was put in the 
cage with a single mouse 
 
2.9.4.2 Intraperitoneal Injection of Fucoidan  
Either low dose of 30 µg/g b.w. or high dose of 100 µg/g b.w. of fucoidan was administered 
by injection according to the mice weight measured daily. An injection volume of 200 µL of 
freshly prepared solution was injected into the lower quadrant of abdomen as described (see 
Section 2.9.4). 
 
2.9.4.3 Intravenous Injection of Fucoidan 
One daily dose of 6 µg/g b.w. fucoidan was administered by injection according to the mice 
weight measured each day. An injection volume of 200 µL of freshly prepared solution was 
injected into the lower quadrant of the abdomen as described (see Section 2.9.4). 
 
2.9.4.4 Intraperitoneal Injection of Arsenic Trioxide 
One daily dose of 2.5 µg/g b.w. ATO was administrated by injection according to the mice 
weight measured each day. An injection volume of 200 µL of freshly prepared solution was 
injected into the lower quadrant of the abdomen as described (see Section 2.9.4). 
 
2.9.4.5 Intraperitoneal Injection of ATRA 
One dose of 1.5 µg/g b.w. ATRA was administrated three times a week by injection according 
to the mice weight measured each day. An injection volume of 200 µL of freshly prepared 
solution was injected into the lateral tail veins as described (see Section 2.9.4). 
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2.9.5 Establishment of Human Leukaemia Xenograft Models 
Acute promyelocytic leukaemia NB4 cell line was cultured in RPMI as explained in 2.1.2.2. 
The medium was replaced with fresh RPMI medium 3 to 4 hours before harvesting. Cells were 
centrifuged at or below 500 g for 5 minutes and washed twice with 20 mL of sterile PBS free 
of serum. Cells were resuspended in sterile PBS at the final concentration of 2.5 × 107 cells/mL 
and transferred to sterile CryoVials. For each mouse, a volume of 200 µL of the prepared cell 
suspension containing 5 × 106 cells was injected. Cells were injected subcutaneously in the 
right flank of each mouse as described in 2.9.4. Mice injected with NB4 cells were monitored 
daily for tumour burden appearance. 
 
2.9.6 Tumour Volume Measurement 
Tumour volume was measured daily and the results were recorded in the monitoring sheet. The 
measuring surface was cleaned and dried. A flexible plastic ruler was sprayed with ethanol 
70% and dried. The general restrain following by lifting the animal with the non-dominant 
hand was performed and the tumour location was faced toward the investigator. The length and 
width of the tumour was measured in millimeter (mm) three times and the mean value was 
recorded. To calculate the tumour volume, the below formula was used: 
Tumour Volume (mm3) = 

 × (length × width2) 
The tumour volume was recorded in the monitoring sheet (see Appendix C) and the experiment 
was terminated if the tumour size reached 1000 mm3. 
 
2.9.7 Animals Euthanasia  
Animals were humanely sacrificed using carbon dioxide as per the AVMA Guidelines on 
Euthanasia 2013 (216). 
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2.9.8 Tumour Volume Doubling Time  
The tumour volume doubling time and tumour growth rate were calculated by the algorithm 
provided by http://www.doubling-time.com (217). 
 
2.9.9 Assessment of the Tumour Mass  
2.9.9.1 Tumour Mass Cell Suspension Preparation 
To remove the tumour mass, an incision was made in the area of the tumour using dissecting 
scissors and microscopic forceps (Met-App Co.) and the tumour mass was carefully removed. 
Fresh tissue sample was dissected and mixed with 2 mL PBS and filtered through a 40 µM 
sterile nylon mesh strainer (Fisher Scientific, Cat. No. 352340). The cell suspension was then 
washed with PBS (500 g for 5 minutes) and the cell pellet was resuspended in 2 mL sterile 
PBS. 
 
2.9.9.2 Cell Surface Marker Analysis 
The cell surface markers of the tumour mass removed from mice were analysed using various 
antibodies by flow cytometry. The prepared cell suspension (50 µL) was mixed with 5 µL of 
desired cell surface antibodies or the appropriate isotype negative controls in 12×75 mm 
polystyrene test tubes and incubated at 4 °C for 30 minutes. PBS (500 mL) containing 10% 
paraformaldehyde was added to the mixture, and the expression of cell markers was analysed 
with FACSCantoTMII flow cytometer (BD Biosciences, U.S.A). The flow cytometry results 
were analysed with Kaluza Software (BD Biosciences, U.S.A). 
  
2.9.10 Natural Killer Cell Activity 
To analyse the cytolytic activity of mice splenic natural killer (NK) cells, the spleen 
mononuclear cells (MNCs) were used as effector cells and the NK sensitive Yac-1 cell line was 
used as target cell. The activity of NK cells in lysing these cells was measured with Cell Trace 
Violet and PI cytotoxicity assay using flow cytometry. 
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2.9.10.1 Preparation of Splenic Mononuclear Cells 
Animals were sacrificed (see 2.9.8) and the mouse body was placed on its back and sprayed 
with 70% ethanol. A small incision was made in the left side of the peritoneum and the spleen 
was gently pulled and the connective tissues behind it were torn. The removed spleen was 
dissected and filtered through 40 µM sterile nylon mesh strainer (Fisher Scientific, Cat. No. 
352340). To do this, the spleen pieces were placed on the strainer and mashed and minced 
using a syringe plunger firmly so the connective tissue remained on the top of the strainer and 
the cells were filtered through by adding PBS. The cell suspension was washed with PBS (500 
g for 5 minutes) and resuspended in 5 mL of PBS. 
To isolate the MNCs, the prepared splenic cell suspension was gently homogenised and slowly 
added to a tube previously loaded with 5 ml of Ficoll-paque®-1077 (Sigma Company, Cat. No. 
10771). The tube was carefully loaded into the centrifuge buckets without disturbing the layers. 
The mixture was centrifuged (400 g, for 30 minutes) using slow acceleration and deceleration 
rates. After centrifugation, the following layers were visible in the tube from top to bottom: 
PBS, a layer of MNCs, Ficoll-Paque, and erythrocytes and poly-morphonuclear cells presented 
in pellet form. The MNC layer was recovered and washed with sterile PBS (500 g for 10 
minutes). The cell pellet was completely resuspended in the remaining PBS and mixed with 
complete RPMI media at 107 cells/ mL. 
 
2.9.10.2 Preparation of Yac-1 Target Cells 
The Yac-1 target cells were labelled with CellTraceTM Violet (CTV) fluorescent dye (Life 
technologies Inc. Cat. No. C34557). Briefly, 1 × 106 Yac-1 cells were pelleted and mixed with 
1 mL of pre-warmed sterile PBS. The cells were mixed with 1 µL of stock CTV and incubated 
for 20 minutes at room temperature with gentle agitation and protected from light. The unbound 
dye remained in solution was the quenched by adding 5 mL of pre-warmed RPMI media (10% 
FCS) and incubated for an extra 5 minutes at room temperature. Finally cells were pelleted and 
resuspended in RPMI at 105 cells/ mL. 
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2.9.10.3 Cell Trace Violet and PI staining Assay 
A 96-well plate was prepared with 100 µL serial halving dilutions of splenic mononuclear cells 
with a range from 100:1 to 3:1 of effector cells: target cells (Figure 2.2). This was achieved by 
adding 200 µL of prepared MNCs in the 100:1 wells and 100 µL of RPMI media in the rest of 
the dilution wells. The MNCs (100 µL) was then transferred as a serial dilution through the 
relevant wells from 100:1 to 3:1. Finally, 100 µL of CTV-labelled Yac-1 cells were added to 
each well. A control well (0:1) was prepared with addition of 100 µL RPMI in 100 µL Yac-1 
cell and no MNCs. All samples were loaded in triplicates. 
Plates were incubated for 4 hours at 37 °C with 5% CO2. PI solution (2.3.1.1) was diluted 1:25 
with PBS and added to the wells right before analysis (25 µL). The amount of lysed Yac-1 cells 
representing NK cell cytotoxic activity was analysed using flow cytometry within two hours. 
Flow cytometry data was analysed using Kaluza Software and the data was normalised by 
subtracting the percentage of spontaneous cell death observed in the wells with target cells only.  
Note 1. The peak emission of CTV is 450 nm and was measured in the FL-1 channel. 
 
 
Figure 2.2. Cell trace violet and PI staining assay 
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2.10 Statistical Analysis 
Data were analysed for significance using GraphPad Prism 5 Software. In-vitro experiments 
were performed in duplicate or triplicate. p values were determined using the Student’s t-test 
accompanied by analysis of variance (ANOVA) as indicated in Figure legends. For in vivo 
experiments, a Kaplan-Meier survival curve was used to estimate the fraction of mice living 
for the certain amount of time after treatment. A p value of less than 0.05 was considered 
significant.  
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3.1 Introduction 
Although chemotherapy is often effective in the treatment of AML, at least in the short term, 
the agents currently in use are associated with undesirable side effects and low survival rate 
(218). Concerns over toxicities from chemotherapeutic chemicals have generated interest in 
exploiting natural products for cancer treatment (219). Among those, fucoidan derived from 
brown seaweeds has gained significance in the treatment of cancer. 
Different experimental studies have shown the tumour-suppressive activity of fucoidan in 
various human cancer cells, including gastric adenocarcinoma (220), prostate cancer (163), 
breast cancer (160), lung carcinoma (171) and colorectal cancer (167). Low toxicity and the in 
vitro cytotoxic effects of fucoidan on cancer cells make it a suitable choice for cancer 
prevention or treatment.  
Despite evidence for the tumour inhibitory effect of fucoidan in different cancer types, there 
are only few studies which have examined the anti-proliferative property of fucoidan in 
haematological malignancies. Aisa et al. and Haneji et al. have reported that fucoidan induces 
apoptosis in human lymphoma HS-Sultan and adult T-cell leukaemia cell lines, respectively 
(155, 165). The first aim of this thesis chapter was to investigate whether anti-proliferative 
effects of fucoidan were observed in myeloid leukaemias in vitro. 
Several studies have examined the mechanisms underlying the observed anti-tumour activities 
and provided some clues to the key pathways involved. Roles in apoptotic protein regulation 
(220), caspase activation (164) oxidative stress induction and mitochondrial dysfunction (167)  
have been reported. However the inconsistent and contradictory evidence to date has been 
challenging to interpret and the mechanisms of action of fucoidan remains unclear. The second 
aim of this chapter was to examine the mechanisms by which fucoidan affect cell growth in 
AML cells, and if the cytotoxic responses were observed in AML cells. To test this, a wide 
range of cellular and molecular pathways including cell proliferation, apoptosis, cell cycle and 
different signal transduction pathways were examined in AML cells after treatment with 
fucoidan. 
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3.2 Experimental Design 
Fucoidan from different seaweed sources were obtained and their inhibitory effects were 
compared in AML cell growth. 
The composition and characteristics of fucoidan from F. vesiculosus (Sigma-Aldrich Co.) and 
purified fucoidan from U. pinnatifida (Marinova Pty. Ltd.) were assessed and compared (see 
Section 2.8). Endotoxin contamination was a potential concern for the fucoidan preparation 
therefore whether endotoxin was present in the fucoidan preparation was determined (see 
Section 2.2). 
AML cell lines including NB4, HL60 and K562 cells (see Section 2.1.1) were treated with 
Marinova Pty. Ltd. supplied purified fucoidan derived from two seaweed sources (U. 
pinnatifida and F. vesiculosus) where indicated with doses ranging from 10 to 2000 µg/mL. 
AML cell lines including NB4, HL60, K562 and KG-1a cells were then treated with fucoidan 
from F. vesiculosus (Sigma-Aldrich Co.) at various doses ranging from 10 up to 100 µg/mL. 
Cell proliferation was measured with WST-8 proliferation assay (see Section 2.4). Cell death 
and apoptosis were analysed by measuring DNA content, annexin V/PI and DNA 
fragmentation assays (see Sections 2.3, 2.5 and 2.6). To investigate the mechanisms by which 
fucoidan induced apoptosis, the expression of various proteins in cell cycle, apoptosis and 
signal transduction pathways were assessed using Western blotting (see Section 2.7). 
 
 
 
 
 
 
 
 
Chapter 3                                                                             Cytotoxic Effects of Fucoidan on AML Cells 
 
 
Page 75 
 
3.3 Results 
(This section has been substantially published in Atashrazm et al. 2015 (221)) 
 
3.3.1 Fucoidan Characteristics 
3.3.1.1 Endotoxin Level Assay in Fucoidan 
To evaluate the pyrogenicity and endotoxin contamination, the endotoxin level was measured 
in fucoidan. According to the "Guidelines on the Validation of the Limulus Amebocyte Lysate 
Test" defined by the FDA (12/87), the endotoxin level for human and animal parenteral drugs, 
biological products and medical devices must be ≤0.5 Endotoxin Units/ml (222). The 
endotoxin level of the fucoidan preparation was measured utilising the standard curve 
generated from E. coli endotoxin standards. Less than 0.1 EU/mL endotoxin was detected in 
fucoidan preparation, which is considered as non-pyrogenic. 
 
3.3.1.2 Analysis of the Two Fucoidan Preparations 
The characteristics of two sources of fucoidan were evaluated; fucoidan from F. vesiculosus 
supplied by Sigma-Aldrich Co. and purified fucoidan from U. pinnatifida supplied by 
Marinova Pty. Ltd. The experiments for characterisation of the fucoidan constituents were 
performed by Samuel S Karpiniec at Marinova Pty. Ltd. The results for the compositional 
analysis of the fucoidans from Sigma-Aldrich Co. and Marinova Pty. Ltd. are shown in Table 
3.1. As indicated, fucoidan from F. vesiculosus (Sigma-Aldrich Co.) had lower molecular 
weight and less fucose content compared to the Marinova Pty. Ltd. supplied fucoidan from U. 
pinnatifida. The amount of other monosaccharaides in addition to sulphate content were similar 
in fucoidan from both sources. The amount of uronic acid in fucoidan from Sigma-Aldrich Co. 
was 4 fold higher than that of fucoidan from Marinova Pty. Ltd. The purity of the fucoidan 
from Sigma-Aldrich Co. was near 80% compared to 98% in purified fucoidan (Marinova Pty. 
Ltd.). In addition, 3.9% polyphenol was found in the Sigma-Aldrich Co. supplied fucoidan 
structure. 
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Table 3.1. Composition and monosaccharide constituents of fucoidan from different 
sources 
 
 
Fucoidan from F. vesiculosus 
 (Sigma-Aldrich Co.) 
Fucoidan from U. pinnatifida  
(Marinova Pty. Ltd.) 
Molecular Weight (kDa) 20.7 61.7 
Fucoidan (%) 79.3 98.0 
Total Carbohydrate (%) 55.9 67.5 
Uronic Acid (%) 5.9 1.4 
Polyphenol (%) 3.9 - 
Cations (%) 6.4 11.9 
Sulphate (%) 26.9 26.6 
 
Monosaccharide 
Composition 
(%) 
Fucose 38.2 53.3 
Xylose 2.7 2.3 
Mannose 0.4 0.8 
Galactose 3.5 3.1 
Glucose 0.1 0.0 
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3.3.2 Purified Fucoidans from U. pinnatifida and F. vesiculosus (Marinova 
Pty. Ltd.) Did Not Suppress the Growth of AML Cells 
To determine whether fucoidan inhibits the growth of AML cells through either cell cycle arrest 
or cell death, cell cycle progression was assessed in cells treated with purified fucoidan 
(Marinova Pty. Ltd.). This was performed by DNA quantitation whereby DNA is labelled and 
the amount of measured dye quantitated (84). Figure 3.1 (left) displays the typical DNA content 
histogram in a healthy cell population. As indicated, the G0/G1 phase cells have the least 
amount of staining intensity as they have the least amount of genetic material (only one copy 
of DNA). G2/M phase cells, in contrast, have the highest amount of staining intensity as they 
contain the highest amount of DNA (two copies of chromosomes). Since the S phase cells are 
synthetising DNA, they have different amounts of DNA varying from one copy to two copies. 
The cell cycle histogram not only gives us information about the status of the living cells, but 
also detects the dead cells. As DNA is degraded in the late stages of the death process, a large 
number of small DNA fragments accumulate in the cells, which can then leach out. Since these 
dying cells have a lower DNA content, they can be observed in the cell cycle histogram as a 
hypo-diploid or sub G0/G1 peak (223). Figure 3.1 compares the cell cycle histogram between 
a normal cell population and a dead cell population. 
 
 
Figure 3.1. Cell cycle histogram in healthy (left) and apoptotic (right) population (224) 
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Phorbol 12-myristate 13-acetate (PMA) was used as a positive control, to ensure that cells were 
responding to chemical agents as expected and to assess efficacy of the assay methodology.  
PMA is a diester of phorbol which induces G0/G1 cell cycle arrest in a variety of cell types. 
The leukaemic cells were treated with 20 ng/mL PMA for 48 hours and DNA content was 
measured using PI staining. As shown in Figure 3.2, PMA inhibited cell proliferation in K562, 
NB4 and HL60 cells, which was indicated by G0/G1 arrest in all three cell lines. 
To investigate the growth inhibitory effect of fucoidan, acute myeloid leukaemia cell lines 
HL60, NB4 and K562 were treated with the two different purified fucoidans from Marinova 
Pty. Ltd. as indicated with doses up to 150 µg/mL. After 48 hours, the DNA content was 
analysed using PI staining. Neither fucoidan preparations influenced the proportion of cells 
present in each of the cell cycle phases as measured by flow cytometry at any of the given 
doses (Figures 3.3, 3.4, 3.5) in the experimental time frame.  A similar result was observed in 
each of the cell lines examined. 
Furthermore, very high doses of the two purified fucoidans from Marinova Pty. Ltd (for up to 
2 mg/mL) were used and no changes were observed in any phases of the cell cycle for either 
fucoidan preparations. Figures 3.6 and 3.7 display DNA content in HL60 cells after treatment 
with very high dose of the two purified fucoidans from Marinova Pty. Ltd. 
DNA fragmentation was also assessed in fucoidan-treated cells at a low (150 µg/mL) and a 
very high dose (2000 µg/mL). In agreement with the DNA content results, the purified fucoidan 
(Marinova Pty. Ltd.) did not induce DNA fragmentation in the treated cell lines (Figure 3.8). 
In summary, purified fucoidans from two sources of U. pinnatifida and F. vesiculosus supplied 
by Marinova Pty. Ltd. did not affect cell proliferation, DNA content and DNA fragmentation 
in different AML cell lines as indicated. Due to inconsistency with literature, this was further 
examined by analysing the anti-proliferative activity of a commercially available fucoidan 
extract, which is the most common source of experimental fucoidan used in literature. 
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Figure 3.2. DNA content analysis in AML cells treated with PMA. HL60, NB4 and K562 
cell lines were treated with 20 ng/mL PMA, and cell cycle phase distribution was measured 
using PI staining and quantitated by flow cytometry. 
 
Green population: G0/G1 phase cells, Blue population: S phase cells, Purple population: 
G2/M phase cells 
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Figure 3.3. DNA content analysis in HL60 cells. HL60 cells were treated with increasing 
doses (from 50 µg/mL to 150 µg/mL) of fucoidan from U. pinnatifida (Marinova Pty. Ltd.), 
and cell cycle phase distribution was measured using PI staining and quantitated by flow 
cytometry. 
 
 
Red population: Sub-G0/G1 phase cells, Green population: G0/G1 phase cells,  
Blue population: S phase cells, Purple population: G2/M phase cells 
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Figure 3.4. DNA content analysis in NB4 cells. NB4 cells were treated with increasing 
doses (from 50 µg/mL to 150 µg/mL) of fucoidan from U. pinnatifida (Marinova Pty. Ltd.), 
and cell cycle phase distribution was measured using PI staining and quantitated by flow 
cytometry. 
 
 
Red population: Sub-G0/G1 phase cells, Green population: G0/G1 phase cells,  
Blue population: S phase cells, Purple population: G2/M phase cells 
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Figure 3.5. DNA content analysis in K562 cells. K562 cells were treated with increasing 
doses (from 50 µg/mL to 150 µg/mL) of fucoidan from U. pinnatifida (Marinova Pty. Ltd.), 
and cell cycle phase distribution was measured using PI staining and quantitated by flow 
cytometry.  
 
 
Red population: Sub-G0/G1 phase cells, Green population: G0/G1 phase cells,  
Blue population: S phase cells, Purple population: G2/M phase cells 
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Figure 3.6. DNA content analysis in HL60 cells treated with high dose fucoidan. HL60 
cells were treated with low (150 µg/mL) and high (2000 µg/mL) doses of fucoidan from U. 
pinnatifida (Marinova Pty. Ltd), and cell cycle phase distribution was measured using PI 
staining and quantitated by flow cytometry. 
 
Red population: Sub-G0/G1 phase cells, Green population: G0/G1 phase cells,  
Blue population: S phase cells, Purple population: G2/M phase cells 
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Figure 3.7. DNA content analysis in HL60 cells treated with high dose fucoidan. HL60 
cells were treated with low (150 µg/mL) and high (2000 µg/mL) doses of fucoidan from F. 
vesiculosus (Marinova Pty. Ltd), and cell cycle phase distribution was measured using PI 
staining and quantitated by flow cytometry. 
 
Red population: Sub-G0/G1 phase cells, Green population: G0/G1 phase cells,  
Blue population: S phase cells, Purple population: G2/M phase cells 
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Figure 3.8. DNA fragmentation assay in AML cells. HL60, NB4 and K562 cell lines were 
treated with low (150 µg/mL) and high (2000 µg/mL) doses of fucoidan from U. pinnatifida, 
and DNA fragmentation was assessed using TUNEL assay. 
Red population: Dead cells with DNA fragmentation, Black population: Live cells 
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3.3.3 Cytotoxicity Activity of Fucoidan (Sigma-Aldrich Co.) in AML Cells 
Fucoidan from F. vesiculosus was obtained from Sigma-Aldrich Co. and its cytotoxicity and 
antiproliferative activities were examined in different types of AML. 
 
3.3.3.1 Fucoidan Inhibited Cell Proliferation in NB4, HL60 and K562 Cell Lines 
To investigate the proliferation inhibitory effects of this fucoidan preparation on AML cells, 
cell lines were treated with increasing doses of fucoidan and after 48 hours cell proliferation 
was measured with the WST-8 proliferation assay (Figure 3.9). The results indicated that 
fucoidan differentially inhibited cell growth in selected leukaemia cell sub-types; it inhibited 
the proliferation of acute promyelocytic leukaemia NB4 and HL60 cell lines in a dose 
dependent manner with the level of cell proliferation decreased to less than 10% at 
concentrations of 25 and 50 µg/mL in NB4 and HL60 cells, respectively. To a lesser extent, 
fucoidan reduced the proliferation of K562 cells and the amount of cell proliferation remained 
more than 70% at a dose of 100 µg/mL. In contrast, fucoidan had almost no effect on KG-1a 
cell proliferation. 
 
3.3.3.2 Fucoidan Increased Sub-G0/G1 Fraction in NB4 and HL60 Cells.  
To investigate whether the reduced proliferation in NB4 and HL60 cells was due to cell cycle 
arrest or increased cell death, cells were treated with fucoidan and DNA content was evaluated 
for up to 48 hours using PI staining. The percentage of sub-G0/G1 fraction representing the 
dead cell population significantly increased in both HL60 and NB4 cells in a time dependent 
manner (Figure 3.10 A, B). Table 3.2 shows the percentage of cells in each phase of the cell 
cycle as measured by PI staining using flow cytometry. 
Furthermore, the effects of fucoidan on cell cycle was determined in K562 and KG-1a cell 
lines. A cell cycle arrest in G0/G1 accompanied by a decrease in S and M phases was observed 
in fucoidan-treated K562 cells (Figure 3.10 C); approximately 60% of the cells treated with 
fucoidan were in the non-proliferative fraction compared to around 40% in untreated cells 
(Table 3.2).  
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Figure 3.9. Inhibitory effect of fucoidan on cell proliferation. Different leukaemia cell 
lines were treated with increasing doses of fucoidan (Sigma-Aldrich Co.) (12.5 µg/mL to 100 
µg/mL) and measured for proliferation with the WST-8 assay. Mean ± SEM of at least three 
replicates is shown. Statistical significance was determined by ANOVA, followed by 
Tukey’s multiple comparison test (***: p≤0.001, **: p≤0.01). 
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Figure 3.10. Representative DNA content analysis. A, B) HL60 and NB4 cells were treated with 100 µg/mL fucoidan and DNA content was 
analysed for up to 48 hours. The sub-G0/G1dead cell fraction increased in a time-dependent manner (p≤0.001). C, D) K562 and KG-1a cells 
were respectively treated with 100 µg/mL fucoidan for 48 hours and DNA content was analysed.  
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Table 3.2. Cell cycle phases distribution. DNA content was assessed in different AML cell lines after treatment with 100 µg/mL fucoidan for 
48 hours. Data represents Mean ± SEM of three independent experiments. Statistical significance was determined by two-way ANOVA, 
followed by Bonferroni post-test (***: p≤0.001). 
Cell line Fucoidan Sub G0/G1 (%) G0/G1 (%) S (%) M (%) 
HL60 Untreated 2.5 ± 1.26 48.4 ± 1.26 29.0 ± 1.04 18.8 ± 3.27 
Treated 78.7 ± 2.45*** 8.3 ± 1.35 7.0 ± 2.95 6.3 ± 1.81 
NB4 Untreated 5.9 ±  2.45 43.3 ± 2.46 32.3 ± 1.72 16.2 ± 1.34 
Treated 97.5 ± 3.004*** 1.5 ± 1.98 0.6 ± 0.68 0.1 ± 0.11 
K562 Untreated 3.3 ± 0.20 42.6 ± 4.66 30.4 ± 3.05 21.5 ± 1.79 
Treated 9.0 ± 0.80 58.3 ± 2.482 24.4 ± 0.92 7.7 ± 1.69 
KG-1a Untreated 1.6 ± 0.41 61.1 ± 1.08 15.9 ± 0.66 20.7 ± 1.85 
Treated 1.3 ± 0.40 60.3 ± 1.19 16.0 ± 1.19 21.6 ± 1.14 
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Unlike the HL60, NB4 and K562 cell lines, the undifferentiated AML cell line KG-1a was 
resistant to the cell cycle modulatory effects of fucoidan (Figure 3.10 D). This was consistent 
with the proliferation assay results as fucoidan neither induced cell cycle arrest nor sub-G0/G1 
dead cell population in KG-1a cells (Table 3.2).  
Taken together, the results indicate that fucoidan reduced proliferation of HL60 and NB4 cell 
lines at the sub-G0/G1 stage and reduced proliferation of K562 cells at the G0/G1 stage, but 
did not inhibit the KG-1a cell growth.  
 
3.3.3.3 Fucoidan Induced Apoptosis in NB4 and HL60 Cells.  
The observed reduced cell proliferation in NB4, HL60 and K562 cells and increased sub-
G0/G1 dead cell population in HL60 and NB4 cells were further examined. The annexin V/PI 
apoptosis assay and DNA fragmentation TUNEL assays were employed to measure apoptosis 
and evaluate mechanisms of cell death induced by fucoidan. 
The annexin V/PI apoptosis assay permits the distinction between apoptosis and necrosis to be 
observed. During the earliest stages of apoptosis there is a loss of asymmetry of the plasma 
membrane, which results in the translocation of the phosphatidylserine (PS) from the inner side of 
the cell membrane to the surface. The exposed PS can then bound to annexin V. In the very earliest 
stages of apoptosis the membrane remains impermeable to the dye PI. Upon the loss of membrane 
integrity at the late stages of apoptosis however PI passes through the cell. Necrotic cells are also 
permeable to PI but its binding to annexin V is relatively low and this allows discrimination of 
early and late apoptotic cells from necrotic cells (225) (Figure 3.11).  
 
 
Figure 3.11. Healthy and apoptotic cells with markers for detection of apoptosis (226) 
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As shown in Figures 3.12 and 3.13, the annexin V/PI apoptosis assay revealed that fucoidan 
significantly increased apoptosis in HL60 (p≤0.01) and NB4 cells (p≤0.001). Consistent with 
the proliferation and DNA content assay results, fucoidan failed to induce apoptosis in K562 
and KG-1a cell lines (Figure 3.12). 
 
DNA fragmentation, which is a feature of late apoptosis, was examined in fucoidan-treated 
cells by TUNEL assay in triplicate and the mean values were analysed (Figure 3.14). DNA 
fragmentation significantly increased in HL60 and NB4 cells in a dose dependent manner. 
Compared to untreated cells, the percentage of cells containing fragmented DNA increased 
from less than 1% to 88.9% in NB4 cells and to 54.8% in HL60 cells treated with 100 µg/mL 
fucoidan (p≤0.01, p≤0.001). In contrast, the DNA fragmentation amount remained unchanged 
in K562 and KG-1a cells treated with up to 100 µg/mL fucoidan (less than 1%). 
Taken together, these results indicate that apoptosis induction by fucoidan within tumour cells 
is cell-type specific and further that promyelocytic cells were more sensitive to fucoidan’s 
action. In the next step, the underpinning mechanisms of the fucoidan’s activity in induction 
of apoptosis was investigated. 
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Figure 3.12. Annexin V/PI apoptosis assay in AML cell lines trated with fucoidan. 
Apoptosis was evaluated using annexin V/PI assay. Cell lines were treated with 100 µg/mL 
fucoidan. Results represent one of three independent experiments. 
 
*: Purple population: Annexin-/PI- (live cells), Blue population: Annexin-/PI+ (necrotic 
cells), Red population: Annexin+/PI- (early apoptotic cells), Green population: Annexin+/PI+ 
(late apoptotic cells),  
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Figure 3.13. Early apoptosis detection. HL60 and NB4 cells were treated with 100 µg/mL 
fucoidan for 24 hours. Apoptosis was assessed using Annexin V/PI assay. Annexin V 
positive/PI negative populations representing early apoptosis were calculated.  Each column 
represents the Mean ± SEM (n=3) values for annexin V positive/PI negative population. 
Statistical significance was determined by one-tailed student t test. 
(***: p≤0.001, **: p≤ 0.01). 
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Figure 3.14. DNA fragmentation TUNEL assay. HL60, NB4, K562 and KG-1a cells were 
treated with increaing doses of fucoidan (from 10-100 µg/mL) and DNA fragmentation was 
measured using the TUNEL assay. Mean ± SEM of at least three replicates is shown. 
Statistical significance was determined by ANOVA, followed by Tukey’s multiple 
comparison test (***: p≤ 0.001, **: p≤ 0.01). 
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3.3.3.4 Fucoidan-Induced Apoptosis was Caspase Dependent 
As NB4 cells showed the highest sensitivity to fucoidan, the further experiments were 
conducted on NB4 cells. To determine the mechanisms by which fucoidan induces apoptosis, 
the activation of caspase 3 as well as the cleavage of poly ADP ribose polymerase (PARP), a 
downstream target of activated caspase 3 in isolated nuclei, were examined using Western 
blotting. Since fucoidan caused near 100% NB4 cells death within 48 hours, the shorter 
incubation time of 24 hours was selected for this assay in order to obtain sufficient amount of 
protein. Fucoidan decreased the level of pro-caspase 3 and increased the cleaved activated 
caspase 3 in treated cells in a dose dependent manner correlated with the detection of cleaved 
PARP (Figure 3.15). 
In order to examine the importance of caspase participation in apoptosis-induced by fucoidan, 
cell proliferation and annexin V apoptosis assays were performed in the presence of the caspase 
inhibitor Z-VAD-fmk in NB4 cells. In the WST-8 assay, the caspase inhibitor Z-VAD-fmk was 
protective and partially ameliorated the anti-proliferative effect of fucoidan (p≤0.001) (Figure 
3.16 A). In the annexin V/PI apoptosis assay, the inhibitory effect of fucoidan was completely 
annulled in the presence of Z-VAD-fmk (p≤0.001) (Figure 3.16 B), indicating that caspase 
activation is required for fucoidan activity. 
The expression of various apoptosis, cell cycle and signalling pathway related molecules were 
then examined. For these experiments, a dose of 50 µg/mL and the incubation time of 24 hours 
were selected in order to obtain sufficient amount of protein.  
To evaluate different apoptosis pathways, the expression of death receptors DR5 and Fas, pro-
apoptotic molecule Bax and anti-apoptotic molecule Bcl-xl in addition to the activation of 
caspases 8 and 9 were examined. There was an increase in the amount of cleaved activated 
caspase 8, which correlated to DR5 activation (Figure 3.17 A). No change in Fas expression 
was observed. Caspase 9, the key caspase in the intrinsic pathway, was also activated by 
fucoidan. Fucoidan increased expression of the pro-apoptotic molecule Bax but did not affect 
expression of the anti-apoptotic molecule Bcl-xl (Figure 3.17 B). 
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Figure 3.15. Analysis of caspase 3 activation and PARP cleavage in fucoidan-induced 
apoptosis by Western blot. NB4 cells were treated with various concentrations of fucoidan 
for 24 hours and cytoplasmic and nuclear fractions were isolated. GAPDH and SP1 were 
used as cytoplasmic and nuclear loading controls, respectively. 
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Figure 3.16. Effects of caspase inhibitor on fucoidan induced apoptosis. NB4 cells were pre-treated with Caspase inhibitor Z-Vad-fmk (40µM) for 1 
hour followed by treatment with fucoidan for 24 hours. A) Cell proliferation was assesed using WST-8 proliferaton assay. B) Apoptosis was analysed 
using Annexin V/PI apoptosis assay. Mean ± SEM of at least three replicates is shown. Statistical significance was determined by two-way ANOVA, 
followed by Bonferroni post-test (***: p≤ 0.001). 
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Figure 3.17. Analysis of the expression of apoptosis related proteins in A) extrinsic 
pathway B) intrinsic pathway by Western blot. NB4 cells were treated with 50 µg/mL 
fucoidan for 24 hours and cytoplasmic fraction was isolated. Protein expression levels of 
cleaved caspase 8, DR5, Fas, cleaved caspase 9, Bcl-xl and Bax were analysed using specific 
antibodies. The cytoplasmic protein β-actin was used as loading control. 
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3.3.3.5 Fucoidan Changed the expression of Cell Cycle Proteins 
Since fucoidan altered the distribution of cell cycle phases in NB4 cell lines, the expression of 
cell cycle regulatory proteins P21/WAF1/CIP1 and cyclin D1 were examined using Western 
blotting. The cyclin dependent kinase inhibitor P21/WAF1/CIP1 is a negative cell-cycle-
regulatory protein. Treatment with 50 µg/mL fucoidan for 24 hours induced a marked increase 
in P21/WAF1/CIP1 expression in NB4 cells. No changes were seen in cyclin D1 expression 
(Figure 3.18). 
 
 
 
 
 
Figure 3.18. Analysis of the expression of cell cycle related proteins by Western blot. 
NB4 cells were treated with 50 µg/mL fucoidan for 24 hours and nuclear fraction was 
isolated. Protein expression and P21/WAF1/CIP1 and cyclin D1 were analysed using specific 
antibodies. The nuclear protein SP-1 was used as loading control. 
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3.3.3.6 Fucoidan Deactivated ERK1/2 and Decreased Phosphorylation of AKT on Thr308 
Residue.  
MAPK and PI3k/AKT signal transduction pathways play major roles in cell proliferation and 
apoptosis, hence both expression and activation levels of two main kinases were examined in 
these pathways; ERK in the MAPK pathway and AKT in the P13K pathway. Whilst total 
protein expression level of these two enzymes was not altered with fucoidan treatment of NB4 
cells, the phosphorylation of both AKT and ERK1/2 enzymes was clearly down-regulated 
(Figure 3.19), AKT is a serine/threonine-specific protein kinase and has two different 
phosphorylation sites; Thr308 and Ser473. By examining the phosphorylation status of AKT 
at both sites it was found that fucoidan did not alter the phosphorylation of AKT on the Ser473 
site in APL cells, but it down-regulated the phosphorylation of AKT on the Thr308 residue as 
indicated. 
 
 
 
 
 
 
 
 
 
 
Figure 3.19. Analysis of the signal transduction pathways involvement in fucoidan-
mediated apoptosis by Western blot. NB4 cells were treated with 50 µg/mL fucoidan for 24 
hours. Protein expression and phosphorylation levels of ERK and AKT were analysed using 
specific antibodies. The cytoplasmic protein β-actin was used as loading control. 
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3.3.3.7 Cellular Signalling and Fucoidan  
To investigate whether fucoidan enters into the cells or functions as an extracellular stimulus, 
NB4 cells were pre-treated with various concentrations of monensin, an endocytosis blocker, 
for 2 hours following treatment with fucoidan for 24 hours. Cell proliferation was analysed 
using WST-8 proliferation assay. It was observed that the endocytosis blockage did not prevent 
the NB4 cell growth inhibition induced by fucoidan (Figure 3.20). However, since the 
endocytosis blocker itself had growth-inhibitory effect and reduced the proliferation of NB4 
cells, the obtained combined-(fucoidan+blocker)-treated-cells data were normalised according 
to blocker only-treated cells. After normalization, no significant difference was observed 
between fucoidan-treated cells with or without pre-treatment with endocytosis blocker (Figure 
3.21). Pre-treatment with endocytosis blocker did not restore the reduced cell proliferation 
caused by fucoidan. 
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Figure 3.20. WST-8 proliferation assay in NB4 cells pre-treated with endocytosis 
blocker; monensin. NB4 cells were pre-treated with an endocytosis blocker for 2 hours 
following treatment with fucoidan for 24 hours. Cell proliferation was assessed using WST-8 
proliferation assay. Mean ± SEM of at least three replicates is shown. Statistical significance 
was determined by two-way ANOVA, followed by Bonferroni post-test. 
 (***: p≤ 0.001, *: p≤ 0.05) 
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Figure 3.21. WST-8 proliferation assay in cells pre-treated with endocytosis blocker, 
monensin, after data normalization. NB4 cells were pre-treated with an endocytosis 
blocker for 2 hours following treatment with fucoidan for 24 hours. Cell proliferation was 
assessed using WST-8 proliferation assay. The data were normalised according to blocker-
only-treated cells. Mean ± SEM of at least three replicates is shown. Statistical significance 
was determined by two-way ANOVA, followed by Bonferroni post-test.  
(***: p≤ 0.001, **: p≤ 0.01*: p≤ 0.05) 
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3.4 Discussion 
Analysis of the tumour inhibitory effect of fucoidan in various types of AML revealed that 
fucoidan specifically inhibited the growth of the APL cell lines NB4 and HL60. The growth-
inhibitory potential of fucoidan in APL cells was mainly due to activation of caspases and 
inactivation of pro-survival signalling pathways. The data presented here also shows the 
differing activity of fucoidan from different sources. 
 
3.4.1 Fucoidan Metabolism and Variable Activities of Fucoidan from 
Different Sources 
Despite the promising findings about the anti-cancer effect of fucoidan, there are still 
challenges impeding utilization of fucoidan in the clinic. The overall review of the literature 
demonstrates wide variability of the effects of fucoidan in different studies. The differences 
and the controversies between the results mainly stem from the variable nature of fucoidan 
(including its structure and molecular weight) depending on its source, amongst other factors.  
In this thesis, fucoidan extracts from various sources revealed different activities. The purified 
fucoidans from two seaweed sources (U. pinnatifida and F. vesiculosus) supplied by Marinova 
Pty. Ltd. did not affect cell proliferation and DNA content even at the very high doses of 2 
mg/mL. In contrast, the fucoidan from F. vesiculosus from Sigma-Aldrich Co. highly inhibited 
the growth of AML cell lines. 
It is well known that the difference in molecular backbone structures of fucoidan extracts can 
result in differences in their bio-properties. Fucoidan structure differs depends on various 
factors such as the harvest season, seaweed sources, the parts of the plant, extraction and the 
purification methods used and the stage of development of the algae. The fucoidan extract from 
F. vesiculosus supplied by Sigma-Aldrich Co. is prepared by dissolving the crude fucoidan in 
deionised water, acidified to precipitate algenic acid, centrifuged, filtered and lyophilised 
whereas Marinova Pty. Ltd. supplied fucoidans are extracted using a cold water technique. We 
believe that differential structural changes observed in the composition analysis of different 
fucoidans could have been due to different extraction methods.  
Sulphate content has the most essential role in bioactivity of fucoidan. The use of de-sulphated 
and over-sulphated fucoidan with the sulphate content varying from 6% to 41% has shown that 
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the minimum necessary sulphate content for anti-proliferative activity of fucoidan against 
CCL39 fibroblast cells is 20% (227). Here, fucoidans from both sources had almost similar 
amount of near 27% sulphate, as a result sulphate content cannot be the reason for the 
differential results. The position of sulphate groups in the molecule structure has also a key 
role in the function of polysaccharides (228), which was not analysed in this study.  
Molecular weight is another factor which plays role in fucoidan bioactivity. Here, the MW for 
purified fucoidan from U. pinnatifida from Marinova Pty Ltd. was three times more than that 
of the fucoidan from F. vesiculosus from Sigma-Aldrich Co. (60 kDa vs 20 kDa). Cho and 
colleagues produced three fucoidan fractions with molecular weights of <5, 5–30 and >30 kDa 
and compared their anti-cancer activity in vitro. Interestingly, the F5-30K revealed the most 
tumour growth inhibitory effect despites the sulphate amount in F<5K was greater than that of 
two other fractions (229). 
Another significant difference between Sigma-Aldrich Co. and Marinova Pty Ltd. supplied 
fucoidans was presence of significantly higher amount of uronic acid in the structure of 
fucoidan from Sigma-Aldrich Co. (more than 4 fold). Uronic acids are acidic carbohydrates, 
structurally similar to monosaccharaides -except having carboxyl group (COOH) instead of 
CH2OH radical in monosaccharaides (230)-, and can be located in the repeating units of 
polysaccharides (231). Uronic acids are stable structures in the fucoidan molecule and can be 
prevalently bound to sulphate groups. Different studies have indicated a critical role for uronic 
acid in the biological activity of polysaccharides (232). In addition, due to the significance of 
uronic acid in polysaccharide functionality, new studies have attempted to assemble more 
active molecules by synthesis of uronic acid building blocks (233).  
Rosenberg et al. (234) compared the structure of highly active and relatively inactive 
preparations of heparin, a sulphated polysaccharide which has marked structural and functional 
resemblance to fucoidan (235), and showed that the highly active heparin contained a greater 
number of uronic acid residues than the relatively inactive substance. In addition, in highly 
active heparin, a large number of non-sulphated uronic acid residues were located in a 
restricted region of the molecule or at penultimate positions within the polysaccharide chain, 
whereas the sulphated uronic acids presented in the main structure. In another study, the anti-
tumour activity of 31 different polysaccharides isolated from a brown seaweed against Ehrlich 
carcinoma was tested in mice. Among those, only L-fucan and fucoidan containing 
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approximately 10% uronic acid exhibited anti-tumour potential (236). Here, the amount of 
uronic acid in Marinova Pty. Ltd. supplied purified fucoidan from U. pinnatifida was near 1.5% 
compared to 6% in Sigma-Aldrich Co. supplied fucoidan from F. vesiculosus. Although the 
position of sulphate and uronic acid on fucoidans’ structure was not examined in this study, the 
significantly low amount of uronic acid in purified fucoidan molecule from Marinova Pty. Ltd. 
might explain its inactivity.  
One factor that can make the results challengeable is the presence of 3.9% polyphenol in the 
fucoidan from Sigma-Aldrich Co. Polyphenol is a phytochemical widely distributed in plants 
including marine plants such as seaweeds and is reported to have anti-oxidant and cytotoxic 
effects (237). As purification of the product was not carried out, it is not clear how much the 
presence of 3.9% polyphenols could have interfered with the cytotoxic effects of the fucoidan. 
Another important unanswered question is that whether fucoidan penetrates into the cell and 
directly performs its activities or remains outside of the cells and exerts its functions through 
attachment to surface receptors and downstream molecules. To answer to this question, cells 
were pre-treated with an endocytosis blocker (monensin) to prevent the entrance of fucoidan 
into the cells. The cell proliferation was then analysed 24 hours after treatment with fucoidan. 
Upon NB4 cell treatment with monensin (alone or in combination with fucoidan), it was 
observed that the monensin itself decreased the NB4 cell proliferation. Monensin is a 
monovalent ion-selective ionophore that prevents the internalization of a variety of ligands. It 
also acts as a Golgi apparatus plug and interferes with vesicular transport. It is established that 
monensin decreases cell proliferation and induces cell death through mitochondrial damage 
and dilatation of the Golgi apparatus in various tumour cells (238). Park et al. showed the 
antiproliferative effects of monensin through cell cycle-related proteins such as p27 in AML 
cell lines (239). Data obtained in this project is consistent with these findings. Similar to 
monensin, fucoidan induces apoptosis via different apoptosis and cell cycle related proteins. 
This may explain the enhanced reduction of cell proliferation in NB4 cells when they were co-
treated with both fucoidan and monensin. 
The data represented here showed that the endocytosis blocker did not restore the apoptosis 
mediated by fucoidan. Since the monensin itself had growth inhibitory effect, the combination 
data were normalised accordingly and yet still endocytosis blockage did not restore the reduced 
cell proliferation by fucoidan suggesting that fucoidan’s action is not associated with its 
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entrance into the cell. Nevertheless, since hydrophobicity of the molecule plays a crucial role 
in its transport across the membrane I believe that this result is not strong enough to conclude 
that fucoidan does not enter the cells and performs its action via surface receptors and 
downstream molecules. In 2002, Deux et al. evaluated the internalisation of LMW fucoidan 
into rabbit smooth muscle cells (SMCs). Fucoidan was shown to be internalised by endocytosis 
at 6 h and the number of vesicles containing fucoidan increased in the peri-nuclear region at 24 
h. However, they did not observe fucoidan’s nuclear internalisation at any time during the study 
(150). In contrast, Kimura et al. investigated the transport of a native fucoidan from 
Cladosiphon okamuranus (MW: 80 kDa) and reported a poor permeation of fucoidan across 
the human colon adenocarcinoma Caco-2 cell monolayer (151). To investigate this further, it 
is suggested that the penetration of fucoidan be analysed using high-performance liquid 
chromatography (HPLC) in whole cell lysate after treatment with fucoidan. This could also be 
assessed using cell imaging system when an antibody against fucoidan becomes available.  
 
3.4.2 Cytotoxic Effects of Fucoidan on different AML cells 
In this chapter, the examination of tumour inhibitory effect of fucoidan in various types of 
AML showed that fucoidan specifically induced apoptosis in APL cell lines (NB4 and HL60), 
but not other AML cell lines. HL-60 cells are negative for t(15;17) whereas NB4 cells are 
positive for t(15;17). The induced cell death was observed in both cell lines indicating that the 
translocation t(15;17) is not required for fucoidan activity.  
Induction of apoptosis is one of the key pathways exploited by anti-cancer agents and is 
activated through either the extrinsic pathway which is activated by a death receptor located on 
the cell membrane or the intrinsic pathway which is activated by Bcl-2 family followed by 
downstream mitochondrial signals. Kim et al. and Lee et al. reported that fucoidan from a 
similar source as ours induced tumour cells apoptosis via activation of caspases (167, 240). In 
contrast, Costa et al. demonstrated that the apoptosis mediated by fucoidan (from Sargassum 
filipendula) in Hela cells was caspase-independent (172). Zhang et al. however reported that 
fucoidan from Mozuku increased activation of caspase 9 only and not caspases 7 or 8 in MCF-
7 breast cancer cells (160). These results imply that the action of fucoidan is highly dependent 
on cell type and fucoidan source. In this thesis, fucoidan activated caspase 8 and this was 
correlated to activation of death receptor DR5 (TNF-related apoptosis-inducing ligand 
Chapter 3                                                                             Cytotoxic Effects of Fucoidan on AML Cells 
 
 
Page 108 
 
(TRAIL) receptor II). Caspase 9 was also activated by fucoidan’s action and this was correlated 
with upregulation of the pro-apoptotic molecule Bax.  The pan-caspase inhibitor, Z-VAD-fmk, 
significantly prevented fucoidan-mediated apoptosis, suggesting that caspases are essential in 
fucoidan-induced apoptosis. Taken together, fucoidan induces apoptosis in APL cells through 
both intrinsic and extrinsic pathways. 
The cyclin dependent kinase inhibitor P21/WAF1/CIP1 is a negative cell-cycle-regulatory 
protein. Transcriptional activation of P21/WAF1/CIP1, either p53-dependent or independent, 
inhibits the accumulation of cyclin-CDK complexes and therefore causes G1/S and G2/M 
arrest. The cell cycle arrest caused by P21/WAF1/CIP1 has also been shown to stimulate the 
cleavage of caspase 9 resulting in apoptosis within the cell (241). Data presented here 
demonstrated that fucoidan led to accumulation of P21/WAF1/CIP1 in APLL cells. This is 
supported by others (163, 166) who have demonstrated the involvement of fucoidan in 
P21/WAF1/CIP1 upregulation in prostate and bladder cancer cell lines, respectively. 
MAPK and PI3/AKT are key components of the signalling pathways involved in cell 
proliferation and transmit signals through enzymes such as Raf, MEK, ERK and AKT (155). 
Since fucoidan has been shown to target cell survival and apoptosis processes, it is 
hypothesised that the mechanism of action is inducing changes in the activation of signalling 
pathway molecules. Here, expression and activation of two kinases involved in these key 
signalling molecules were evaluated; ERK and AKT in the MAPK and P13K pathways 
respectively. Fucoidan reduced activation of both enzymes through hypo-phosphorylation, but 
it did not alter their total expression levels. 
PI3K/AKT is a signal transduction pathway whose activation mediates multiple biological 
processes such as cell survival, growth and proliferation and inhibits apoptosis. AKT is one of 
the key enzymes in this pathway and, as mentioned, fucoidan suppressed AKT activation, 
leading to cell death. Our findings regarding the observed inactivation of AKT are similar to 
those of others (171, 242). It has also been reported that AKT over-activation is associated with 
drug resistance, tumour cell survival and migration (243). AKT activation occurs following 
phosphorylation of two different residues: Thr308 (in the activation loop) and Ser473 (in the 
C-terminal hydrophobic motif). Activation of Thr308 and not Ser473 correlates with poor 
prognosis in AML (244). The analysis of the phosphorylation of AKT in both Thr308 and 
Ser473 residues indicated that fucoidan did not alter the phosphorylation of AKT on the Ser473 
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site in APL cell lines, but it down-regulated the phosphorylation of AKT on the Thr308 residue. 
This is the first study that has reported a selective effect of fucoidan on AKT phosphorylation 
sites.  
In this study, fucoidan markedly inactivated ERK. Studies by Patel et al. and Aisa et al. also 
showed that the anti-mitogenic property of fucoidan is mediated by hypo-phosphorylation and 
deactivation of ERK1/ERK2 in vascular smooth muscle cells and in human lymphoma cells, 
respectively (155, 182). In contrast, Hsu and colleagues proposed that fucoidan causes ERK 
activation rather than inactivation (190). It is known that the ERK signalling pathway is 
complex and induces a range of different responses including cell proliferation, differentiation, 
migration and even apoptosis depending on cell type, the type of stimulus and duration of 
activation. For instance, it is generally believed that the ERKs progress cell proliferation in 
most types of cells, while in some studies, the ERKs have shown pro-apoptotic (and not 
mitogenic) influences on renal cell lines (245). In contrast to this thesis, Jin and colleagues 
reported activation of ERK in NB4 and HL60 cells (170). It should be highlighted that duration 
of activation and timing are the main variables in signal transduction pathways studies. ERK 
activation was measured after 24 hours but in the study by Jin et al., the ERK activation was 
measured after only 15 minutes.  
In contrast to APL cell lines, fucoidan did not induce apoptosis in the AML cell lines KG-1a 
and K562. This cell-type specific growth inhibitory activity of fucoidan has been previously 
reported. Fukahori et al. examined 6 different hepatocarcinoma cell lines revealing selective 
and differing inhibitory effects of fucoidan (169). Cell lineage and maturation stage of 
haematopoietic cells are governed by altered regulation and differential expression of sets of 
genes in different pathways and these differences are likely to affect the cell response to drugs. 
The CD34+/CD38- cells isolated from both K562 and KG-1a cell lines are reported to have less 
phosphorylated p38 MAPK than those isolated from human cord blood (246). It has been 
suggested that this reduced phosphorylation of p38 may reduce the sensitivity of these cell 
types to activation of apoptosis. Xiao et al. showed that modification of p38 through over-
phosphorylation induced growth arrest and apoptosis in both K562 and KG-1a cell lines (246). 
Previously published studies have also reported that fucoidan induces apoptosis in monocytic 
U937 cells through p38 activation (247). Here, it is hypothesised that lower phosphorylation 
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of p38 in K562 and KG-1a cell lines could possibly protect them against the anti-tumour 
activity of fucoidan. 
In agreement with data obtained here, Jin et al. also reported that fucoidan does not induce 
apoptosis in K562 cells (170). However, the cell proliferation study in this project revealed that 
fucoidan slightly decreased proliferation of K562 cells after 48 hours. To investigate this 
further, the DNA content was analysed and a marked increase in G0/G1 cell population was 
found in treated K562 cells. This indicates that fucoidan induces cell cycle arrest without 
switching on the apoptosis pathway in this cell type. Unlike the NB4, HL60 and K562 cell 
lines, the undifferentiated AML cell line KG-1a was resistant to the growth inhibitory function 
of fucoidan. In DNA content analysis, fucoidan induced neither cell cycle arrest nor sub G0/G1 
dead cell population.  
In summary, it is concluded that fucoidan’s action against tumour cells is cell-type specific and 
further that APL cells showed higher response to fucoidan. Fucoidan was found to reduce the 
activation of ERK1/2 and AKT in APL cells and induce the activation of caspases 8, 9 and 3 
where fucoidan’s action was attenuated using a pan-caspase inhibitor. 
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 Chapter Four –Prophylactic Anti-Tumour Activity of Fucoidan in 
AML
Prophylactic Anti-Tumour 
Activity of Fucoidan in AML 
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4.1 Introduction 
Seaweed, a common food source in Asian countries, is rich in bioactive metabolites such as 
poly-phenols, sulphated polysaccharides (fucoidan and laminarin) and primary carotenoid 
(fucoxanthin). Epidemiological and experimental evidence supporting the protective effect of 
these active ingredients against cancer development have been growing in the last three decades 
(248-251). Epidemiological studies have supported this with reports of low risk and mortality 
from certain types of cancers in populations with daily consumption of seaweeds.  
Japanese women with regular seaweed consumption are reported to have 1/3 the rate of 
premenopausal and 1/9 the rate of postmenopausal breast cancers (252). The risk of cancer 
between seaweed- to non-seaweed-consuming American postmenopausal women has been 
also evaluated in a clinical trial (253). In this study, consumption of 5 g / day brown seaweeds 
for duration of one month resulted in 50% reduction in systematic concentration of the Uri-
kinase receptor (uPAR) whose overexpression is associated with higher risk of cancer and 
tumour cell invasion and metastasis (254). 
The anti-cancer activities of the dietry seaweed have been further explored. Teas et al. reported 
a significant delay in adenocarcinoma development in female rats fed with dietary Seaweed 
(Laminaria) (188). In 1991, Furusawa et al. investigated the prophylactic activity of a dietary 
seaweed Undaria pinnatifida extract, referred as Viva-Natural, against Rauscher murine 
retrovirus-induced erythroleukaemia (255) which is characterised by development of 
splenomegaly within 2-3 weeks after virus inoculation. They pre-treated mice with IP 
administration of seaweed extract on day 3 or day 1 or 1 hour prior to virus inoculation and 
analysed the leukaemia progression on day 21. Pre-treatment on 3 days prior to inoculation 
significantly inhibited the growth of leukaemic cells. Pre-treatment with the extract was not 
effective on tumour growth when administrated on day -1 or 1 h before virus inoculation (256). 
It has been subsequently found that fucoidan is the main brown seaweed ingredient which 
possessed tumour inhibitory effects. Despite the reported anti-tumour activity of fucoidan in 
different types of cancers, very little in vivo work has focused on protective activity of fucoidan 
against cancer development; but rather has focused on its therapeutic effects after tumours have 
been established in animals.  
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Several theories have been proposed about prophylactic activity of fucoidan. One hypothesis 
is its anti-oxidant activity. The association between oxidative stress involving active states of 
oxygen and tumourigenesis process is well established (257). Oxidative stress agents, or free 
radicals such as reactive oxygen species (ROS) and reactive nitrogen species (RNS) (e.g. 
hydrogen peroxide and nitric oxide) are highly reactive chemicals that harm cells through 
damaging lipids, proteins and DNA (258). Antioxidants function as free radical scavengers and 
protect cells against oxidative damages. Rocha de Souza et al. study has shown that fucoidan 
exhibits the highest antioxidant and superoxide radical scavenging activity amongst different 
polysaccharides derived from brown seaweeds (259). In vitro and in vivo evidences have also 
indicated that fucoidan prevented the free radical synthesis, reversed the oxidative damages 
and restored the increases in free radicals in the spleen tissue caused by oxidative agents (260). 
 The second hypothesis arises from the demonstrated immunomodulatory activity of fucoidan 
(261). Fucoidan enhanced the anti-tumour immune response through various pathways 
including increased phagocyte activity of macrophages (262), enhanced functional maturation 
of dendritic cells (263), and increased number of NK and cytotoxic T-cells (185). It also 
modulated the production of cytokines by immune cells. Interferon-γ (IFN-γ) is a cytokine that 
promotes the innate and adaptive immune responses and has a critical protective role against 
tumour development. Fucoidan markedly increased the intracellular level of IFN-γ in NK cells 
in vitro (264), and elevated secretion of IFN- γ in serum in vivo (187).  
The aim of this chapter was to investigate the prophylactic activity of fucoidan against human 
acute myeloid leukaemia development in mice. To determine the immunomodulatory activity 
of fucoidan was the second aim of this chapter. To address this, the splenic natural killer cell 
cytotoxicity activity was examined in mice that were orally pre-treated with fucoidan.  
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4.2 Experimental Design 
4.2.1 Analysis of Prophylactic Activity of Fucoidan in Vivo 
The acute promyelocytic leukaemia NB4 cells were selected as they were sensitive to fucoidan. 
NB4 cells provide a suitable model for xenograft human APL. Five to seven week old BALB/c 
athymic nu/nu mice were randomly divided into two groups; the control group (n=8) and the 
fucoidan group (n=9) (Table 4.1). The animals in the fucoidan group were daily fed with 150 
µg/g b.w. fucoidan from F. vesiculosus (Sigma-Aldrich Co.) mixed with peanut butter for two 
weeks (see Section 2.9.4.1). The control group was fed with the same amount of peanut butter 
mixed with vehicle (distilled water). The animal’s body weight was measured daily in both 
groups until the end of the study and doses were calculated daily according to body weight. 
After 14 days, NB4 cells were injected subcutaneously in the right flank of each mouse and the 
xenograft tumour appearance and growth were monitored daily. When the transplanted tumour 
volume reached 1000 mm3, the mice were humanely euthanised (see Section 2.9.7). Tumour 
volume doubling time and tumour growth rate were calculated for each mouse.  
Table 4.1. The Number and Gender of Mice Used for Prophylactic Study 
 Control Fucoidan 
Female 4 4 
Male 4 5 
Total 8 9 
 
4.2.1 Analysis of Immunomodulatory Activity of Fucoidan in Vivo 
To investigate the underpinning mechanism of the prophylactic activity of fucoidan on tumour 
growth, the immunomodulatory effect of fucoidan and its role in mice’s NK cell function was 
investigated. To do this, twelve 5-7 week old male BALB/c athymic nu/nu mice were randomly 
divided into two groups; the control group (n=6) and the fucoidan group (n=6). Animals were 
fed with 150 µg/g b.w. fucoidan (Sigma Co.) or distilled water in peanut butter (as described 
in Chapter 2). After 14 days, the mice were humanely euthanised with inhalation of CO2 and 
the cytotoxic activity of spleen NK cells was investigated using flow cytometry (see Section 
2.9.10). 
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4.3 Results 
(This section has been substantially published in Atashrazm et al. 2015 (221)) 
 
4.3.1 Oral Fucoidan Delayed the AML Appearance and Growth in Mice 
To analyse the protective activity of fucoidan on leukaemia development, 17 mice were pre-
fed with fucoidan followed by tumour cell injection and the effect of orally administered 
fucoidan on subcutaneous xenograft tumour development was examined. Three out of eight 
female mice including 1 in control group and 2 in fucoidan group did not develop tumour for 
up to 50 days. As a result the experimental animals were limited into 14 mice: 7 in each control 
and fucoidan group. No signs of toxicity were observed in mice fed with fucoidan. 
No significant difference was observed in body weight in animals and it slightly increased in 
both control mice and fucoidan mice; mean ± SD of body weight gain was 3.25±1.65 g and 
3.85±1.95 g in control and fucoidan groups, respectively (see Appendix D).  
Significant anti-tumour activity was observed in mice fed with fucoidan compared to the 
control (p≤0.001) (Figure 4.1). Following inoculation with NB4 cells the subcutaneous tumour 
mass appeared in less than 10 days in 5 out of 7 mice in the control group and 2 out of 7 mice 
in the pre-treated fucoidan group. The mean of doubling time for the tumour mass was 1.8 days 
in the control group compared to 4.64 days in the fucoidan group. The growth rate which is the 
number of volume doublings that occurred per day was also calculated. The mean of tumour 
growth rate was 0.37 in the control group and 0.23 in the fucoidan groups. 
The tumour size reached the end point in less than 12 days after tumour appearance in all mice 
in the control group compared to 1 mouse in the fucoidan group. Figure 4.2 shows the tumour 
mass at day 19 after tumour cell injection in two representative mice from fucoidan and control 
groups. Figure 4.3 compares the tumour volume in both groups at four-day intervals for up to 
12 days when all mice in control group were sacrificed. 
Chapter 4                                                         Prophylactic Anti-Tumour Activity of Fucoidan in AML 
 
 
Page 116 
 
 
 
Figure 4.1. Tumour appearance and growth in mice fed with vehicle or fucoidan. Mice were fed with fucoidan or vehicle for 14 days 
(n=7/group). NB4 cells were injected into mice and tumour volume was measured daily. Each line represents the daily tumour volume in one 
mouse in fucoidan group (green) and control group (red). 
* Due to tumour rupture, two mice (1/group) were sacrificed before the tumour size reached the end point.  
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Figure 4.2. Representative tumour mass at day 19 after NB4 cells injection. Mice were 
either fed with fucoidan or vehicle for 14 days. NB4 cells were then injected SC in the mice’s 
right flank. The images demonstrate the tumour mass in one mouse in each group at day 12 
after injection. 
 
 
 
 
 
Figure 4.3. tumour Volume in fucoidan and control groups at 4-day intervals. Mice were 
fed with fucoidan or vehicle for 14 days (n=7/each group). NB4 cells were injected into mice 
and tumour volume was measured daily. The tumour mass in all control mice reached the end 
point within 12 days after the tumour appearance. The columns and bars represent mean ± SD 
(***: p≤0.001, *: p≤0.05). 
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4.3.2 Fucoidan Increased Splenic NK-cell Activity in Vivo 
Given our observation and the known immunomodulatory activity of fucoidan, it was 
hypothesised that fucoidan increases the cytotoxic activity of splenic NK cells when it is orally 
administrated. Twelve additional mice were fed with either fucoidan or distilled water (6 in 
each group) for 14 days and the mice were humanely euthanised and their spleen was removed. 
The viability of isolated splenic mononuclear cells (MNCs) was assessed using trypan blue 
exclusion and was more than 90% for all animals. 
To measure the ability of MNCs to lyse the NK cell-sensitive YAC-1 cells, the target YAC-1 
cells were first labelled with the fluorescent dye CellTrace™ Violet (CTV). As shown in Figure 
4.4A, YAC-1 cells 100% labelled with CTV was established before being used for the 
experiment. The CTV+ YAC-1 cells were then combined with effector MNCs at effector cells 
to target cells ratios of 3:1, 6:1, 12:1, 25:1, 50:1 and 100:1. Each sample was plated in triplicate 
and a control YAC-1 cell sample was included. After 4 hours incubation, the dead YAC-1 cells 
were measured using PI staining with flow cytometer. The amount of spontaneous dead YAC-
1 cells was measured in YAC-1 control wells only (Figure 4.4B). To calculate the specific 
YAC-1 cell lysis by NK cells, the amount of spontaneous dead YAC-1 cells in control wells 
was subtracted from the results of the experiments (Figure 4.4C). The results for one 
representative mouse in each group are shown in Figures 4.5 and 4.6.  
As shown in Figure 4.7, the cytotoxic activity of NK cells from the fucoidan group was higher 
than that of the control group in all six effector to target cells ratios (p=0.3). The difference 
was statistically significant at 50:1 and 100:1 effector:target cells ratio (p≤0.05, p≤0.001 
respectively). This result suggests that consumption of fucoidan can modulate the innate 
immune system by increasing the cytolytic activity of NK cells. 
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Figure 4.4. Flow cytomety histograms for NK cell cytotoxicity assay in one representative 
experiment. The YAC-1 cells were labelled with CTV and used as targets for splenic NK cells 
as effectors. Left histograms show cell population based on size (FSC) and granularity (SSC). 
Debris was excluded and the remaining cells were gated as “Gate A”. Middle histograms show 
PI versus CTV in “Gate A” population. The CTV+ cells were gated as “Gate B”. Right 
histograms show PI versus CTV in “Gate B” population. Results from this histogram were used 
for calculation.  
A) “CTV-labelled target cells only” without PI. This control was used to ensure all target 
cells were labelled with CTV. As shown in the middle graph, all YAC-1 cells were 100% 
labelled with CTV. The CTV+ cells were gated and used for NK cell-mediated cytotoxicity 
analysis. B) “CTV-labelled target cells only” with PI. The 0:1 effector to target cells were 
used as the minimum control cells. The amount of PI+ dead YAC-1 cells (green population) 
was calculated as spontaneous cell death. C) CTV-labelled target cells plus effector cells. 
Splenic mononuclear cells obtained from each mouse were added to the target cells. The 
amount of PI+ dead YAC-1 cells (green population) was calculated. The percentage of 
spontaneous dead cells was subtracted from these results.  
Red population: live target cells (CTV+/PI-), Green population: dead target cells (CTV+/PI+), 
Purple population: effector cells (CTV-) 
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Figure 4.5. NK cell cytotoxicty assay in one representative mouse in control group. Mice 
were fed with vehicle for 14 days (n=6). Splenic mononuclear cells were isolated and NK cell 
cytotoxicity was analysed using flow cytometry. The CTV+ YAC-1 cells were used as targets 
for splenic NK cells (effectors). The dead YAC-1 cells were analysed with PI staining. Each 
histogram demonstrates the live (red) and dead (green) YAC-1 cells in various dilutions of 
effector:target. To measure the spontaneous cell death, minimum control cells (0:1) containing 
target cells only were prepared. Results represent one of three replicates in 1 out of 6 mice. 
Red population: CTV+/PI- (live target cells), Green population: CTV+/PI+ (dead target cells) 
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Figure 4.6. NK cell cytotoxicty assay in one representative mouse in fucodian group. Mice 
were fed with fucoidan for 14 days (n=6). Splenic mononuclear cells were isolated and NK cell 
cytotoxicity was analysed using flow cytometry. The CTV+ YAC-1 cells were used as targets 
for splenic NK cells (effectors). The dead YAC-1 cells were analysed with PI staining. Each 
histogram demonstrates the live (red) and dead (green) YAC-1 cells in various dilutions of 
effector:target. To measure the spontaneous cell death, minimum control cells (0:1) containing 
target cells only were prepared. Results represent one of three replicates in 1 out of 6 mice. 
Red population: CTV+/PI- (live target cells), Green population: CTV+/PI+ (dead target cells) 
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Figure 4.7. Splenic NK cell cytotoxicity. Percentage of dead targets cells (YAC-1 cells) in 
mice fed with fucoidan (green) and control mice (red) were calculated (n=6/group). Data 
represent mean ± SD. Statistical significance was determined by two-way ANOVA, followed 
by Bonferroni post-test (***: p≤ 0.001, *: p≤0.05). 
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4.4 Discussion 
Data in this chapter presents evidence that fucoidan has protective effects against development 
of acute promyelocytic leukaemia in a xenograft mouse model. APL appearance and growth 
were significantly delayed in mice that were pre-fed with fucoidan. This was possibly through 
modulation of immune system as fucoidan enhanced cytolytic activity of NK cells in mice. 
4.4.1 Protective Effect of Fucoidan against AML development in Mice 
A large number of epidemiologic, animal and laboratory studies indicate that dietary factors 
play a key role in cancer prevention and progression. Several studies have associated 
consumption of seaweeds containing fucoidan with low risk of cancers (265). The preventive 
effect is highly related to the anti-inflammatory and immunomodulatory activities of this 
component. Herein, the prophylactic effects of fucoidan on an acute myeloid leukaemia mouse 
model were examined. Development of APL following NB4 cell inoculation was investigated 
in mice that were pre-fed with fucoidan and it was observed that fucoidan significantly 
protected mice against APL development. 
Few studies have shown that fucoidan inhibits the neoplastic transformation. In a study by Teas 
et al., a group of female Sprague-Dawley rats were fed with dietary seaweed (laminira) for 34 
days and then were given carcinogen 7,12-dimethylbenz(a) anthracene. Feeding was continued 
per day for the entire period of the study. The animals were monitored for 26 weeks and the 
rate of tumour development was examined. Experimental rats showed a significant delay in 
tumour appearance; the median time from carcinogen administration until first tumour 
appearance was 19 weeks in the seaweed-fed rats and 11 weeks in the control rats (253). The 
delayed tumour appearance observed in Teas et al. study is similar to results in this Chapter. 
Although mice were treated for a shorter period of time than their study and feeding was not 
continued after tumour inoculation, fucoidan still could protect the animals against tumour 
development. 
In a recent study by Huang et al, oral administration of fucoidan prophylactically alleviated 
cachectic symptom of lung carcinoma (266). In their study inoculation of Lewis lung 
carcinoma cells in mice resulted in body weight loss in tumour-bearing animals compared to 
non-bearing-tumour control mice. But mice orally fed with fucoidan (1 or 3 mg /mouse) had 
significant increase in the body weight compared to tumour-bearing mice receiving water. In 
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this thesis, there was no significant difference in body weight, and animals in both control and 
fucoidan groups slightly gained similar amount of weight during the study. Difference between 
these results and those of Huang et al. study may be due to various tumour model used as they 
established systematic tumour through IV injection of tumour cells while the model developed 
here was a subcutaneous transplanted tumour. 
Data presented in this chapter of thesis showed that the utilised animal model had some 
limitations as 37.5% of female mice (3 out of 8) did not develop tumours. Prior to commencing 
the main experiments and to investigate whether xenograft transplantation with human NB4 
cells would be feasible in nude mice, 5 female mice were obtained and injected subcutaneously 
with NB4 cells (Data not shown). It was demonstrated that 40% of mice (2 out of 5) from that 
batch also did not develop tumour for up to 3 months. In contrast, the xenograft transplantation 
in male mice was 100% successful and all mice grew tumour within 7-14 days. Due to these 
observations, the experiments evaluating the immunomodulatory activity of fucoidan were 
conducted on male mice only. The reason behind the tumour establishment failure in female 
mice is not clear to us. Several studies have used female nude mice for establishment of 
different types of cancers including NB4 cells (267, 268). In a report by Zhang et al., NB4 cell 
transplantation into nude mice was unsuccessful in their unpublished data (269). However, they 
did not report whether or not the unsuccessful tumour growth was sex dependent. The 
hormone-rich environment presenting in females might be one of the factors that affected the 
NB4 cell growth. Moreover, some nude mice have been shown to have extra-thymic T-cells, 
which can affect the tumour development. Hence optimization assays are suggested for cancer 
research using xenograft transplantation in nude mice. Moreover, it is suggested that using 
NOD-SCID mice (non-obese diabetic-severe combined immunodeficiency) might be a better 
choice for xenograft models as they lack T-cells, B-cells and NK cells. 
4.4.2 Immunomodulatory Activity of Fucoidan in Vivo  
To evaluate the mechanisms underpinning the delayed tumour growth in mice pre-fed with 
fucoidan, the immune system was examined in mice as it is pivotal for cancer development. 
In a recent study, Zuo and colleagues examined immune system in mice orally fed with 
fucoidan (270). They examined the intestinal tissue samples from mice being fed with fucoidan 
and reported that dietary fucoidan markedly increased the mRNA level of IL-6 and IL-10. In 
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addition, a significant increase in IgA expression was observed in intestinal samples, which 
probably occurred upon upregulation of the aforementioned cytokines.  
Recently, Zhang et al. showed that IP injection of 50 µg/g b.w. fucoidan significantly increased 
the percentage and cell number of NK cells in C57BL/6 mice (264). Here, we also investigated 
the effect of fucoidan on NK cells which are the key component of body’s innate immune 
system. Although, the focus of this thesis was on the effects of fucoidan on NK cell function.  
Although athymic nude mice lack T-cells, they have functional NK cells. NK cells are a subset 
of lymphocytes, characterised by their ability to kill tumour cells spontaneously. Data 
presented showed that the cytolytic activity of NK cells in mice that were fed with fucoidan for 
two weeks significantly increased compared to the control group. This was shown by the 
amount of dead target cells in fucoidan group which was higher than that of the control group 
in all six effector:target cells ratios with a maximum of 1.6 fold at 100:1 ratio. Maruyama et al. 
have similarly reported higher NK cell activity in fucoidan-treated mice. Although, they report 
2.3 fold higher than the control group which could be as a result of the different route of 
administration as they injected 50 µg/g b.w. of fucoidan intraperitoneally (271). 
NK cells mediate their anti-cancer function through cytokine production and also by regulating 
cytokine production of other immune cells. IFNγ is a major anti-cancer cytokine produced by 
immune cells such as T-cells and NK cells, and itself modulates NK cell function. A clinical 
trial has shown that the amount of IFNγ producing immune cells increased to 114% in 
individuals given a fucoidan mix orally for 30 days. In a recent in vitro study, fucoidan 
treatment activated NK cells and stimulated the production of IFN-γ by them (264). These data 
support the involvement of activated NK cells –and potentially through increased IFNγ- in 
delaying the tumour growth in the in vivo experiments in this thesis. 
In conclusion, it was found that consumption of fucoidan even over a very short time period 
could protect the animals against APL development and growth and suggested that fucoidan 
intake has a prominent effect to enhance the immune cell activity and to eliminate the tumour 
cell development. 
1 
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5.1 Introduction 
Although therapeutic strategies using ATRA plus anthracycline-based chemotherapy increases 
the cure rate in majority of new cases of APL, potential short-term and long-term side effects 
are reported (272). Hyper-leucocytosis and differentiation syndrome (DS) are some short-term 
sequelae (273), and extra-medullary diseases at the recurrence (274), secondary cancers such 
as myelodysplastic syndrome (275), and delayed cardiomyopathy (276) are examples of the 
long term side effects.  
Arsenic trioxide (ATO) is the most active single agent in APL treatment. Single administration 
of ATO induces complete remission in approximately 85-90% of the patients (277, 278). 
Currently, ATO is administrated for refractory or relapsed APL, or older patients who are 
unable to tolerate anthracycline-based therapies (38). However, clinical trials are under way to 
evaluate if revised strategies incorporating ATO in the treatment of newly diagnosed cases of 
APL could possibly prevent the above mentioned complications caused by 
ATRA+chemotherapies. 
ATO acts through multiple mechanisms. It induces apoptosis, inhibits proliferation and 
angiogenesis and stimulates cell differentiation (279). Interestingly, ATO has a dose-dependent 
dual effect on abnormal promyelocytes; at high concentrations of 0.5-2 µM, ATO induces 
apoptosis in malignant promyelocytes, while at low doses of 0.1-0.5 µM, it induces partial 
differentiation (32). Apoptosis is mediated by down regulation of the anti-apoptotic molecule 
Bcl-2 expression both at mRNA and protein level, disruption of mitochondrial transmembrane 
potentials ( m), induction of accumulation of ROS and modulation and degradation of the 
PML-RARα hybrid protein (280).  
Administration of ATO has been linked with several mild to moderate haematologic and non-
haematologic side effects. ATO is reported to induce leucocytosis in about 50% of the cases 
and also mild to severe hepatic toxicities in a large number of the patients (281, 282). Similar 
to ATRA, its usage can cause development of the potentially fatal complication, DS, 
characterised by fever, acute respiratory distress, acute renal failure and potentially death (273). 
In spite of its high efficacy in induction of complete remission in a majority of the patients 
(283), the 2-year disease free survival remains quite low (42%) in refractory patients (282). 
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Therefore, it is of interest to develop complementary treatment strategies which increase the 
efficacy of current treatment while minimizing the toxicities.  
This dissertation has outlined the potential advantages of natural products, and the growing 
interest in their anti-cancer activities. Due to their multi-functional properties, natural products 
are also being tested as adjuvants for use in synergy with chemotherapeutic agents.  
In recent years, there is an emerging body of work investigating the combined effects of 
fucoidan with standard anti-tumour agents. For example, fucoidan from Saccharina 
cichorioides was reported to synergise with the anti-tumour activity of low dose resveratrol on 
the invasive and highly motile HCT 116 colon cancer cell line (195). In a xenograft 
transplantation study, the effect of fucoidan alone or in combination with cyclophosphamide 
was examined on tumour growth. Nine days after the injection of Lewis lung carcinoma cells 
into C57BL/6 mice, fucoidan from Fucus evanescens was administered to animals alone or 
combined with cyclophosphamide. The fucoidan group showed marked anti-tumour (33% 
tumour growth inhibition) and anti-metastatic (29% reduction of the number of metastases) 
activities. Although fucoidan did not exhibit a synergistic effect with cyclophosphamide on 
primary tumour growth, but significantly decreased the lung cancer cell metastasis (284). 
In Chapters 3 and 4 of this thesis, fucoidan was shown to possess antiproliferative activities in 
human APL cell lines both in vitro and in vivo. It is postulated that the induction of apoptosis 
by ATO is via mitochondrial dysfunction and further cleavage of PARP1 which is a crucial 
enzyme involved in DNA repair (285). In Chapter 3, fucoidan was shown to induce apoptosis 
through a caspase-dependent mechanism and further inactivation of PARP-1 in the acute 
promyelocytic leukaemia NB4 and HL60 cell lines. Both fucoidan and ATO cleave PARP-1 
but through two different pathways, therefore it was hypothesised that the combination of these 
two agents could synergistically enhance apoptosis in APL cells and that fucoidan may 
potentiate the anti-tumour activity of the APL standard treatment ATO. 
 
 
 
Chapter 5    Investigation of Possible Synergistic Effects of Fucoidan and ATO in APL Treatment in Vitro and in Vivo  
 
 
Page 129 
 
5.2 Experimental Design 
5.2.1 The synergistic Effect of fucoidan with ATO in APL Cell Apoptosis in Vitro  
The chromosomal t(15;17) translocation positive human APL cell line NB4 was treated with 
low concentration of fucoidan from F. vesiculosus (10 and 20 µg/mL) alone, ATO alone (0.25, 
0.5, 1 µM) or combination (see Section 2.2). After 48 hours, cell proliferation and apoptosis 
were analysed using WST-8 proliferation, Annexin V/PI, DNA fragmentation and cell cycle 
assays (see Sections 2.3 to 2.6).  
The non-APL Kasumi-1 AML cell line was used as control and similarly treated as described 
above for up to 96 hours. Cell proliferation was assessed using the colorimetric WST-8 cell 
proliferation assay (see Section 2.4). 
 
5.2.2 The Synergistic Anti-Tumour Activity of fucoidan with ATO in APL-Bearing 
Mice 
An optimization experiment was performed to determine the route and the dose of fucoidan 
administration. A subcutaneous xenograft tumour was established in 14 female BALB/c nu/nu 
athymic mice (see Section 2.9.5) and fucoidan was delivered with different doses (high and 
low) and routes (IP and IV) once tumours was appeared. The best route and dose were selected 
for the rest of the experiments in chapters 5 and 6 of the thesis. 
To examine the anti-tumour effects of fucoidan and its synergy with ATO, 28 mice (n=7/group) 
were randomly divided into four treatment groups; the control, fucoidan, ATO and 
fucoidan+ATO. A subcutaneous xenograft tumour was established by injecting NB4 cells in 
the right flank of mice (see Section 2.9.5). Treatment was commenced following tumour 
appearance at the following doses: 100 µg/g body weight (b.w.) fucoidan, 2.5 µg/g b.w. ATO 
or in combination, daily. The control group was treated with IP injection of vehicle (sterile 
PBS). Mouse weight and tumour volume were measured daily. Once tumour volume reached 
1000 mm3, this time point was considered as the end point and the mice were humanely 
euthanised with inhalation of CO2 (see Section 2.9.7). Tumour volume doubling time was 
calculated for each mouse. 
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5.3 Results 
5.3.1 Fucoidan Increases the Anti-proliferative Activity of ATO in APL Cells 
in Vitro. 
The acute promyelocytic leukaemia NB4 cell line was treated with fucoidan plus clinical and 
sub-clinical doses of ATO for 48 hours, and cell proliferation and apoptosis were evaluated 
using different assays. 
NB4 cell proliferation was significantly decreased when cells were co-treated with fucoidan 
and ATO, compared to single treatment with either agents (Figures 5.1, 5.2). The decreased 
proliferation was observed in both low (0.25, 0.5 µM) and clinical doses of ATO (1 µM).  
At lowest dose of 0.25 µM ATO, combination of 10 µg/mL fucoidan with ATO resulted in 
decreased cell proliferation to approximately 80%. Whereas combination of 20 µg/mL of 
fucoidan with ATO reduced the cell proliferation to near 60%. According to the results 
obtained, fucoidan at the concentration of 20 µg/mL was used for the rest of the apoptosis 
experiments. 
In the clinic, ATO is only used for treatment of acute promyelocytic leukaemia and not for 
other sub-types of AML as it is not effective in treatment of other subtypes (286). To examine 
whether the ATO activity observed was specific to APL cells, the non-APL t(8;21) positive 
AML Kasumi-1 cell line was similarly treated with ATO plus fucoidan. Neither combined 
fucoidan+ATO nor single treatment with fucoidan and ATO decreased the proliferation of 
Kasumi-1 cells and the percentage of viable cells in all groups remained at >80% for up to 96 
hours (Figure 5.3).   
To investigate whether the reduced cell proliferation in NB4 cells was due to cell death or cell 
cycle arrest, the DNA content of the NB4 cells treated with fucoidan+ATO was analysed using 
flow cytometry. The amount of the sub-G0/G1 population, which represents dead cells, 
significantly increased when cells were treated with fucoidan+ATO compared to ATO alone 
at both therapeutic and sub-therapeutic doses (p≤0.001) (Figure 5.4). Table 5.1 displays 
distribution of all cell cycle phases in NB4 cells. 
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Figure 5.1. Inhibitory effects of ATO plus 10 µg/mL fucoidan on APL cell proliferation. 
NB4 cells were treated with low to high doses of ATO with or without fucoidan for 48 hours 
and cell proliferation was evaluated using the WST-8 assay. Mean ± SEM of at least three 
replicates is shown. Statistical significance was determined by two-way ANOVA, followed 
by Bonferroni post-test (***:p≤ 0.001, *:p≤ 0.05). 
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Figure 5.2. Inhibitory effects of ATO plus 20 µg/mL fucoidan on APL cell proliferation. 
NB4 cells were treated with low to high doses of ATO with or without fucoidan for 48 hours, 
and cell proliferation was evaluated using the WST-8 assay. Mean ± SEM of at least three 
replicates is shown. Statistical significance was determined by two-way ANOVA, followed 
by Bonferroni post-test (***: p ≤ 0.001). 
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Figure 5.3. Inhibitory effects of ATO combined with fucoidan on non-APL Kasumi-1 
cell proliferation. Kasumi-1 cells were treated with low and high doses of ATO with or 
without 20 µg/mL fucoidan, and cell proliferation was evaluated using WST-8 assay after 96 
hours. Mean ± SEM of at least three replicates is shown. Statistical significance was 
determined by ANOVA, followed by Tukey’s multiple comparison test. 
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Table 5.1. Cell cycle phase distribution. NB4 cells were treated with various doses of ATO 
with or without fucoidan (20 µg/mL), and DNA content was assessed using flow cytometry 
after 48 hours. Data represents mean ± SEM of at least three replicates. 
 
 
  Sub G0/G1 G0/G1 S Mitosis 
ATO 
0.25 µM 
Control 1.93 ± 0.30 42.46 ± 1.39 22.34 ± 0.06 31.67 ± 1.34 
Fucoidan 18.34 ± 1.75 28.66 ± 1.42 22.38 ± 2.70 29.18 ± 3.38 
ATO 2.73 ± 1.08 45.10 ± 0.54 20.22 ± 0.41 30.39 ± 0.87 
Combination 20.69 ± 1.54 31.30 ± 0.09 25.8 ± 2.68 19.44 ± 2.04 
ATO 
0.5 µM 
Control 1.93 ± 0.30 42.46 ± 1.39 22.34 ± 0.06 31.67 ± 1.34 
Fucoidan 18.34 ± 1.75 28.66 ± 1.42 22.38 ± 2.70 29.18 ± 3.38 
ATO 2.39 ± 1.08 46.10 ± 0.54 20.22 ± 0.41 29.39 ± 0.87 
Combination 25.57 ± 0.86 38.42 ± 1.38 15.20 ± 0.34 18.14 ± 1.66 
ATO 
1.0 µM 
Control 1.93 ± 0.30 42.46 ± 1.39 22.34 ± 0.06 31.67 ± 1.34 
Fucoidan 18.34 ± 1.75 28.66 ± 1.42 22.38 ± 2.70 29.18 ± 3.38 
ATO 15.13 ± 0.40 39.81 ± 3.82 16.56 ± 0.80 25.50 ± 2.11 
Combination 74.51 ± 2.26 7.29 ± 1.36 9.28 ± 2.28 6.76 ± 0.70 
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Figure 5.4. Effects of ATO plus fucoidan on accumulation of sub G0/G1 dead cells. NB4 
cells were treated with various doses of ATO with or without fucoidan (20 µg/mL) and cell 
cycle was analysed after 48 hours. Sub G0/G1 population representing the dead cells 
significantly increased when fucoidan was combined with ATO at both clinical and low 
doses. Mean ± SEM of at least three replicates is shown. Statistical significance was 
determined by two-way ANOVA, followed by Bonferroni post-test. 
 (***: p ≤ 0.001, *: p ≤ 0.05) 
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5.3.2 Fucoidan Synergises with ATO in ATO-Mediated Apoptosis in APL 
Cells.  
To determine if cell death was due to apoptosis, the annexin V/PI assay was employed. Figure 
5.5 shows a representative flow cytometry result for each treatment. As shown, combination of 
fucoidan with ATO significantly enhanced apoptosis in NB4 cells. At low doses of ATO, the 
percentage of apoptotic cells (annexin V positive cells) increased from approximately 6% (0.25 
µM ATO only) to 32% (fucoidan+0.25 µM ATO) and from 5% (0.5 µM ATO only) to 52% 
(fucoidan+0.5 µM ATO) (p≤0.001). At the therapeutic dose of 1 µM ATO, the percentage of 
apoptotic cells increased from approximately 18% (ATO only) to 71% (fucoidan+ATO) 
(p≤0.001).  
Furthermore, the TUNEL assay was employed to measure the amount of DNA fragmentation; 
which is one of the main features of apoptosis. Consistent with the annexin V/PI assay data, 
co-treatment of fucoidan with ATO significantly enhanced apoptosis compared to treatment 
with ATO only (p≤0.001). As shown in Figure 5.6, the mean percentage of cells with 
fragmented DNA increased to 42.5% (fucoidan+0.25 µM ATO), 60% (fucoidan+0.5 µM 
ATO), and 79% (fucoidan+1 µM ATO) compared to 1.5%, 1% and 12%, respectively, for the 
same doses of ATO alone. 
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Figure 5.5. Representative annexin V/PI apoptosis assay. NB4 cells were treated with 
increasing doses of ATO with or without fucoidan (20 µg/mL) and apoptosis was measured 
using annexin V/PI apoptosis assay. Results represent flow cytometry histograms of one of 
three replicates. 
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Figure 5.6. DNA fragmentation. The percentage of apoptotic cells with fragmented DNA 
significantly increased when fucoidan (20 µg/mL) was combined with ATO at both low and 
high doses. Mean ± SEM of at least three replicates is shown. Statistical significance was 
determined by two-way ANOVA, followed by Bonferroni post-test (***: p ≤ 0.001). 
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5.3.3 High Dose Fucoidan Delayed Tumour Growth  
To optimise the route and the dose of fucoidan administration, 14 female mice were divided 
into three groups according to the dose (low or high) and the route (IP or IV) of fucoidan 
administration as follow: 
 
1. IP low dose (30 µg/g b.w.) 
2. IP high dose (100 µg/g b.w.) 
3. IV (6 µg/g b.w.) 
 
A subcutaneous xenograft tumour was established in mice and treatments were applied daily 
at the mentioned conditions. Out of 14 mice, 5 mice (2 in each IP group and 1 in IV group) did 
not develop tumours for up to 50 days. These mice were excluded from the experiments and 
data analysis. The number of mice in different groups was therefore restricted to 9 animals as 
shown in Figure 5.7. 
In the 9 remaining mice, a visible tumour mass (4~10 mm3) appeared in 8 mice after 8-14 days. 
The tumour appeared in the last mouse at day 20. 
Despite using different techniques, attempts to administer fucoidan through IV injection failed. 
Due to the small size of nude mice and thin tail blood vessels, fucoidan could not be injected 
IV for more than 2 or 3 days. As a result, the IV injection was excluded from the experiments 
and the three mice in IV group were transferred to the IP groups (Figure 5.7).  
Figure 5.8 displays the tumour appearance and growth for the optimization assay. The tumour 
size in all mice in IP-low dose group reached the end point (1000 mm3) in less than 12 days 
after the treatment commenced. In the IP-high dose group, the tumour size reached the end 
point between days 13 to 26. The high dose treatment did not induce any side effects (such as 
weight loss and/or behavioural changes) in the mice. As a result, the dose of 100 µg/g b.w. and 
IP injection route were selected for the main experiments in this Chapter and Chapter 6.  
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Figure 5.7. Total animal number used in optimization assay. The number of animals 
decreased due to tumour establishment and IV injection failure. 
 
 
 
 
 
 
Final animal number due to IV injection failure
IP low dose (n=5) IP high dose (n=4)
Reduced animal number due to tumour establishment failure
IP low dose (n=3) IP high dose (n=3) IV (n=3)
Initial experimental animal number
IP low dose (n=5) IP high dose (n=5) IV (n=4)
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Figure 5.8. Tumour mass growth in mice treated with different doses of fucoidan. 
Xenograft tumour was established in mice with injection of NB4 cells and treatment with low 
and high doses of fucoidan (IP) was commenced after tumour appearance. Tumour volume 
was measured daily. Each graph represents the daily tumour volume of one mouse in high-
dose (green) and low dose (red) groups (n=4 in low dose/n=5 in high dose groups). 
 
* Due to tumour rupture, one mouse in the IP-low dose group was sacrificed at day 6 of 
treatment. 
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5.3.4. Co-treatment of Fucoidan with ATO Significantly Delayed the Growth 
of APL in Mice.  
To evaluate the possible synergy of ATO and fucoidan in vivo, a subcutaneous xenograft APL 
mass was established in 28 male nude mice (n=7/group) and single or combined treatments of 
fucoidan and ATO were commenced following tumour appearance. Tumour mass volume was 
monitored and median survival was identified using the Kaplan-Meier survival analysis.  
A visible tumour mass (4~10 mm3) appeared after 8-14 days in all 28 mice. During the 
treatment, none of the mice showed any side effects (e.g. weight loss or behavioural changes) 
to the administered doses. Of the 7 mice treated with fucoidan+ATO, only 2 mice completed 
the full 28-days treatment. All remaining mice were sacrificed as per animal ethics guidelines 
prior to 28-days treatment as tumour volume reached 1000 mm3.  
Treatment with “fucoidan only” and “fucoidan+ATO” significantly slowed the increase in 
tumour mass with the tumours in these animals reaching the maximal end point much later than 
the control group (p≤0.05). The median survival of the mice was 14.5, 18.5, 16.5 and 20 days 
in control, fucoidan alone, ATO alone and combination groups, respectively (Figure 5.9). 
Although a higher median survival in combination group was observed, the difference between 
treated groups was not statistically significant.  
Tumour aggressiveness was evaluated by tumour volume doubling time which increased in 
treated groups compared to the control group. The mean tumour volume doubling time was 
2.72, 3.70, 3.42 and 3.86 days in control, fucoidan, ATO and combination groups, respectively 
(Figure 5.10). 
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Figure 5.9. The Kaplan-Meier survival analysis over 28 days of treatment. Mice with 
APL were treated with vehicle (red), fucoidan (green), ATO (blue) and their combination 
(purple) and their life span was analysed over 28 days of treatment (n=7/ group). p values 
refer to comparison between each treatment group with the control group. 
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Figure 5.10. Mean tumour volume doubling time.  Mice with APL were treated with 
vehicle (red), fucoidan (green), ATO (blue) and their combination (purple) and their mean 
tumour volume doubling time was compared to that of the control group (n=7/group). 
Statistical significance was determined by ANOVA, followed by Tukey’s multiple 
comparison test (*: p≤0.05). Each column shows mean ± SD. 
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5.4 Discussion 
Herein, the synergistic effects of fucoidan with ATO in ATO-induced apoptosis was examined 
in vitro and in vivo. Evidence provided here supports the hypothesis that combining fucoidan 
with ATO enhanced apoptosis at both clinically-used and low doses of ATO, in vitro. In 
addition, enhanced survival and delayed tumour growth were observed in APL-bearing mice 
when treated with combined fucoidan and ATO. This is the first study to examine the potential 
therapeutic activity of fucoidan in leukaemia in vivo. 
 
5.4.1 Synergistic Effect of Fucoidan with ATO in Vitro 
In the last decade, combined treatment of natural components with chemotherapeutic agents 
has gained considerable attention. The potential synergistic activities of these agents could be 
exploited to reduce the toxicity of chemotherapy by achieving the same (or even higher) 
efficacy at lower doses. ATO was first used for APL treatment in the early 1990s and improved 
the complete remission rate in APL patients (280). Further studies and clinical trials showed 
that it induced a sustained molecular remission when it was used alone in relapsed patients (37, 
38). However, the currently used clinical doses of ATO has been accompanied with 
morbidities.  
Few studies have examined the combinatory activity of natural derived compounds with ATO 
in treatment of APL. Lu et al. reported that combination of a crude methanolic extract 
of Mucuna macrocarpa with ATO suppressed proliferation of APL cell line HL60 and 
increased apoptosis through accumulation ROS (287). Fan et al. also showed that addition of 
resveratrol, a stilbene enriched in red wine, to ATO significantly enhanced the anti-cancer 
effect of ATO in APL cell line NB4 (288). In a recent investigation, the synergistic activity of 
Icarrin, a natural flavonoid derived from several plants, with ATO was evaluated in NB4 cell 
apoptosis (289). The combination of these extracts resulted in continuous accumulation of ROS 
and excessive cellular oxidative stress.  
As mentioned before, the clinical doses of 1 µM of ATO can cause side effects in patients. The 
aforementioned studies have used high doses of ATO; from 2 to 12 µM, which are considerably 
higher than clinical doses. Here, it was postulated that lower concentrations of ATO could 
attenuate its undesirable side effects. Therefore APL cells were co-treated with lower doses of 
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ATO and compared the outcomes with therapeutic doses. Addition of fucoidan to ATO 
significantly increased the efficacy of ATO in induction of apoptosis in NB4 cells both at low 
and clinical doses of ATO.  
It should be noted that due to the cytotoxic effect of fucoidan in NB4 cells, ultra-low 
concentrations of fucoidan were used in this chapter than previously used in Chapter 3 (10-20 
µg/mL vs 50-100 µg/mL). The lower doses of fucoidan allowed us to identify the effect of 
fucoidan on ATO-induced apoptosis, and yet even the combination of this low concentration 
of fucoidan with ATO decreased cell proliferation to less than 20% compared to around 80% 
in ATO-alone treated cells. 
It is well known that ATO induces apoptosis at higher doses whereas it induces myeloid 
differentiation at lower doses. Here, as expected, high dose of ATO (1 µM) increased the sub-
G0/G1 dead cell population in the cell cycle assay. Consistent with the literature, lower doses 
of ATO (0.25 and 0.5 1 µM) did not induce apoptosis in APL cells and did not increase the sub 
G0/G1 dead cell population. However, they induced G0/G1 arrest with 42% cells in control 
compared to near 46% in ATO-treated cells. The slight G0/G1 arrest within 48 hours could be 
associated with initiation of differentiation in APL cells in response to low dose ATO. This 
effect will be discussed in detail in Chapter 6. 
AKT, a serine/threonine kinase, is a key molecule in PI3K/AKT signaling pathway which 
inhibits apoptosis and is reported to be frequently upregulated in various tumours (290). The 
results of Chapter 3 of this thesis together with other studies have shown that fucoidan down-
regulates the activity of AKT (163, 180). Further, there are several reports that show that ATO 
triggers apoptosis via inhibition of AKT (291, 292). Evidence indicates that fucoidan and ATO 
trigger the same pathway and therefore it could be postulated that double inhibition of AKT 
may explain the observed synergistic activity.  
Evidence shows that apoptosis mediated by ATO is caspase independent (293, 294). It induces 
apoptosis through down-regulation of anti-apoptotic molecule Bcl-2 expression, induction of 
accumulation of reactive oxygen species (ROS) and disruption of mitochondrial 
transmembrane potentials ( m), eventually resulting in increased cleavage of PARP-1 and 
subsequent cell death. PARP-1 is a nuclear enzyme which modifies various nuclear proteins 
involved in different cellular processes. PARP-1 has a key role in DNA repair and cell recovery 
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from DNA damage through maintenance of genomic integrity and its inactivation is highly 
associated with apoptosis (295). Cleavage of PARP-1 is one of the main mechanisms triggered 
by a wide range of anti-cancer agents. Similar to ATO, in Chapter 3 it was shown that fucoidan 
significantly increased the cleavage of PARP-1, however through a caspase dependent process. 
Thereby, although fucoidan and ATO recruits different pathways, both agents eventually 
induce cleavage of PARP-1 (285). This may explain the severe induced DNA fragmentation 
when ATO was combined with fucoidan (80%) compared to when it was used alone (about 
15%). 
 
5.4.2 Therapeutic Potential of Fucoidan in APL-Bearing Mice 
Next, the therapeutic effects of fucoidan on APL-bearing mice was examined and its synergy 
with current APL therapies was evaluated in vivo.  
In previous in vivo studies examining the therapeutic effect of fucoidan, the range of utilised 
doses mostly resides between 5 to 500 µg/g b.w. To select the more effective dose, Lee and 
colleagues treated mice with a range of 0, 10, 50, 100, 200 and 400 µg/g b.w. fucoidan 24 hrs 
and 1 hr before irradiating the mice. The mice injected with 100 µg/g b.w. fucoidan showed 
the best survival rate at 30 days post-irradiation (296). Here, mice were treated with 30 µg/g 
b.w. and 100 µg/g b.w. and it was found that the mice treated with high doses of fucoidan had 
delayed tumour growth compared to the low-dose treated group, suggesting the therapeutic 
potential of fucoidan in treatment of mice bearing APL.  
Similar to Chapter 4 (see Sections 4.3.1 and 4.4), the utilised mouse model had some limitations 
and female mice were less susceptible to developing tumours. Thereby, subsequent 
experiments were conducted on male mice.  
 
5.4.3 Synergistic Effect of Fucoidan with ATO in Vivo 
Despite many in vitro studies investigating the synergistic activity of fucoidan with anti-cancer 
drugs, in vivo studies have been limited. Alekseyenko et al. reported that in C57Bl/6 mice 
fucoidan significantly potentiated the anti-metastatic, but not anti-tumour activity of the 
chemotherapeutic agent cyclophosphamide (284). In a clinical trial, fucoidan similarly did not 
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affect the efficacy of standard chemotherapeutic agents in patients with colorectal cancer, but 
reduced the toxicities of chemotherapy (193). The previous reported experiments in this 
Chapter and Chapter 4 provided evidence that fucoidan was effective in delaying tumour 
growth in vivo. These data led to examining the combinatory therapeutic effects of fucoidan 
with low doses of ATO in APL-bearing mice. 
Unlike other AML subtypes, early death is the primary cause of treatment failure in patients 
with APL, mainly due to the toxicity of therapeutic agents themselves (297). This toxicity has 
been reported in in vivo studies as well. In an in vivo study, Jing and colleagues treated APL-
bearing mice with 8 µg/g b.w. of ATO and reported toxicity with weight loss and early-
treatment associated deaths in mice (40). Lallemand-Breitenbach et al. also reported that 10 
µg/g b.w. of ATO was toxic and caused many early deaths due to hepatic toxicity and 
widespread pulmonary edema (41). Hence, they used a reduced dose of 5 µg/g b.w. ATO in 
mice bearing APL. In this thesis, with the assumption that the lower concentrations could 
attenuate the side effects of these drugs, the dose was reduced even further (2.5 µg/g b.w. ATO) 
and no toxicity was observed when it was used alone or in combination with fucoidan. 
Treatment with fucoidan plus low dose ATO increased the tumour volume doubling time 
compared to the control (p=0.0175) and ATO alone (p=0.56) groups. The survival rate in the 
combination group was the highest between all treated groups, although it was only significant 
compared to the control group but not the single fucoidan and single ATO treated groups.  
ATO alone did not have a significant impact on mouse survival and the tumour doubling time 
compared to the control group. The utilised low dose may explain the non-significant anti-
tumour effects of ATO alone in these investigations. More importantly, in contrast with studies 
by Jin et al and Lallemand-Breitenbach et al., no toxicity was observed when this low dose of 
ATO was used alone or in combination with fucoidan. Even though very low doses were used, 
the efficacy of combined treatment was still higher than that of standard APL treatment alone.  
In conclusion, the data presented in this chapter suggest that the usage of fucoidan as a 
supplementary agent to the APL standard treatment ATO may represent a promising new 
strategy for management of APL.  
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6.1 Introduction 
The PML/RARα gene product of the chromosomal t(15;17) translocation blocks the differentiation 
of malignant promyelocytes in APL (22). In the late 1970s, the hypothesis of inducing 
differentiation rather than apoptosis in tumour cells was proposed and drugs with differentiation-
inducing property were developed (26). ATRA was the first successful differentiation-based therapy 
used in patients with APL. However it could only induce transient remission (298). Further pre-
clinical studies showed a dramatic synergy between ATRA and arsenic trioxide in inducing 
differentiation and clearing the APL cells in animal models (41). Today, ATO+ATRA is a standard 
therapeutic strategy which provides an effective differentiation-based therapy, potentially avoiding 
use of anthracycline-based chemotherapy. 
Retinoic acid receptor alpha (RARα) is a ligand-dependent transcription factor that regulates the 
expression of a number of genes involved in cell differentiation and proliferation. In normal 
promyelocytes, RARα binds to the promoter region of target genes and recruits various molecules 
such as nuclear co-repressor proteins (N-coR). These molecules form complexes with histone 
deacetylase enzymes (HDACs), leading to transcriptional repression and differentiation block (28). 
ATRA is a retinoid derivative which is present physiologically in human plasma. At normal 
physiological concentrations (10-9 to 10-8 M), conformational changes occurs in the RARα, leading 
to dissociation of the co-repressors/HDAC complex and re-expression of differentiation-related 
proteins (Figure 6.1A). In malignant promyelocytes the fusion protein PML-RARα is attached to 
the gene promoters and at physiological concentrations, ATRA cannot dissociate the co-
repressors/HDAC complex, causing the persistence of transcriptional repression and differentiation 
arrest (28, 283) (Figure 6.1B). At higher pharmacological doses of ATRA, within range of 10-7 to 
10-6 M, the co-receptor proteins are removed, relieving transcriptional repression complexes leading 
to terminal differentiation of abnormal promyelocytes (Figure 6.1C). This is known as the 
“reactivation” model. The terminally differentiated mature cells arising from neoplastic clones 
eventually undergo apoptosis (299). 
An additional model for the ATRA-mediated differentiation has been proposed. ATRA has been 
shown to induce the catabolism of the PML-RARα fusion protein through binding to and targeting 
the RARα moiety for ubiquitin/proteasome pathway. The degradation of the fusion protein can thus 
promote differentiation in abnormal promyelocytes (300). This is known as the “de-repression” 
model. Figure 6.2 represents the two proposed models. 
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Figure 6.1. Proposed mechanisms of actions of ATRA on nuclear co-repressor complex and 
PML-RARα fusion protein in APL. In the absence of ATRA, RARα associate with the co-
repressor/HDAC complex, which induces reorganization of chromatin structure into a repressed 
state that is inaccessible to basal transcription factors. A) In the normal promyelocyte, 
physiological doses of ATRA binds to RARα, dissociate the co-repressor complex and causes 
association of a co-activator such as SRC-1 (301) allowing the access of transcription factors and 
transcription activation. B) In APL, physiological doses of ATRA is not sufficient to dissociate 
PML-RARα fusion protein from the co-repressor complex. C) In APL, pharmacological doses of 
ATRA are required to dissociate the PML-RARα from co-repressor complex and activate 
transcription and differentiation (Modified image from (302)). 
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Figure 6.2. Reactivation and de-repression models for the role of ATRA and ATO in 
induction of differentiation in APL cells. Two current models of ATRA action on 
differentiation through gene transcription re-activation (top) and action of ATRA and ATO on 
degradation of PML-RAR or de-repression (bottom) ((Modified image from (298)).  
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As discussed in Chapter 5, ATO induces both partial differentiation and apoptosis in leukaemic 
promyelocytes. Similar to ATRA, ATO induces the degradation of the PML-RARα fusion protein, 
but through targeting the PML moiety (303). Promyelocytic leukaemia (PML) protein is a tumour 
suppressor protein involved in the regulation of apoptosis, and therefore its degradation upon ATO 
exposure induces apoptosis in malignant promyelocytes. In terms of the ATO-mediated partial 
differentiation, it does not change the nuclear receptor signalling and therefore the transcription 
“reactivation” model cannot account for its action. As mentioned above, ATO degrades PML-RAR 
fusion protein. Thus, it has been proposed that ATO induces differentiation through abrogation of 
PML/RARα-mediated gene repression (the “de-repression” model) (304) (Figure 6.2).  
It is notable that the advantage of ATRA plus ATO therapy is reduced toxicity compared to standard 
ATRA plus anthracycline-based chemotherapy. However, despite the enormous improvement in 
APL treatment, the use of ATRA plus ATO is not free of side effects. Several clinical trials have 
reported that the prolonged administration of high doses of ATRA results in resistance (32). 
Moreover, this combination can cause differentiation syndrome; a potentially fatal complication 
which occurs in approximately 25% of APL patients (281). It has also been reported that the 
efficiency of myeloid cell differentiation could be diminished due to down-regulation of RARα in 
the duration of the treatment (305). Therefore, it is of interest to develop complementary treatment 
strategies which increase the sensitivity of myeloid cells to the action of ATRA+ATO therapy. New 
adjuvants permitting lower doses of ATRA and ATO to be used could also reduce the toxicity of 
current treatment regimens in some patients. 
As discussed in the previous chapters, fucoidan induces strong anti-tumour activities in various 
tumour cells and has been shown to be non-toxic when consumed. In recent years, some studies 
have investigated the synergistic effects of fucoidan with standard anti-cancer agents. Lv et al. 
showed that fucoidan reduced the migration and invasion of multiple myeloma (MM) cells treated 
with the chemotherapy drug cytarabine (194). Dietary fucoidan synergistically reduced cell growth 
in the OE33 cell line when it was combined with lapatinib, a targeted therapy that acts as a tyrosine 
kinase inhibitor in advanced HER2-positive breast cancer cells (197). In Chapter 5 of this thesis, 
the study of combined effects of fucoidan and the APL standard treatment ATO showed that 
fucoidan synergistically increased apoptosis induced by ATO in APL cells in vitro. 
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Here, it is hypothesised that fucoidan synergistically enhances the effects of current APL therapeutic 
regimens, ATRA and ATO, in APL cell differentiation. It has been well documented that exposure 
of APL cells to ATRA at a concentration of 1 µM results in 95% of cells differentiating 
accompanied by loss of their capacity to proliferate (306). ATO however induces APL cell partial 
differentiation at lower doses of 0.1 to 0.5 µM. Since the clinical doses of 1 µM of ATRA and ATO 
can cause side effects in patients, it is hypothesised that the reduced concentrations could reduce 
the side effects of these drugs. Therefore, the synergistic effects of fucoidan with ATRA+ATO were 
investigated in APL cell myeloid differentiation at sub-pharmacological doses in vitro and in vivo. 
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6.2 Experimental Design 
6.2.1 The Synergistic Effect of Fucoidan with Low Doses of ATRA+ATO in APL 
Cell Differentiation in vitro 
The chromosomal t(15;17) translocation positive human APL cell line NB4 was treated with ultra-
low dose (5 µg/mL) of fucoidan from F. vesiculosus alone, 0.5 µM ATRA alone, 0.5 µM ATO 
alone or in combinations for 120 hours (see Section 2.2). Monitoring of NB4 cell differentiation 
was performed by quantitation of the cell surface myeloid differentiation marker CD11b and cell 
cycle assay by flow cytometry (see Section 2.3).  
 
6.2.2 The synergistic Anti-Tumour Activity of fucoidan with ATRA in APL-
Bearing Mice 
To examine the anti-tumour activity of fucoidan and its synergy with ATRA, 32 mice (n=8/group) 
were randomly divided into four treatment groups; the control, fucoidan, ATRA and 
fucoidan+ATRA. A subcutaneous xenograft tumour was established by injecting NB4 cells in the 
right flank of mice (see Section 2.9.5). Treatment was commenced by IP injection following tumour 
appearance at the following doses:  100 µg/g b.w. fucoidan (daily), 1.5 µg/g b.w. ATRA (three 
times a week) or in combination. The control group was treated with sterile vehicle (see Section 
2.9.4). Mouse weight and tumour volume were measured daily. Once tumour volume reached 1000 
mm3, this time point was considered as the end point and the mice were humanely euthanised with 
inhalation of CO2 (see Section 2.9.7). Tumour volume doubling time was calculated for each mouse. 
At the end point, tumour mass was removed and tumour cell differentiation was analysed by CD11b 
expression. 
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6.3 Results 
6.3.1 Fucoidan Enhances ATRA-Induced Differentiation in APL Cells.  
Increasing surface expression of CD11b is a marker of myeloid cells undergoing differentiation 
(307). To identify the expression level of CD11b, cells were incubated with anti-CD11b antibody 
and isotype-matched negative control and analysed by flow cytometry. The intensity of CD11b 
expression was determined using mean fluorescent intensity (MFI). This was first optimised using 
untreated NB4 cells (Figure 6.3). As shown in Figure 6.3, the signals lower than 101 contributed to 
“neg/low” CD11b expression (non-differentiated cells) and signals higher than 101 contributed to 
“high” CD11b expression (differentiated cells). 
Myeloid differentiation was assessed by quantitating CD11b expression following treatment with 
low doses of ATRA and ATO for 48, 72, 96 and 120 hours. The non-differentiated or low-
differentiated CD11bneg/low cells were excluded from the analysis. The percentage of CD11bhigh cells 
was quantified as differentiated cells. As shown in Figure 6.4 and 6.5, the CD11b expression 
increased in ATRA-treated cells from 48 hours and reached a maximum of 83.5% after 120 hours. 
In contrast, the differentiation induced by ATO was delayed; with increases after 96 hours and 
reached 20% after 120 hours compared to 2.66% at time zero. For the rest of the experiments, 120 
hours was selected for incubation time for the differentiation assay. 
To determine the effect of combining fucoidan with ATRA and ATO on APL cell differentiation, 
NB4 cells were treated with fucoidan, sub-clinical doses of ATRA and ATO, or in combination for 
120 hours and differentiation was measured by expression of CD11b as described above. Figure 6.6 
demonstrates representative flow cytometry histograms in cells treated with single or combination 
of different compounds as indicated. As shown, 0.5 µM ATRA increased the differentiated cells 
from approximately 6% to 83%, while addition of fucoidan to ATRA increased the differentiated 
cells to 94%. Low-dose ATO similarly increased the differentiated cells from 6% to 14% while 
ATO+fucoidan enhanced the percentage of differentiated cells to 20.2%. Finally, APL cells treated 
with all three reagents in combination resulted in a 99% CD11bhigh cells after the 5-day incubation 
period, compared to 87% when cells were co-treated with ATRA+ATO. 
Taken together, combined treatment of fucoidan with ATRA and ATO significantly increased 
myeloid differentiation in APL cells after 120 hours (Figure 6.7). Fucoidan alone did not affect 
myeloid differentiation in APL cells in vitro compared to untreated control (Figure 6.7).  
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Figure 6.3. Cell differentiation assay. NB4 cells were labelled with isotype negative control 
(left) and CD11b (right) antibody. The non-specific antibody binding was excluded using the 
isotype negative antibody (left histogram-D-). According to the level of CD11b expression in the 
right histogram, the fluorescent intensity of 101 was determined as the cut off for differentiation. 
To quantify the cell differentiation, the percentage of CD11bhigh cells (signals higher than 101) 
was analysed. 
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Figure 6.4. Cell differentiation assay. NB4 cells were treated with ATRA (0.5 µM) or ATO (0.5 µM), and CD11b expression was analysed by 
flow cytometry at various time points for up to 120 hours. Each peak with different colour represents the expression of CD11b at different time 
points compared to the control (red peak). The table below demonstrates the percentage of differentiated NB4 cells (CD11bhigh) induced by 
ATRA and ATO. 
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Figure 6.5. Representative cell differentiation assay at various time points. NB4 cells were treated with ATRA (0.5 µM) or ATO (0.5 µM), 
and CD11b expression was analysed by flow cytometry at various time points for up to 120 hours. Low and high CD11b expressing cells were 
determined using fluorescence intensity (Above demonstrative histogram). Changes in CD11b expression in different treatment conditions are 
demonstrated in below dot plots with different colours.  Green population indicates non/low differentiated population (CD11bneg/low), and Blue 
population indicates differentiated cells (CD11bhigh).
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Figure 6.6. Representative cell differentiation analysis. NB4 cells were treated with ATRA 
alone (0.5 µM), ATO alone (0.5 µM), fucoidan alone (5 µg/mL) or in combination. CD11b 
expression was analysed by flow cytometry after 120 hours. CD11bneg/low cells were excluded, and 
the CD11bhigh population was calculated. In dot plot histograms, green population indicates 
differentiated population while red population represents non-differentiated cells. 
Dot plot (left) histogram: Red population: non/low differentiated CD11bneg/low population, 
Green population: CD11bhight differentiated cells. 
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Figure 6.7. Effects of combination of fucoidan with ATRA and ATO on cell differentiation. 
NB4 cells were treated with ATRA alone (0.5 µM), ATO alone (0.5 µM), fucoidan alone (5 
µg/mL) or in combination, and CD11b expression was analysed after 120 hours. Mean ± SEM of 
at least three replicates is shown. Statistical significance was determined by ANOVA, followed by 
Tukey’s multiple comparison test (***: p≤0.001, **: p≤ 0.01). 
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6.3.2 Fucoidan Combined with ATRA and ATO Enhances G0/G1 arrest in APL 
Cells.  
Cells undergoing differentiation normally stop dividing and exit the cell cycle dividing phases. 
Hence, the DNA content was assessed and the percentage of the non-dividing G0/G1 population, 
indicative of differentiation, was analysed in APL cells treated with single or combination of 
fucoidan, ATRA and ATO (Figure 6.8). Consistent with the observed changes in CD11b expression, 
a significant increase in the non-dividing G0/G1 population was observed in cells co-treated with 
ATRA+fucoidan compared to ATRA alone, and in cells co-treated with ATRA+ATO+fucoidan 
compared to ATRA+ATO (Table 6.1). Figure 6.9 compares the G0/G1 arrest in NB4 cells treated 
with different agents. 
It should be noted that at the very low doses of fucoidan used, the amount of the sub G0/G1 dead 
cell population did not change in treated cells compared to the untreated cells (Table 6.1). 
 
Table 6.1. Cell cycle phase distribution. NB4 cells were treated with ATRA (0.5 µM) and ATO 
(0.5 µM) with or without fucoidan (5 µg/mL), and DNA content was assessed using flow 
cytometry after 120 hours. Data represents mean ± SEM of at least three replicates. 
 
 
 G0/G1 S Mitosis 
 
Agents alone 
Control 60.64 ± 0.41 20.65 ± 1.1 18.07 ± 0.89 
Fucoidan 65.10 ± 1.54 20.77 ± 1.44 13.3 ± 0.10 
ATRA 76.01 ± 1.05 8.53 ± 1.00 15.12 ± 0.08 
ATO 64.40 ± 0.95 18.29 ± 1.29  16.64 ± 0.31 
 
Combination 
ATRA+fucoidan 84.28 ± 1.81 5.24 ± 0.21 10.24 ± 1.61 
ATO+fucoidan 66.01 ± 2.95 21.94 ± 1.77 11.38 ± 1.02 
ATRA + ATO 82.44 ± 0.53 6.78 ± 0.06 10.58 ± 0.65 
ATRA+ATO+fucoidan 89.86 ± 1.11 4.42 ± 0.94 5.41 ± 0.16 
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Figure 6.8. Representative cell cycle analysis. NB4 cells were treated with fucoidan alone (5 µg/mL), ATRA alone (0.5 µM), ATO alone (0.5 
µM), or combinations of these agents. Cell cycle was assessed using flow cytometry. Results represent one of the three replicates. 
Dot plot (left) histogram: Green population: G0/G1 phase. Blue population: S phase. Yellow population: G2/M phase  
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Figure 6.9. Effects of combination of fucoidan with ATRA and ATO on accumulation of 
the non-dividing G0/G1 cells. NB4 cells were treated with ATRA alone (0.5 µM), ATO 
alone (0.5 µM), fucoidan alone (5 µg/mL) or combinations of these agents, and DNA content 
was analysed after 120 hours. Mean ± SEM of at least three replicates is shown. Statistical 
significance was determined by ANOVA, followed by Tukey’s multiple comparison test. 
 (**: p≤0.01, *: p≤0.05) 
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6.3.3 Co-treatment of Fucoidan with ATRA Significantly Delayed the 
Growth of APL in Mice.  
To evaluate the possible synergy of fucoidan and ATRA in vivo, a subcutaneous xenograft APL 
mass was established in 32 nude mice (n=8/group), and single or combined treatments of 
fucoidan and ATRA were commenced following tumour appearance. Tumour mass volume 
was monitored and median survival was identified using the Kaplan-Meier survival analysis.  
A visible tumour mass (4~10 mm3) appeared after 8-14 days in all 32 mice. During the 
treatment, none of the mice showed any side effects (e.g. weight loss or behavioural changes) 
to the administered doses. One animal in the fucoidan alone group and one animal in the ATRA 
alone group completed the full 28-days treatment. All remaining mice were sacrificed as per 
animal ethics guidelines prior to 28-days treatment as tumour volume reached 1000 mm3.  
Treatment with all three treated groups significantly slowed the increase in tumour mass with 
the tumours in these animals reaching the maximal end point much later than the control group. 
The median survival of the mice was 13, 19, 19 and 19.5 days in control, fucoidan alone, ATRA 
alone and combination groups, respectively (Figure 6.10). No significant difference was seen 
between treatment groups with each other. 
Tumour aggressiveness was evaluated by tumour volume doubling time which decreased in all 
treatment groups compared to the control group. The mean tumour volume doubling time was 
2.43, 3.92, 3.42 and 3.53 days in control, fucoidan, ATO and combination groups, respectively 
(Figure 6.11) indicating that the tumour in the control group grew more quickly than in treated 
mice. No significant difference was seen between treatment groups with each other.  
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Figure 6.10. The Kaplan-Meier survival analysis over 28 days of treatment. Mice with 
APL were treated with vehicle (red), fucoidan (green), ATRA (blue) and their combination 
(purple) and their life span was analysed over 28 days of treatment (n=8/group). p values 
refer to comparison between each treatment group with the control group. 
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Figure 6.11. Mean tumour volume doubling time.  Mice with APL were treated with 
vehicle (red), fucoidan (green), ATRA (blue) and their combination (purple) and their mean 
tumour doubling time was compared to that of the control group (n=8/group). Each column 
shows mean ± SD. Statistical significance was determined by ANOVA, followed by Tukey’s 
multiple comparison test (**:p≤0.01, *: p≤0.05).  
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6.3.4 Fucoidan Significantly Increased the Differentiation of APL Cells in 
Vivo.  
At the end of the in-vivo study of the combinatory effect of fucoidan plus ATRA, the tumour 
mass was removed from the mice and myeloid differentiation was assessed. To do this, a cell 
suspension from the removed tumour mass was prepared following labelling with anti-CD11b 
antibody. Since almost all NB4 cells express CD44, tumour cells were identified by CD44 
expression. CD44 is an adhesion molecule which is highly expressed in more than 95% of the 
NB4 cells and its expression does not change upon differentiation and maturation. To analyse 
myeloid differentiation, CD11bhighCD44+ cells were quantified.  
Figure 6.12 shows representative CD11b expression histograms in tumour mass obtained from 
one representative mouse in each treatment group. As shown, a significant increase in 
differentiation was observed in tumour mass treated with fucoidan alone (p≤0.05) and 
ATRA+fucoidan (p≤0.05). The mean values of differentiated cells were approximately 10%, 
24%, 19% and 22% in control, fucoidan, ATRA and combination groups, respectively (Figure 
6.13). There was no significant difference between treated groups with each other.  
Furthermore, a different immunophenotypic pattern in expression of CD44 and CD11b was 
observed in different treatment groups (Blue population in Figure 6.12). Evaluating the 
expression of CD44 on differentiated cells, the ratio of CD11bhighCD44- cells to 
CD11bhighCD44+ cells was calculated (Figure 6.14). As shown in Figure 6.14, compared to the 
control group, the ratio was reversed in mice treated with ATRA+fucoidan, indicating that the 
percentage of CD44-negative differentiated cells was higher than the CD44-positive 
differentiated cells. This ratio was 0.58, 0.83, 0.87 and 1.14 in control, fucoidan alone, ATRA 
alone and combination groups, respectively, indicating decreased expression of CD44 in mice 
treated with fucoidan+ATRA. 
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Figure 6.12. Representative flow cytometry analysis of CD11b expression in cells 
obtained from tumour mass. The tumour-bearing mice were treated with fucoidan, ATRA 
and combination, and differentiation was assessed using CD11b expression. Histograms show 
the flow cytometry results from one representative tumour mass in each treated group. The 
percentage of differentiated CD11bhigh cells was calculated (left graphs). The graphs in the 
right hand column demonstrate the expression of CD11b and CD44. 
Blue population: CD11bhigh , Green and Gray populations: CD11blow 
Red populations: CD11bneg 
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Figure 6.13. Myeloid differentiation in tumour mass obtained from mice treated with 
fucoidan, ATRA and combination compared to the control group. Differentiation was 
measured calculating CD11bhigh cells. Each column represents the mean ± SD of CD11bhigh 
cells in each experimental group (n=8/group). Statistical significance was determined by 
ANOVA, followed by Tukey’s multiple comparison test (*: p≤0.05).  
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Figure 6.14. The ratio between CD44-/CD11b+ to CD44+/CD11b+ cells in tumour mass 
obtained from mice. Mice with APL were treated with vehicle, fucoidan, ATRA and 
combination. Expression of CD44 and CD11b was measured using flow cytometry and the 
ratio between CD44-negative to CD44-positive differentiated cells was calculated in each 
experimental group. Statistical significance was determined by ANOVA, followed by 
Tukey’s multiple comparison test (**: p≤0.01). Each column represents the mean ratio of 
CD44- to CD44+ differentiated cells with error bars the SD. 
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6.4 Discussion 
Herein, the synergistic effects of fucoidan with ATRA and ATO in induction of myeloid 
differentiation was investigated. It was found that combining fucoidan with sub-therapeutic 
doses of ATRA and ATO enhanced myeloid differentiation in vitro. In addition, enhanced 
survival and delayed tumour growth were observed in APL-bearing mice when treated with 
combined fucoidan and low doses of ATRA. Analysis of myeloid differentiation in the tumour 
mass obtained from mice showed that treatment with fucoidan alone and combined with ATRA 
significantly increased tumour cell differentiation, in vivo. This is the first study to show that 
treatment of mice with fucoidan+ATRA down-regulates the expression of the adhesion 
molecule CD44 in APL cells. 
 
6.4.1 Synergistic Effect of Fucoidan with ATRA and ATO in Vitro 
Severe toxicity is frequently observed in newly diagnosed APL patients treated with traditional 
chemotherapeutic agents. Several studies and trials have investigated whether the combination 
of ATRA+ATO with minimal or no chemotherapy can replace standard therapy (308). 
Haematological remission is observed in 80-90% of refractory and relapsed patients treated 
with ATRA+ATO (272), however the use of this combination in newly diagnosed and high-
risk patients remains clinically challenging and can induce serious complications such as 
hyperleucocytosis and differentiation syndrome (309, 310). Therefore, the use of adjuvants 
increasing the efficiency of ATO+ATRA on the one hand and decreasing the risk of side effects 
on the other gained strong interest.  
Fucoidan’s biological activities such as anti-tumour and immunomodulatory effects are highly 
relevant to its potential as an adjuvant therapy. In a recent study by Zuo et al., the role of 
fucoidan in minimising intestinal mucositis induced by chemotherapy was examined in mice 
(270). Mucositis is a common problem in patients under chemotherapy and is related to 
significant morbidity and rarely mortality. Zuo et al. developed a mouse model of mucositis 
induced by the chemotherapy drug cyclophosphamide and showed that administration of 
fucoidan significantly reduced the intestinal damage caused by chemotherapy. This was 
accompanied by an improved intestinal immune system as fucoidan altered the expression of 
intestinal immune system cytokines and maintained the Th1/Th2 immune balance. Fucoidan 
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has also been shown to increase the efficacy of chemotherapeutic agents. Zhang et al. reported 
that combining fucoidan with standard chemotherapeutic agents increased apoptosis in breast 
cancer cell lines, potentially through induction of oxidative stress (196). To the best of our 
knowledge, there is no study examining the combinatory effect of fucoidan with standard 
treatments in leukaemias.  
Failure to differentiate is a feature of the abnormal promyelocytes in APL (286). ATRA and 
ATO are two main standard differentiation-based therapies which stimulate terminal and partial 
differentiation of the accumulated abnormal promyelocytes, respectively (40, 311). The 
selective growth inhibitory effect of fucoidan in APL cells was demonstrated in Chapter 3. 
Results in Chapter 5 also provided evidence that fucoidan has synergistic effect with standard 
APL therapy regimen (ATO) in induction of apoptosis. Here, further investigations were 
carried out to determine whether fucoidan can enhance the effectiveness of ATRA+ATO in 
induction of differentiation in APL cells.  
CD11b or integrin alpha M (ITGAM) is the alpha subunit of the heterodimeric integrin alpha 
M beta 2 (αMβ2) protein which is also known as macrophage antigen-1 (Mac-1) or complement 
receptor 3 (CR3). This adhesion molecule is highly expressed on the surface of many 
leucocytes (312). The surface expression of CD11b is gradually increased upon the myeloid 
differentiation and maturation  and hence its overexpression is an indicator of differentiation.  
Previous studies have analysed the ATRA-mediated granulocytic differentiation of NB4 cells 
at various time points. Yang et al. analysed the expression profiles of more than 12,000 genes 
in NB4 cells after treatment with 1 µM ATRA at various time points (from 12 to 96 hours), 
and compared them to those of untreated cells (314). Differentiation markers began to increase 
after 24 hours with the maximum differentiation (more than 85%) at 96 hours after ATRA 
treatment. Here, the expression of CD11b was analysed in NB4 cells after treatment with 
ATRA from 48 to 120 hours, and the maximum differentiation was observed after 120 hours 
of treatment. The same analysis were conducted in NB4 cells treated with ATO. The 
granulocytic differentiation began 72-96 hours after the ATO treatment compared to the 
control. This is consistent with the literature as it is well documented that ATO induces only 
partial differentiation and slight changes in CD11b expression in NB4 cells compared to the 
terminal differentiation induced by ATRA (315). 
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Cell cycle assay is another tool for analysing cell differentiation. In vitro, proliferating cells are 
characterised by an active cell cycle leading to cellular divisions. With initiation of the 
differentiation process, cells exit from the dividing phases of the cell cycle. This is observed 
with decrease in the fraction of cells in S phase and mitosis phase parallel with increase in the 
non-dividing G0/G1 phase fraction (316). In this Chapter, the cell cycle status was measured 
to assess the differentiation after 120 hours. The amount of the S-phase population decreased 
from approximately 21% to 8% in the ATRA-treated NB4 cells. This decrease was consistent 
with the literature (314). 
After the optimization assays, NB4 cells were treated with fucoidan plus sub-clinical doses of 
ATRA and ATO. In this chapter, an ultra-low dose of fucoidan was selected for the 
differentiation assay to minimise the fucoidan-mediated apoptosis in NB4 cells over the 120-
hour incubation time. Co-stimulation of NB4 cells with fucoidan and ATRA+ATO resulted in 
synergistic induction of myeloid differentiation characterised by increased expression of 
CD11b and G0/G1 arrest. When fucoidan was combined with ATRA+ATO, almost all cells 
underwent differentiation. In contrast, when cells were treated with ATRA alone or 
ATRA+ATO, a proportion of cells remained undifferentiated. During chemotherapy, the drug-
resistant cell population is the main source of cancer recurrence in patients. The findings of 
this thesis suggest that the number of resistant cells in response to ATRA could be limited in 
patients by addition of fucoidan to the standard APL regimen.  
ATRA and ATO induce differentiation through the degradation of the oncoprotein PML-
RARα, the main barrier of differentiation in APL cells (317). Previous studies on fucoidan’s 
anti-cancer effects have shown that fucoidan mostly regulates the protein levels rather than 
mRNA levels. Hence it will be worthwhile to investigate the effects of fucoidan on the 
expression of PML-RARα fusion protein as it might alter the expression of the fusion protein 
or enhance its degradation through regulating the ubiquitin/proteasome pathway. 
Although fucoidan significantly increased APL cell differentiation when it was combined with 
ATRA and ATO, fucoidan alone had almost no effect on NB4 cell differentiation in vitro. 
Reports examining differentiation response in other cell types have been reported, for example 
in osteoblasts and mesenchymal stem cells. In a recent study, fucoidan significantly increased 
differentiation in human mesenchymal stem cells at doses between 0.1-1 µg/mL after 120 
hours. Differentiation was however markedly decreased at 5 and 10 µg/mL fucoidan (318). 
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Here, differentiation was not altered when cells were treated with lower or higher doses of 
fucoidan alone (1 µg/mL and 20 µg/mL) (data were not shown). 
 
6.4.2 Synergistic Effect of Fucoidan with ATRA in Vivo 
Following the in vitro findings, the synergistic effects of fucoidan with ATRA were examined 
in vivo. Several in vivo studies have reported side effects caused by high doses of ATO and 
ATRA. In a study by Jing et al., 10 µg/g ATRA increased the lifespan of mice bearing APL. 
However, combination of this dose of ATRA with ATO was toxic with weight loss and early 
therapy-associated death (40). Here, lower concentration of ATRA (1.5 µg/g b.w.) was 
employed, with the presumption that this may minimise the toxicities of the anti-cancer drugs. 
Due to small size of the utilised nude mice and risk of toxicity, administration of higher 
concentrations of ATRA was impossible. Knowing that previously published papers used at 
least 5 µg/gr b.w. of ATRA, at the beginning of the study a dose of 2.5 µg/gr b.w. of ATRA 
was selected for the in vivo investigations, but initiation of treatment led to the early death of 
animals where two mice died two days after treatment commencement (data were not shown). 
As a result the ATRA dose was further reduced to 1.5 µg/gr b.w. and observed no toxicity 
when it was used alone or in combination with fucoidan.  
To address the effects of fucoidan on APL cell differentiation in vivo, the myeloid 
differentiation of the tumour mass obtained from mice treated with fucoidan and ATRA was 
lastly measured. In contrast with the in vitro findings, in which fucoidan alone had little effects 
on NB4 cell differentiation, in vivo, fucoidan alone induced 1.3-fold more differentiation in 
NB4 cells than did ATRA alone. Granulocytic differentiation includes a highly regulated 
process which occurs upon stimulation of several cytokines (319). The microenvironment and 
cellular cross talk are other critical factors that can influence the maturation and differentiation 
process. As fucoidan has been shown to change the production of various cytokines in vivo 
(320), it is suggested that the different results between fucoidan’s action in vivo and in vitro 
could be explained by the effect of fucoidan on alteration of the cytokines that have regulatory 
effects on myeloid maturation. Fucoidan also affects the mobilization of the white blood cells 
from bone marrow to the peripheral blood through various mechanisms. Irhimeh et al. showed 
that fucoidan increased the expression of CXCR4 on haematopoietic stem cells resulting in the 
migration of these cells into the circulatory blood (321). Furthermore, it has been reported that 
Chapter 6  Investigation of Possible Synergistic Effects of Fucoidan and ATRA in APL Treatment in Vitro and in Vivo 
 
 
Page 176 
 
fucoidan has a synergistic effect with granulocyte colony stimulating factor (G-CSF) to alter 
leucocyte trafficking and mobilization (321). Changes in the pattern of circulatory blood cells 
combined with the altered stimulation of cytokine production by immune cells could lead to a 
different microenvironment around engrafted NB4 cells compared to in-vitro-cultured NB4 
cells. G-CSF is a major cytokine, which increases granulocytic differentiation (322). Synergy 
of fucoidan with G-CSF in induction of differentiation is another hypothesis which needs to be 
investigated in future studies. 
The combined fucoidan and ATRA treatment of mice bearing APL not only caused myeloid 
differentiation, but reduced CD44 expression. This was not observed in those mice treated with 
ATRA or fucoidan alone. Evaluating the expression of CD44 on differentiated cells, the ratio 
of CD44- cells to CD44+ cells was measured, and it was found that when mice were treated 
with combined agents, the pattern of CD44 expression reversed upon maturation compared to 
the other groups. The observed reversal following combined ATRA+fucoidan treatment could 
be suggestive of two hypotheses: 1. the differentiating cells have lost their CD44 upon 
maturation 2. the existing CD44- cells have undergone higher amount of maturation than the 
existing CD44+ cells. However, since more than 95% of NB4 cells express CD44 at high level, 
the second hypothesis seems implausible.  
CD44 is an adhesion molecule involved in cell proliferation, differentiation, migration and 
angiogenesis (323). It is well documented that upregulation of CD44 on cancer cells is 
correlated with poor prognosis as it can enhance cell migration and metastasis (324). As 
mentioned above, development of the differentiation syndrome caused by ATRA and ATO is 
one of the main clinical challenges in treatment of APL, whereby the accumulated 
differentiated young neutrophils infiltrate into various body sites, particularly lungs, and cause 
fatal complications (325). The observed increase in differentiated cells with low or no 
expression of CD44 in mice treated with fucoidan+ATRA adds further evidence that it may 
decrease the migration of these cells. However, further analysis including developing murine 
models of differentiation syndrome following treatment with ATRA plus fucoidan is needed. 
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Final Discussion and Conclusion 
This thesis focussed on examining the anti-tumour activity of the natural product, fucoidan, in 
haematological malignancies (HMs) both in vitro and in vivo. The chemical composition of 
fucoidan from different seaweed sources and their cytotoxicity activity on HMs were analysed 
and compared. In-vitro studies indicated that fucoidan selectively inhibited the growth of acute 
promyelocytic leukaemia (APL) cell lines through activation of apoptotic molecules and 
inactivation of signal transduction molecules involved in cell survival. The anti-tumour activity 
of fucoidan was supported by an in-vivo evidence which demonstrated that oral doses of 
fucoidan prior to inoculation with a human APL cell line significantly delayed tumour growth 
in the xenograft model, potentially by increasing the cytolytic activity of NK cells. In addition, 
significant synergy between fucoidan and anti-leukaemic activity of APL standard treatments 
ATO and ATRA was observed in the APL cells in vitro. In vivo, treatment of APL-bearing 
mice with fucoidan plus ATRA and fucoidan plus ATO resulted in delayed tumour growth and 
significantly prolonged the tumour volume doubling time compared to the control group. 
There is considerable scope to improve treatment efficiency outcomes as the high mortality 
and morbidity associated with relapse, drug resistance and the risk of the development of 
therapy related cancers have remained unchanged in last decades. The challenges in the 
successful treatment of HMs arise largely because of the nature of the cancer. The 
dissemination of leukaemic cells in HMs limits the use of localised therapeutic strategies such 
as surgery and radiation (326). Further, by generating key growth and survival signals, bone 
marrow stroma provides a nurturing environment for leukaemic cells, leading to tumour 
progression, and resistance against the cytotoxic effects of chemotherapeutic agents (327).  
Identification of novel and potent agents that target the cancer cell death while having 
minimum impact on normal cells is the main key toward developing successful therapeutic 
strategies. Thereby, agents with anti-cancer activity and reduced toxicity such as some natural 
products have attracted strong interest. The multifunctional properties of many natural products 
many of which are also known to be well tolerated make them ideal targets in anti-cancer 
research. Vinblastine and vincristine, for instance, are amongst the main chemotherapeutic 
agents, that are derived from the Madagascar periwinkle known as rosy periwinkle (328). The 
usage of these drugs in childhood leukaemia has improved the survival rate from 10% to 95%. 
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Eribulin is another natural-based anticancer agent, that has been developed from a sea sponge 
and its usage in metastatic breast cancer was approved by FDA in 2010 (329).  
Fucoidan is a water soluble polysaccharide derived from brown seaweeds, and is consumed as 
a regular part of diet in Asian countries. Recent epidemiological studies have linked the 
consumption of seaweeds containing fucoidan with low risk of certain cancer types particularly 
female breast cancer (252). The biological properties of fucoidans derived from Undaria 
pinnatifida and Fucus vesiculosus have been under recent investigations. However, there are 
few studies on the growth inhibitory effects of these fucoidans in HMs. This is the first study 
to investigate the anti-tumour activity of fucoidan in HMs in vivo. 
Different factors such as the source of fucoidan, the time and location of harvesting and the 
extraction method can affect the fucoidan’s bioactivities (137).  Fucoidan from two sources of 
Undaria pinnatifida and Fucus vesiculosus was used in this study. The purified fucoidan from 
Undaria pinnatifida and Fucus vesiculosus (Marinova Pty. Ltd) used in Chapter 3 are extracted 
by a neutral cold process and ultrafiltration. This process leaves the product with its native 
structure intact with a high molecular weight. These fucoidans were found to have no cytotoxic 
activity in any of the leukaemic cells utilised. Wang and colleagues extracted fucoidan from 
the sporophyll of Undaria pinnatifida using hot water extraction and alcohol grade 
precipitation (330). The product had a purity of >90% with the molecular weight of 104 kDa 
and contained 21% sulphate. At the dose of 250 µg/mL, this purified fucoidan inhibited growth 
in mouse hepatocarcinoma cells. The fucoidan from Undaria pinnatifida used in this thesis had 
almost similar characteristics to that of Wang et al., with a purity of 99%, MW of 61.2 kDa 
and a sulphate content of 26.6%. However, even at very high doses of 2.5 mg/mL it did not 
affect the leukaemia cell growth and cell cycle. This difference can possibly be explained by 
factors such as cell types and other structural characteristics. 
Fucoidan from Fucus vesiculosus obtained from Sigma Co. was further utilised and tested. This 
Fucus fucoidan is the one most commonly reported to be used in research in this field. It is 
produced using acid hydrolysis and ethanol precipitation. The chemical constituent analysis in 
this thesis revealed structural differences between two fucoidan sources. For instance, the 
fucoidan from Sigma Co. had three times lower MW than that produced by Marinova Pty. Ltd. 
In addition, the purity of this fucoidan was near 80% compared to 98% in fucoidan from 
Marinova Pty. Ltd. In contrast with the purified fucoidan (Marinova Pty. Ltd.), the fucoidan 
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from Sigma Co. revealed strong cytotoxic activity in some AML cell lines. To ensure to avoid 
false results, the endotoxin level of the commercial fucoidan was measured and no endotoxin 
activity was detected.  
The reason for the observed difference in results obtained from different fucoidans is not clear, 
although this has been noticed by others. Mak et al. isolated crude fucoidan from Undaria 
pinnatifida with 70% fucoidan purity and prepared three different fractions with higher purities, 
and compared the biological properties of these fractions with fucoidan from Fucus vesiculosus 
(Sigma Co.) (249). Cell proliferation assay in various cell lines showed that their own crude 
fucoidan had the highest cytotoxic activity than purified fractions and commercial fucoidan 
against the MCF-7 breast cancer cells and A-549 lung cancer cells. Another study by 
Choosawad et al. also reported a stronger inhibitory effect of crude fucoidan from Utricularia 
aurea on KB nasopharynx cancer cells than its purified fractions (331). It is generally believed 
that fucoidans with lower MW and higher sulphate content have higher growth inhibitory effect 
on cancer cells. However, in the Mak et al. report, the crude fucoidan had the highest MW and 
lowest sulphate content compared to those of the purified fractions but had the highest anti-
cancer activity. Here, the different fucoidan preparations utilised had similar sulphate content. 
This could suggest that sulphate content in the range of 20% might not have a large impact on 
the fucoidan bio-properties.  
Another difference between the three fucoidans studied in this thesis is the presence of 3.9% 
polyphenols in the fucoidan from Sigma Co. Polyphenols are phytochemicals widely 
distributed in plants and marine plants such as seaweeds and have been reported to have anti-
oxidant and cytotoxic effects (237). It is not clear how much the presence of 3.9% polyphenols 
contributed to the cytotoxic effects of the fucoidan. In a recent study, Yang et al. showed that 
the polyphenol extracted from the brown seaweed Laminaria japonica Aresch had anti-
proliferative activity on P388 leukaemia cell line with the IC50 value of >200 µg/mL (p>0.05) 
(332). To the best of our knowledge, the previously published articles studying the anti-cancer 
activity of fucoidan have not examined polyphenol content of their fucoidans. 
Fucoidan has been shown to be non-toxic in normal tissues. For in-vitro studies, some 
researchers have utilised normal cells such as normal fibroblasts alongside tumour cell lines, 
and have examined the proliferation inhibitory effect of fucoidan on both tumour and normal 
cells. These studies have revealed that fucoidan did not induce apoptosis within normal cells 
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at the doses which were toxic for the studied cancer cell lines. In vivo and clinical trials using 
fucoidan from different sources have also reported no or mild side effects. For instance, long-
term administration of fucoidan from Undaria pinnatifida in a form of 560 mg capsules did not 
induce side effects even when the participants took 4 capsules a day (333).  
In this dissertation, it was determined that fucoidan from Fucus vesiculosus (Sigma Co.) 
effectively and selectively induced cell death in the APL cell lines NB4 and HL60 but did not 
have any inhibitory effect on proliferation of the minimally differentiated AML cell line KG-
1a. It also slightly reduced the proliferation of the acute erythroleukaemic cell line K562 
through induction of cell cycle arrest and not cell death. The induced cell death in APL cells 
was revealed to have features characteristic of apoptosis and not necrosis. Necrosis is a 
pathological cell death that causes inflammation upon the release of the cellular content in the 
surrounding environment. In contrast, during apoptosis the intracellular contents are not 
released and inflammation does not occur in the cellular environment. Therefore, the type of 
cell death induced by fucoidan makes it a desirable therapeutic agent.  
Speculation of fucoidan’s targets leading to its wide range of activities including cell death 
process in cancer cells is still a matter of debate and controversy. Here, fucoidan induced 
apoptosis through reducing the activation of survival molecules ERK1/2 and AKT in APL 
cells. It also hyper-activated the apoptosis enzymes caspases 8, 9 and 3, and its cytotoxic 
activity was attenuated using a pan-caspase inhibitor indicating that fucoidan’s apoptosis 
induction is caspase dependent in APL cells.  
Consumption of fucoidan even over a very short time period was found to significantly delay 
the development and growth of APL, suggesting that fucoidan intake may enhance the immune 
cell activity. Other studies have also shown that fucoidan can inhibit neoplastic transformation 
in other in vivo models. In a chemical carcinogen rat model, fucoidan delayed the median time 
for tumour appearance when fucoidan was intraperitoneally administrated for 34 days prior to 
carcinogen exposure (253). In a recent study, the prophylactic activity of oral fucoidan in the 
prevention of Lewis Lung Carcinoma cell invasion and metastasis was investigated (266). 
Fucoidan prophylactically inhibited lung metastasis colonisation of tumour cells in C57BL/6 
mice.  
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Treatment with fucoidan alone has been shown to be effective in multiple cancer types in vivo. 
Many bioactive substances function to modulate multiple pathways including apoptosis, cell 
proliferation and differentiation. Therefore, use of combinations of such natural compounds 
with two or more targeted anti-cancer agents may achieve a more successful outcome.  
APL is one of the most aggressive types of AML with the unusually young average age of 40 
years. Despite the improvement in APL survival rate, drug resistance and side effects such as 
hyperleucocytosis and differentiation syndrome remain the clinical challenges. Here, the anti-
tumour activity of fucoidan in different types of AML was examined, and it was found that 
fucoidan treatment inhibited APL cell proliferation. This finding led us to examine whether 
fucoidan combined with standard APL treatments would have therapeutic benefit.  
A strong synergistic effect on apoptosis was noted in fucoidan and ATO treated cells. 
Combination treatment led to significant increase in DNA fragmentation and annexin V 
positive apoptotic cells. ATO plus ATRA traditionally targets the differentiation of malignant 
promyelocytes. As ATO can additionally induce apoptosis in APL cells, the involvement of 
ATO plus other therapeutic strategies in induction of apoptosis in promyelocytes is a target of 
cancer research studies. Treatment of human cervix carcinoma cells with ATO and ionised 
radiation enhanced apoptosis with loss of mitochondrial membrane potential and activation of 
caspases (334). The combination of ATO with the tyrosine kinase inhibitor imatinib also 
significantly increased chronic myelocytic leukaemic cell apoptosis through activation of the 
apoptosis intrinsic pathway, compared to stress-mediated apoptosis induced by ATO alone 
(335). ATO is currently administrated in refractory APL but not in newly diagnosed cases. This 
work is in agreement with other aforementioned studies (334, 335) that show more effective 
apoptotic action can be achieved using ATO plus other therapies rather than ATO alone. This 
observed synergy raises the possibility that ATO combined with other therapeutic agents such 
as fucoidan in newly diagnosed APL patients may be a viable option particularly arising from 
our observation of synergism between fucoidan with low doses of ATRA and ATO. These 
findings could be beneficial in clinics as the administration of lower doses of ATRA and ATO 
could reduce their observed toxicities. 
The synergistic effect of fucoidan on APL cell differentiation induced by ATRA and ATO was 
further determined in the human APL cell line, NB4. Triple combinations of these agents were 
found to induce the strongest influence on cell cycle arrest compared to single or any double 
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combinations of the compounds. The cell cycle arrest observed was consistent with the data 
obtained from the differentiation assay and the triple combination resulted in the highest 
amount of differentiated cells where almost all cells underwent differentiation. In NB4 cells 
treated with dual combination of ATRA+ATO, a small proportion of resistant cells (~15%) 
remained undifferentiated. The primary cause of relapse is drug resistance and therefore 
incomplete clearance of tumour cells. The findings presented in this thesis have implications 
for improving treatment response in APL cells as the addition of fucoidan to standard 
ATRA+ATO therapy could overcome resistance and relapse in APL. 
Although combination of low dose fucoidan with ATRA or ATO synergistically enhanced the 
differentiation, no dual dose dependent effect was observed for fucoidan alone treatment such 
as was seen in ATO-treated APL cells. As mentioned before, ATO induces apoptosis at higher 
doses while it induces myeloid differentiation at lower doses. In contrast, fucoidan only 
induced cell death at higher dose but did not induce differentiation at the lower dose when it 
was administered alone.  
Finally, the synergy of fucoidan+ATO or fucoidan+ATRA was investigated in vivo. The 
combination of ATRA plus fucoidan retarded tumour growth as indicated by increased tumour 
volume doubling time. However, overall the maximal effect was observed in fucoidan+ATO 
treated mice. Approximately 28% of the mice treated with fucoidan+ATO completed the full 
treatment program, with tumour volume reaching the end point after 28 days compared to none 
in fucoidan+ATRA treated mice. Furthermore, the tumour volume doubling time was maximal 
in fucoidan+ATO treated mice compared to all other groups in all studies. This could be 
because of the very low dose of ATRA used here due to toxicity encountered as described 
previously. This low dose may explain the lower efficacy of fucoidan+ATRA compared to 
fucoidan+ATO treatment and to the in vitro results. 
The anti-tumour activity of fucoidan treatment as a single agent was demonstrated, and 
consistent outcomes were achieved. Further, in combination with ATRA and ATO, fucoidan 
was again demonstrated to potentiate the anti-tumour activities. The results obtained from the 
optimisation assay (see Section 5.3.3), the fucoidan+ATO assay (see Section 5.3.4) and the 
fucoidan+ATRA assay (see Section 6.3.3) reveal the anti-tumour activity of fucoidan alone 
treatment compared to the control group in APL-bearing mice. Figure 7.1 compares the tumour 
volume doubling time and the median survival in fucoidan alone treated mice and the control 
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group in two independent assays in Chapters 5 and 6. As shown, almost similar outcomes were 
observed in the fucoidan treated mice in both studies. The reproducibility and observed 
consistent anti-cancer activity of fucoidan when used alone strengthens the hypothesis that 
fucoidan has anti-tumour activity against APL. 
 
 
 
Figure 7.1. Comparison of the data obtained in two independent studies in Chapters 5 
and 6. Results show tumour volume doubling time and median survival in the control (blue) 
and fucoidan alone (green) treated mice from studies in Chapter 5 (left) and Chapter 6 (right).  
 
When the differentiation activity of fucoidan treatment alone was assessed, myeloid 
differentiation of APL cells was observed in vivo, while no such effect was observed in vitro. 
We believe that fucoidan treatment alters the microenvironment around engrafted NB4 cells 
compared to in-vitro-cultured NB4 cells. Fucoidan’s influences on cell cross-talk and cytokine 
production in vivo may explain the induced differentiation in APL cells in mice.  
Another novel observation was to identify the altered ratio of CD44- cells to CD44+ cells in the 
tumour masses of those mice treated with fucoidan+ATRA compared to single treatment and 
control groups. It is not clear whether co-treatment of ATRA with fucoidan reduced the 
expression of CD44 upon differentiation or induced differentiation of existing CD44- NB4 cells 
more than the CD44+ NB4 cells. Although as it is known that almost 95% of the NB4 cells 
express CD44 on their surface, reduction in CD44 expression appears plausible. CD44 plays a 
major role in migration of tumour cells to other sites of the body and therefore downregulation 
of CD44 by combined fucoidan and ATRA may reduce the migration of APL cells in 
differentiation syndrome caused by ATRA and ATO. Although, this remains to be proven and 
further investigation on the underpinning mechanisms of this action should be undertaken. This 
could be analysed by labelling the CD44- NB4 cells prior to injection into mice. 
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Future Directions 
This thesis provides the first evidence that the combination of fucoidan with APL standard 
therapy delays APL growth and enhances the survival of APL-bearing mice. More animal 
experiments using larger numbers and additional treatment groups such as a triple combination 
of fucoidan, ATRA and ATO are suggested. Also, future studies which examine systemic 
leukaemia closely mimicking circulatory leukaemia cells in humans should be undertaken with 
establishment of APL via injection of the tumour cells intravenously. The use of NOD/SCID 
mice would permit tumour burden to be examined in the absence of NK cells, B-cells and T-
cells, and tumour establishment would be more successful. NOD-SCID mice can also tolerate 
higher doses of ATRA compared to nude mice. 
The research presented in this thesis also provides evidences for immunomodulatory activity 
of fucoidan through changes in NK cell behaviour in vivo. Whether the increased activity of 
NK cells were due to increased numbers or function remains to be determined. In addition, the 
role of fucoidan on other immune response elements such as IFN- level could be examined in 
future studies.  
As it is hypothesised that fucoidan reduces the toxicity of ATRA and ATO through its 
immunomodulatory effects, it is worthwhile to analyse the protective activity of fucoidan on 
differentiation syndrome which is one of the main features of ATRA and ATO therapies. This 
could be done by establishment of differentiation syndrome model in mice bearing systemic 
APL treated with high dose ATRA, and assessing specific outcomes such as lung edema and 
pulmonary effusion which are indicators of differentiation syndrome. 
This thesis also provides solid evidence of synergy of fucoidan plus ATO plus ATRA in vitro 
in NB4 cell differentiation. The combination of fucoidan+ATRA+ATO resulted in myeloid 
differentiation of >99% of treated cells compared to 87% when cells were treated with 
ATRA+ATO. ATRA and ATO induce differentiation through degradation of the oncoprotein 
PML-RARα, the main barrier of differentiation in APL cells (317). Further future 
investigations to examine the effects of fucoidan on the expression of PML-RARα fusion 
protein are suggested. 
This work provides evidence about the protective effect of fucoidan in prevention and delayed 
growth of APL. These data have implications for future epidemiological studies. Randomised 
Chapter 7                                                                                              Conclusion and Future Directions  
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controlled trials may seek to evaluate the effect of dietary fucoidan supplementation or brown 
seaweed intake on leukaemia prevention. These data could also be a basis for clinical trials in 
order to assess the association between oral administration of fucoidan and immune system 
functions such as NK cell activity as was shown in this project. 
  
Page 187 
 
References 
1. American Cancer Society. Cancer Facts & Figures 2014. Atlanta: American Cancer 
Society 2014. 
2. Australian Institute of Health and Welfare 2014. Cancer in Australia, An overview 
2014. Cancer Series no 90 Cat no CAN 88 Canberra: AIHW. 
3. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 
2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms 
and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-51. 
4. Juliusson G, Lazarevic V, Horstedt AS, Hagberg O, Hoglund M. Acute myeloid 
leukemia in the real world: why population-based registries are needed. Blood. 
2012;119(17):3890-9. 
5. Australian Institute of Health and Welfare & Australasian Association of Cancer 
Registries 2012. Cancer in Australia: An overview 2012. Cancer series no 74 Cat no CAN 70 
Canberra: AIHW. 
6. Hutchison RE, Schexneider KI. Leukocytic disorders. In: McPherson RA, Pincus MR, 
editors. Henry's Clinical Diagnosis and Management by Laboratory Methods. 22 ed2011. 
7. Australian Institute of Health and Welfare 2012. Cancer survival and prevalence in 
Australia: period estimates from 1982 to 2010. Cancer Series no 69 Cat no CAN 65 Canberra: 
AIHW. 
8. Deschler B, Lubbert M. Acute myeloid leukemia: epidemiology and etiology. Cancer. 
2006;107(9):2099-107. 
9. Schiffer CA, Stone RM. Acute Myeloid Leukemia in Adults. In: Kufe DW, Pollock 
RE, Weichselbaum RR, Bast RC, Gansler TS, Holland JF, et al., editors. Holland-Frei Cancer 
Medicine. 6 ed: Hamilton (ON): BC Decker; 2003. p. 1. 
10. Samiev D, Bhatt VR, Armitage JD, Maness LJ, Akhtari M. A primary care approach to 
myelodysplastic syndromes. Korean journal of family medicine. 2014;35(3):111-8. 
11. Padua RA, McGlynn A, McGlynn H. Molecular, cytogenetic and genetic abnormalities 
in MDS and secondary AML. Cancer treatment and research. 2001;108:111-57. 
12. Häggström M. Hematopoiesis. In: Image:Hematopoiesis_(human)_diagram.png, 
editor. Wikipedia2009. 
13. SEER (Surveillance Epidemiology and End Results). Cancer Statistics Review, 1975-
2011. National Cancer Institute; 2014. 
  
Page 188 
 
14. Schlenk RF. Post-remission therapy for acute myeloid leukemia. Haematologica. 
2014;99(11):1663-70. 
15. Ravandi F, Estey EH, Appelbaum FR, Lo-Coco F, Schiffer CA, Larson RA, et al. 
Gemtuzumab ozogamicin: time to resurrect? Journal of clinical oncology : official journal of 
the American Society of Clinical Oncology. 2012;30(32):3921-3. 
16. Avvisati G, Mele A, Stazi MA, Vegna ML, Pasquini P, Mandelli F. Epidemiology of 
acute promyelocytic leukemia in Italy. APL Collaborating Group. Annals of oncology : official 
journal of the European Society for Medical Oncology / ESMO. 1991;2(6):405-8. 
17. Hillestad LK. Acute promyelocytic leukemia. Acta medica Scandinavica. 
1957;159(3):189-94. 
18. Bernard J, Mathe G, Boulay J, Ceoard B, Chome J. [Acute promyelocytic leukemia: a 
study made on 20 cases]. Schweizerische medizinische Wochenschrift. 1959;89:604-8. 
19. Roussel MJ, Lanotte M. Maturation sensitive and resistant t(15;17) NB4 cell lines as 
tools for APL physiopathology: nomenclature of cells and repertory of their known genetic 
alterations and phenotypes. Oncogene. 2001;20(49):7287-91. 
20. Rowley JD, Golomb HM, Dougherty C. 15/17 translocation, a consistent chromosomal 
change in acute promyelocytic leukaemia. Lancet. 1977;1(8010):549-50. 
21. Pandolfi PP. Oncogenes and tumor suppressors in the molecular pathogenesis of acute 
promyelocytic leukemia. Human molecular genetics. 2001;10(7):769-75. 
22. Tallman MS, Altman JK. Curative strategies in acute promyelocytic leukemia. 
Hematology / the Education Program of the American Society of Hematology American 
Society of Hematology Education Program. 2008;2008:391-9. 
23. Palmer M, Chan A, Dieckmann T, Honek T. Cell type-specific anticancer drugs. In: 
Palmer M, Chan A, Dieckmann T, Honek T, editors. Notes to biochemical pharmacology: 
Wiley; 2013. 
24. Tallman MS, Nabhan C, Feusner JH, Rowe JM. Acute promyelocytic leukemia: 
evolving therapeutic strategies. Blood. 2002;99(3):759-67. 
25. Sanz MA, Jarque I, Martin G, Lorenzo I, Martinez J, Rafecas J, et al. Acute 
promyelocytic leukemia. Therapy results and prognostic factors. Cancer. 1988;61(1):7-13. 
26. Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. 
Blood. 2008;111(5):2505-15. 
27. Iland HJ, Collins M, Bradstock K, Supple SG, Catalano A, Hertzberg M, et al. Use of 
arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic 
leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a 
non-randomised phase 2 trial. The Lancet Haematology. 2015;2(9):e357-66. 
  
Page 189 
 
28. Özpolat B. Acute promyelocytic leukemia and differentiation therapy: molecular 
mechanisms of differentiation, retinoic acid resistance and novel treatments. Turkish Journal 
of Hematology. 2009;26:47-61. 
29. Lotan R. Effects of vitamin A and its analogs (retinoids) on normal and neoplastic cells. 
Biochimica et biophysica acta. 1980;605(1):33-91. 
30. Huang ME, Ye YC, Chen SR, Zhao JC, Gu LJ, Cai JR, et al. All-trans retinoic acid 
with or without low dose cytosine arabinoside in acute promyelocytic leukemia. Report of 6 
cases. Chin Med J (Engl). 1987;100(12):949-53. 
31. Lo Coco F, Nervi C, Avvisati G, Mandelli F. Acute promyelocytic leukemia: a curable 
disease. Leukemia. 1998;12(12):1866-80. 
32. Warrell RP, Jr. Retinoid resistance in acute promyelocytic leukemia: new mechanisms, 
strategies, and implications. Blood. 1993;82(7):1949-53. 
33. Montesinos P, Sanz MA. The differentiation syndrome in patients with acute 
promyelocytic leukemia: experience of the pethema group and review of the literature. 
Mediterranean journal of hematology and infectious diseases. 2011;3(1):e2011059. 
34. Liu J, Lu Y, Wu Q, Goyer RA, Waalkes MP. Mineral arsenicals in traditional 
medicines: orpiment, realgar, and arsenolite. The Journal of pharmacology and experimental 
therapeutics. 2008;326(2):363-8. 
35. Zhu J, Chen Z, Lallemand-Breitenbach V, de The H. How acute promyelocytic 
leukaemia revived arsenic. Nature reviews Cancer. 2002;2(9):705-13. 
36. Sun HD, Ma L, Hu XC, Zhang TD. Ai-lin 1 treated 32 cases of acute promyelocytic 
leukemia. Chinese Journal of Integrative Medicine. 1992;12:170-1. 
37. Antman KH. Introduction: the history of arsenic trioxide in cancer therapy. The 
oncologist. 2001;6 Suppl 2:1-2. 
38. Mayorga J, Richardson-Hardin C, Dicke KA. Arsenic trioxide as effective therapy for 
relapsed acute promyelocytic leukemia. Clinical journal of oncology nursing. 2002;6(6):341-
6. 
39. Falchi L, Verstovsek S, Ravandi-Kashani F, Kantarjian HM. The evolution of arsenic 
in the treatment of acute promyelocytic leukemia and other myeloid neoplasms: Moving 
toward an effective oral, outpatient therapy. Cancer. 2015. 
40. Jing Y, Wang L, Xia L, Chen GQ, Chen Z, Miller WH, et al. Combined effect of all-
trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in 
vivo. Blood. 2001;97(1):264-9. 
41. Lallemand-Breitenbach V, Guillemin MC, Janin A, Daniel MT, Degos L, Kogan SC, 
et al. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute 
promyelocytic leukemia. The Journal of experimental medicine. 1999;189(7):1043-52. 
  
Page 190 
 
42. Shen ZX, Shi ZZ, Fang J, Gu BW, Li JM, Zhu YM, et al. All-trans retinoic acid/As2O3 
combination yields a high quality remission and survival in newly diagnosed acute 
promyelocytic leukemia. Proceedings of the National Academy of Sciences of the United 
States of America. 2004;101(15):5328-35. 
43. Tallman MS. Treatment of relapsed or refractory acute promyelocytic leukemia. Best 
practice & research Clinical haematology. 2007;20(1):57-65. 
44. Long ZJ, Hu Y, Li XD, He Y, Xiao RZ, Fang ZG, et al. ATO/ATRA/anthracycline-
chemotherapy sequential consolidation achieves long-term efficacy in primary acute 
promyelocytic leukemia. PloS one. 2014;9(8):e104610. 
45. Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, et al. Retinoic 
acid and arsenic trioxide for acute promyelocytic leukemia. The New England journal of 
medicine. 2013;369(2):111-21. 
46. Zhu HH, Wu DP, Jin J, Li JY, Ma J, Wang JX, et al. Oral tetra-arsenic tetra-sulfide 
formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic 
leukemia: a multicenter randomized controlled trial. Journal of clinical oncology : official 
journal of the American Society of Clinical Oncology. 2013;31(33):4215-21. 
47. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57-70. 
48. Pecorino L. Introduction; what is cancer.  Molecular Biology of Cancer: Mechanisms, 
Targets, and Therapeutics: Oxford University Press; 2012. p. 3. 
49. Nath S, Mukherjee P. MUC1: a multifaceted oncoprotein with a key role in cancer 
progression. Trends in molecular medicine. 2014;20(6):332-42. 
50. Xing X, Lian S, Hu Y, Li Z, Zhang L, Wen X, et al. Phosphatase of regenerating liver-
3 (PRL-3) is associated with metastasis and poor prognosis in gastric carcinoma. Journal of 
translational medicine. 2013;11:309. 
51. Kerr J, Wyllie A, Currie A. Apoptosis: a basic biological phenomenon with wide-
ranging implications in tissue kinetics. British Journal of Cancer. 1972;26(4):239-57. 
52. Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 
2007;35(4):495-516. 
53. Abadeer A. Cell Death and Cell Renewal.  The Cell: A Molecular Approach. 5 ed: 
Sinauer Associates, Inc.; 2011. 
54. Kam P, Ferch N. Apoptosis: mechanisms and clinical implications. Anaesthesia. 
2000;55(11):1081-93. 
55. Lawen A. Apoptosis-an introduction. BioEssays. 2003;25(9):888-96. 
56. http://www.hixonparvo.info/model.html. Apoptosis Pathway. In: apoptosis.jpg, editor. 
  
Page 191 
 
57. Favaloro B, Allocati N, Graziano V, Di Ilio C, De Laurenzi V. Role of apoptosis in 
disease. Aging. 2012;4(5):330-49. 
58. Kothakota S, Azuma T, Reinhard C, Klippel A, Tang J, Chu K, et al. Caspase-3-
generated fragment of gelsolin: effector of morphological change in apoptosis. Science (New 
York, NY). 1997;278(5336):294-8. 
59. Gewies A. Introduction to Apoptosis 2003 [July 2015]. Available from: 
http://www.ihcworld.com/_books/apointro.pdf. 
60. Kasibhatla S, Tseng B. Why target apoptosis in cancer treatment? Molecular cancer 
therapeutics. 2003;2(6):573-80. 
61. Wilkinson J, Cepero E, Boise LH, Duckett C. Upstream regulatory role for XIAP in 
receptor-mediated apoptosis. Molecular and cellular biology. 2004;24(16):7003-14. 
62. Johnson P, Watt S, Betts D, Davies D, Jordan S, Norton A, et al. Isolated follicular 
lymphoma cells are resistant to apoptosis and can be grown in vitro in the CD40/stromal cell 
system. Blood. 1993;82(6):1848-57. 
63. Ott G, Rosenwald A. Molecular pathogenesis of follicular lymphoma. Haematologica. 
2008;93(12):1773-6. 
64. Inoue K, Kohno T, Takakura S, Hayashi Y, Mizoguchi H, Yokota J. Frequent 
microsatellite instability and BAX mutations in T cell acute lymphoblastic leukemia cell lines. 
Leukemia research. 2000;24(3):255-62. 
65. Devarajan E, Sahin A, Chen JS, Krishnamurthy R, Aggarwal N, Brun A, et al. Down-
regulation of caspase 3 in breast cancer: a possible mechanism for chemoresistance. Oncogene. 
2002;21(57):8843-51. 
66. Takeuchi S, Takeuchi N, Fermin A, Taguchi H, Koeffler H. Frameshift mutations in 
caspase-5 and other target genes in leukemia and lymphoma cell lines having microsatellite 
instability. Leukemia research. 2003;27(4):359-61. 
67. Ozoren N, El-Deiry WS. Cell surface Death Receptor signaling in normal and cancer 
cells. Seminars in cancer biology. 2003;13(2):135-47. 
68. Gronbaek K, Straten P, Ralfkiaer E, Ahrenkiel V, Andersen M, Hansen N, et al. 
Somatic Fas mutations in non-Hodgkin's lymphoma: association with extranodal disease and 
autoimmunity. Blood. 1998;92(9):3018-24. 
69. Searle J, Lawson T, Abbott P, Harmon B, Kerr J. An electron-microscope study of the 
mode of cell death induced by cancer-chemotherapeutic agents in populations of proliferating 
normal and neoplastic cells. The Journal of pathology. 1975;116(3):129-38. 
70. Greaney P, Nahimana A, Lagopoulos L, Etter A, Aubry D, Attinger A, et al. A Fas 
agonist induces high levels of apoptosis in haematological malignancies. Leukemia research. 
2006;30(4):415-26. 
  
Page 192 
 
71. Nahimana A, Aubry D, Lagopoulos L, Greaney P, Attinger A, Demotz S, et al. A novel 
potent Fas agonist for selective depletion of tumor cells in hematopoietic transplants. Blood 
cancer journal. 2011;1(12):e47. 
72. Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura 
Y, et al. Lethal effect of the anti-Fas antibody in mice. Nature. 1993;364(6440):806-9. 
73. Havell E, Fiers W, North R. The antitumor function of tumor necrosis factor (TNF), I. 
Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically 
dependent, and limited by severe toxicity. The Journal of experimental medicine. 
1988;167(3):1067-85. 
74. Wang S, Ren W, Liu J, Lahat G, Torres K, Lopez G, et al. TRAIL and doxorubicin 
combination induces proapoptotic and antiangiogenic effects in soft tissue sarcoma in vivo. 
Clinical Cancer Research. 2010;16(9):2591-604. 
75. Borthakur G, O’Brien S. Pharmacology and clinical potential of oblimersen sodium in 
the treatment of chronic lymphocytic leukemia. Blood and Lymphatic Cancer: Targets and 
Therapy. 2012;2:137-43. 
76. Kline M, Rajkumar S, Timm M, Kimlinger T, Haug J, Lust J, et al. ABT-737, an 
inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells. 
Leukemia. 2007;21(7):1549-60. 
77. Cang S, Iragavarapu C, Savooji J, Song Y, Liu D. ABT-199 (venetoclax) and BCL-2 
inhibitors in clinical development. Journal of hematology & oncology. 2015;8(1):129. 
78. Davids MS, Pagel JM, Kahl B, .S., Wierda WG, Miller TP, Gerecitano JF, et al. Bcl-2 
Inhibitor ABT-199 (GDC-0199) Monotherapy Shows Anti-Tumor Activity Including 
Complete Remissions In High-Risk Relapsed/Refractory (R/R) Chronic Lymphocytic 
Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL). Blood. Nov 2013;122(21):872. 
79. Peterson Q, Goode D, West D, Ramsey K, Lee JJ, Hergenrother P. PAC-1 Activates 
Procaspase-3 in Vitro through Relief of Zinc-Mediated Inhibition. Journal of molecular 
biology. 2009;388(1):144-58. 
80. Tamm I, Wagner M, Schmelz K. Decitabine activates specific caspases downstream of 
p73 in myeloid leukemia. Annals of hematology. 2005;84 Suppl 1:47-53. 
81. Lodish H, Berk A, Zipursky SL, Matsudaira P, Baltimore  D, Darnell J. Overview of 
the Cell Cycle and Its Control.  Molecular Cell Biology. 4 ed. New York: W. H. Freeman; 
2000. 
82. Sbia M, Parnell EJ, Yu Y, Olsen AE, Kretschmann KL, Voth WP, et al. Regulation of 
the yeast Ace2 transcription factor during the cell cycle. The Journal of biological chemistry. 
2008;283(17):11135-45. 
83. Vats P, Yu J, Rothfield L. The dynamic nature of the bacterial cytoskeleton. Cellular 
and molecular life sciences : CMLS. 2009;66(20):3353-62. 
  
Page 193 
 
84. Jayat C, Ratinaud MH. Cell cycle analysis by flow cytometry: principles and 
applications. Biol Cell. 1993;78(1-2):15-25. 
85. Malumbres M, Barbacid M. Milestones in cell division : To cycle or not to cycle: a 
critical decision in cancer. Nature Reviews Cancer. 2001;1(December):222-31. 
86. Pagano M, Pepperkok R, Verde F, Ansorge W, Draetta G. Cyclin A is required at two 
points in the human cell cycle. The EMBO Journal. 1992;11(3):961-71. 
87. Lavoie JN, L'Allemain G, Brunet A, Muller R, Pouyssegur J. Cyclin D1 expression is 
regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. 
The Journal of biological chemistry. 1996;271(34):20608-16. 
88. Gladkikh A, Potashnikova D, Korneva E, Khudoleeva O, Vorobjev I. Cyclin D1 
expression in B-cell lymphomas. Experimental hematology. 2010;38(11):1047-57. 
89. Scuderi R, Palucka KA, Pokrovskaja K, Bjorkholm M, Wiman KG, Pisa P. Cyclin E 
overexpression in relapsed adult acute lymphoblastic leukemias of B-cell lineage. Blood. 
1996;87(8):3360-7. 
90. Iida H, Towatari M, Tanimoto M, Morishita Y, Kodera Y, Saito H. Overexpression of 
cyclin E in acute myelogenous leukemia. Blood. 1997;90(9):3707-13. 
91. Della Ragione F, Mercurio C, Iolascon A. Cell cycle regulation and human leukemias: 
the role of p16INK4 gene inactivation in the development of human acute lymphoblastic 
leukemia. Haematologica. 1995;80(6):557-68. 
92. Ogawa S, Hirano N, Sato N, Takahashi T, Hangaishi A, Tanaka K, et al. Homozygous 
loss of the cyclin-dependent kinase 4-inhibitor (p16) gene in human leukemias. Blood. 
1994;84(8):2431-5. 
93. Byrd JC, Lin TS, Dalton JT, Wu D, Phelps MA, Fischer B, et al. Flavopiridol 
administered using a pharmacologically derived schedule is associated with marked clinical 
efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood. 
2007;109(2):399-404. 
94. Lacrima K, Valentini A, Lambertini C, Taborelli M, Rinaldi A, Zucca E, et al. In vitro 
activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell 
lymphomas. Annals of oncology : official journal of the European Society for Medical 
Oncology / ESMO. 2005;16(7):1169-76. 
95. Berg J, ymoczko JL, Stryer L. Signal-Transduction Pathways: An Introduction to 
Information Metabolism.  Biochemistry. 5 ed. New York: W.H. Freeman; 2002. 
96. Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. 
Oncogene. 2007;26(22):3279-90. 
97. Giehl K, Skripczynski B, Mansard A, Menke A, Gierschik P. Growth factor-dependent 
activation of the Ras-Raf-MEK-MAPK pathway in the human pancreatic carcinoma cell line 
  
Page 194 
 
PANC-1 carrying activated K-ras: implications for cell proliferation and cell migration. 
Oncogene. 2000;19(25):2930-42. 
98. Hemmings BA, Restuccia DF. The PI3K-PKB/Akt Pathway. Cold Spring Harbor 
perspectives in biology. 2015;7(4). 
99. Robey RB, Hay N. Is Akt the "Warburg kinase"?-Akt-energy metabolism interactions 
and oncogenesis. Seminars in cancer biology. 2009;19(1):25-31. 
100. Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, et al. BRAF and RAS 
mutations in human lung cancer and melanoma. Cancer research. 2002;62(23):6997-7000. 
101. Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a 
multistep transformation process. Blood. 1998;91(1):3-21. 
102. Janssen JW, Steenvoorden AC, Lyons J, Anger B, Bohlke JU, Bos JL, et al. RAS gene 
mutations in acute and chronic myelocytic leukemias, chronic myeloproliferative disorders, 
and myelodysplastic syndromes. Proceedings of the National Academy of Sciences of the 
United States of America. 1987;84(24):9228-32. 
103. Park S, Chapuis N, Tamburini J, Bardet V, Cornillet-Lefebvre P, Willems L, et al. Role 
of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia. Haematologica. 
2010;95(5):819-28. 
104. Blackburn JS, Liu S, Wilder JL, Dobrinski KP, Lobbardi R, Moore FE, et al. Clonal 
evolution enhances leukemia-propagating cell frequency in T cell acute lymphoblastic 
leukemia through Akt/mTORC1 pathway activation. Cancer cell. 2014;25(3):366-78. 
105. Cohen PR, Bedikian AY, Kim KB. Appearance of New Vemurafenib-associated 
Melanocytic Nevi on Normal-appearing Skin: Case Series and a Review of Changing or New 
Pigmented Lesions in Patients with Metastatic Malignant Melanoma After Initiating Treatment 
with Vemurafenib. The Journal of clinical and aesthetic dermatology. 2013;6(5):27-37. 
106. Lancet JE, Gojo I, Gotlib J, Feldman EJ, Greer J, Liesveld JL, et al. A phase 2 study of 
the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously 
untreated acute myelogenous leukemia. Blood. 2007;109(4):1387-94. 
107. Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS, et al. 
PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis 
inhibitors. Molecular cancer therapeutics. 2011;10(3):558-65. 
108. Khan KH, Yap TA, Yan L, Cunningham D. Targeting the PI3K-AKT-mTOR signaling 
network in cancer. Chinese journal of cancer. 2013;32(5):253-65. 
109. Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, et al. Idelalisib 
and rituximab in relapsed chronic lymphocytic leukemia. The New England journal of 
medicine. 2014;370(11):997-1007. 
  
Page 195 
 
110. Forcello N, Saraiya N. Idelalisib: The First-in-Class Phosphatidylinositol 3-Kinase 
Inhibitor for Relapsed CLL, SLL, and Indolent NHL. Journal of the advanced practitioner in 
oncology. 2014;5(6):455-9. 
111. Finn OJ. Immuno-oncology: understanding the function and dysfunction of the immune 
system in cancer. Annals of oncology : official journal of the European Society for Medical 
Oncology / ESMO. 2012;23 Suppl 8:viii6-9. 
112. Highfill SL, Cui Y, Giles AJ, Smith JP, Zhang H, Morse E, et al. Disruption of CXCR2-
mediated MDSC tumor trafficking enhances anti-PD1 efficacy. Science translational medicine. 
2014;6(237):237ra67. 
113. Wang SY, Racila E, Taylor RP, Weiner GJ. NK-cell activation and antibody-dependent 
cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b 
component of complement. Blood. 2008;111(3):1456-63. 
114. O'Day SJ, Hamid O, Urba WJ. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): 
a novel strategy for the treatment of melanoma and other malignancies. Cancer. 
2007;110(12):2614-27. 
115. Wolchok JD, Saenger Y. The mechanism of anti-CTLA-4 activity and the negative 
regulation of T-cell activation. The oncologist. 2008;13 Suppl 4:2-9. 
116. Philips GK, Atkins M. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies. 
International immunology. 2015;27(1):39-46. 
117. Terunuma H, Deng X, Dewan Z, Fujimoto S, Yamamoto N. Potential role of NK cells 
in the induction of immune responses: implications for NK cell-based immunotherapy for 
cancers and viral infections. International reviews of immunology. 2008;27(3):93-110. 
118. Smyth MJ, Cretney E, Kershaw MH, Hayakawa Y. Cytokines in cancer immunity and 
immunotherapy. Immunological reviews. 2004;202:275-93. 
119. Huang V, Hepper D, Anadkat M, Cornelius L. Cutaneous toxic effects associated with 
vemurafenib and inhibition of the BRAF pathway. Archives of dermatology. 2012;148(5):628-
33. 
120. Dotan E, Aggarwal C, Smith MR. Impact of Rituximab (Rituxan) on the Treatment of 
B-Cell Non-Hodgkin's Lymphoma. P & T : a peer-reviewed journal for formulary 
management. 2010;35(3):148-57. 
121. Khazir J, Riley DL, Pilcher LA, De-Maayer P, Mir BA. Anticancer agents from diverse 
natural sources. Natural product communications. 2014;9(11):1655-69. 
122. Kingston DG. The shape of things to come: structural and synthetic studies of taxol and 
related compounds. Phytochemistry. 2007;68(14):1844-54. 
  
Page 196 
 
123. George SK, Rajesh R, Kumar SS, Sulekha B, Balaram P. A polyherbal ayurvedic drug-
-Indukantha Ghritha as an adjuvant to cancer chemotherapy via immunomodulation. 
Immunobiology. 2008;213(8):641-9. 
124. Caliceti P, Salmaso S, Bersani S. Polysaccharide-Based Anticancer Prodrugs. In: 
Reddy LH, Couvreur P, editors. Macromolecular Anticancer Therapeutics: Springer New 
York; 2010. p. 163-6. 
125. Aravind SR, Joseph MM, Varghese S, Balaram P, Sreelekha TT. Antitumor and 
immunopotentiating activity of polysaccharide PST001 isolated from the seed kernel of 
Tamarindus indica: an in vivo study in mice. TheScientificWorldJournal. 2012;2012:361382. 
126. Atashrazm F, Lowenthal RM, Woods GM, Holloway AF, Dickinson JL. Fucoidan and 
Cancer: A Multifunctional Molecule with Anti-Tumor Potential. Marine drugs. 
2015;13(4):2327-46. 
127. Jimenez-Escrig A, Goni Cambrodon I. Nutritional evaluation and physiological effects 
of edible seaweeds. Archivos latinoamericanos de nutricion. 1999;49(2):114-20. 
128. Irhimeh M.R. Clinical haemopoietic implications of fucoidan treatment. Australia: 
University of Tasmania; 2008. 
129. Vasseur E. Chemical studies on the jelly coat of the sea-urchin egg. Acta Chemistry 
Scandinavia. 1948;2:900-13. 
130. Mulloy B, Ribeiro A, Alves A, Vieira R, Mourao P. Sulfated fucans from echinoderms 
have a regular tetrasaccharide repeating unit defined by specific patterns of sulfation at the O-
2 and O-4 positions. J Biol Chem. 1994(269):22113-23. 
131. Ribeiro A, Vieira R, Mourao P, Mulloy B. A sulfated a-L-fucan from sea cucumber. 
Carbohydrate Research. 1994; 255:225-40. 
132. Bo Li B, Lu F, Wei X, Zhao R. Fucoidan: Structure and Bioactivity. Molecules (Basel, 
Switzerland). 2008;13:16711695. 
133. Mak WWF. Extraction, Characterization and Antioxidant Activity of Fucoidan from 
New Zealand Undaria pinnatifida (Harvey) Suringar: Auckland University of Technology; 
2012. 
134. Frenette P, Weiss L. Sulfated glycans induce rapid hematopoietic progenitor cell 
mobilization: evidence for selectin dependent and independent mechanisms. Blood. 
2000;96:2460-8. 
135. Lee JB, Hayashi K, Hashimoto M, Nakano T, Hayashi T. Novel antiviral fucoidan from 
sporophyll of Undaria pinnatifida (Mekabu). Chemical & pharmaceutical bulletin (Tokyo). 
2004;52(9):1091-4. 
136. Fitton JH. Therapies from fucoidan; multifunctional marine polymers. Marine drugs. 
2011;9(10):1731-60. 
  
Page 197 
 
137. Mabeau S, Kloareg B, Joseleau J. Fractionation and analysis of fucans from brown 
algae. Phytochemistry. 1990;29:2441-5. 
138. Black WAP. The seasonal variation in the combined L-fucose content of the common 
British Laminariaceae and fucaceae. J Sci Food Agr. 1954;5(9):445-8. 
139. Kloareg B, Demarty M, Mabeau S. Polyanionic characteristic of purified sulphated 
homofucans from brown algae. International journal of biological macromolecules. 
1986;8:380-6. 
140. Curiel D, Bellemo G, Marzocchi M, Scattolin M, Parisi G. Distribution of introduced 
Japanese macroalgae Undaria pinnatifida, Sargassum muticum (Phaeophyta) and 
Antithamnion pectinatum (Rhodophyta) in the Lagoon ofVenice. Hydrobiologia. 1998;385:17-
22. 
141. Castric-Fey A, Beaupoil C, Bouchain J, Pradier E, L’Hardy-Halos M. The introduced 
alga Undaria pinnatifida (Laminariales, Alariaceae) in the rocky shore ecosystem of the St. 
Malo area: growth rate and longevity of the sporophyte. Botanica Marina. 1999;42:83-96. 
142. Fletcher R, Manfredi C. The occurrence of Undaria pinnatifida (Phaeophyceae, 
Laminariales) on the south coast of England. Botanica Marina. 1995;38:355–8. 
143. Hay C, Luckens P. The Asian kelp Undaria pinnatifida (Phaeophyta: Laminariales) 
found in a New Zealand Harbour. New Zealand Journal of Botany. 1987;25:329-32. 
144. Casas G, Piriz M. Surveys of Undaria pinnatifida (Laminariales, Phaeophyta) in Golfo 
Nuevo, Argentina. Hydrobiologia. 1996; 326/327:231–15. 
145. Campbell S, Bite J, Burridge T. Seasonal patterns in the photosynthetic capacity, tissue 
pigment, and nutrient content of different developmental stages of Undaria pinnatifida 
(Phaeophyta: Laminariales) in Port Phillip Bay, South-Eastern Australia. Botanica Marina. 
1999;42:231–41. 
146. Sanderson J. A preliminary survey of the introduced macroalga, Undaria pinnatifida 
(Harvey) Suringar on the east coast of Tasmania. Botanica Marina. 1990;33:153–7. 
147. Silchenko AS, Kusaykin MI, Kurilenko VV, Zakharenko AM, Isakov VV, Zaporozhets 
TS, et al. Hydrolysis of fucoidan by fucoidanase isolated from the marine bacterium, Formosa 
algae. Marine drugs. 2013;11(7):2413-30. 
148. Irhimeh MR, Fitton JH, Lowenthal RM, Kongtawelert P. A quantitative method to 
detect fucoidan in human plasma using a novel antibody. Methods and findings in experimental 
and clinical pharmacology. 2005;27(10):705-10. 
149. Tokita Y, Nakajima K, Mochida H, Iha M, Nagamine T. Development of a fucoidan-
specific antibody and measurement of fucoidan in serum and urine by sandwich ELISA. 
Bioscience, biotechnology, and biochemistry. 2010;74(2):350-7. 
  
Page 198 
 
150. Deux JF, Meddahi-Pelle A, Le Blanche AF, Feldman LJ, Colliec-Jouault S, Bree F, et 
al. Low molecular weight fucoidan prevents neointimal hyperplasia in rabbit iliac artery in-
stent restenosis model. Arteriosclerosis, thrombosis, and vascular biology. 2002;22(10):1604-
9. 
151. Kimura R, Rokkaku T, Takeda S, Senba M, Mori N. Cytotoxic effects of fucoidan 
nanoparticles against osteosarcoma. Marine drugs. 2013;11(11):4267-78. 
152. Thelen T, Hao Y, Medeiros AI, Curtis JL, Serezani CH, Kobzik L, et al. The class A 
scavenger receptor, macrophage receptor with collagenous structure, is the major phagocytic 
receptor for Clostridium sordellii expressed by human decidual macrophages. Journal of 
immunology (Baltimore, Md : 1950). 2010;185(7):4328-35. 
153. Yamasaki Y, Yamasaki M, Tachibana H, Yamada K. Important role of beta1-integrin 
in fucoidan-induced apoptosis via caspase-8 activation. Bioscience, biotechnology, and 
biochemistry. 2012;76(6):1163-8. 
154. Ding Z, Issekutz TB, Downey GP, Waddell TK. L-selectin stimulation enhances 
functional expression of surface CXCR4 in lymphocytes: implications for cellular activation 
during adhesion and migration. Blood. 2003;101(11):4245-52. 
155. Aisa Y, Miyakawa Y, Nakazato T, Shibata H, Saito K, Ikeda Y, et al. Fucoidan induces 
apoptosis of human HS-sultan cells accompanied by activation of caspase-3 and down-
regulation of ERK pathways. Am J Hematol. 2005;78(1):7-14. 
156. Zhu XD, Zhuang Y, Ben JJ, Qian LL, Huang HP, Bai H, et al. Caveolae-dependent 
endocytosis is required for class A macrophage scavenger receptor-mediated apoptosis in 
macrophages. The Journal of biological chemistry. 2011;286(10):8231-9. 
157. Kim M, Joo H. Immunostimulatory effects of fucoidan on bone marrow-derived 
dendritic cells. Immunology Letters. 2008;115(2):138-43. 
158. Zhao X, Xue C, Cai Y, Wang D, Fang Y. The study of antioxidant activities of fucoidan 
from Laminaria japonica. High Technology Letters. 2005;11:91-4. 
159. Kwak JY. Fucoidan as a marine anticancer agent in preclinical development. Marine 
drugs. 2014;12(2):851-70. 
160. Zhang Z, Teruya K, Eto H, Shirahata S. Fucoidan extract induces apoptosis in MCF-7 
cells via a mechanism involving the ROS-dependent JNK activation and mitochondria-
mediated pathways. PloS one. 2011;6(11):e27441. 
161. Riou D, Colliec-Jouault S, Pinczon du Sel D, Bosch S, Siavoshian S, Le Bert V, et al. 
Antitumor and antiproliferative effects of a fucan extracted from ascophyllum nodosum against 
a non-small-cell bronchopulmonary carcinoma line. Anticancer research. 1996;16(3a):1213-8. 
162. Moreau D, Thomas-Guyon H, Jacquot C, Jugé M, Culioli G, Ortalo-Magné A, et al. An 
extract from the brown alga Bifurcaria bifurcata induces irreversible arrest of cell proliferation 
  
Page 199 
 
in a non-small-cell bronchopulmonary carcinoma line. Journal of applied phycology. 
2006;18:87-93. 
163. Boo HJ, Hong JY, Kim SC, Kang JI, Kim MK, Kim EJ, et al. The anticancer effect of 
fucoidan in PC-3 prostate cancer cells. Marine drugs. 2013;11(8):2982-99. 
164. Banafa AM, Roshan S, Liu YY, Chen HJ, Chen MJ, Yang GX, et al. Fucoidan induces 
G1 phase arrest and apoptosis through caspases-dependent pathway and ROS induction in 
human breast cancer MCF-7 cells. Journal of Huazhong University of Science and Technology 
Medical sciences = Hua zhong ke ji da xue xue bao Yi xue Ying De wen ban = Huazhong keji 
daxue xuebao Yixue Yingdewen ban. 2013;33(5):717-24. 
165. Haneji K, Matsuda T, Tomita M, Kawakami H, Ohshiro K, Uchihara JN, et al. Fucoidan 
extracted from Cladosiphon okamuranus Tokida induces apoptosis of human T-cell leukemia 
virus type 1-infected T-cell lines and primary adult T-cell leukemia cells. Nutrition and cancer. 
2005;52(2):189-201. 
166. Cho TM, Kim WJ, Moon SK. AKT signaling is involved in fucoidan-induced inhibition 
of growth and migration of human bladder cancer cells. Food Chem Toxicol. 2014;64:344-52. 
167. Kim EJ, Park SY, Lee JY, Park JH. Fucoidan present in brown algae induces apoptosis 
of human colon cancer cells. BMC gastroenterology. 2010;10. 
168. Yamasaki-Miyamoto Y, Yamasaki M, Tachibana H, Yamada K. Fucoidan induces 
apoptosis through activation of caspase-8 on human breast cancer MCF-7 cells. J Agric Food 
Chem. 2009;57(18):8677-82. 
169. Fukahori S, Yano H, Akiba J, Ogasawara S, Momosaki S, Sanada S, et al. Fucoidan, a 
major component of brown seaweed, prohibits the growth of human cancer cell lines in vitro. 
Mol Med Rep. 2008;1(4):537-42. 
170. Jin JO, Song MG, Kim YN, Park JI, Kwak JY. The mechanism of fucoidan-induced 
apoptosis in leukemic cells: involvement of ERK1/2, JNK, glutathione, and nitric oxide. Mol 
Carcinog. 2010;49(8):771-82. 
171. Boo H, Hyun J, Kim S, Kang J, Kim M, Kim S, et al. Fucoidan from Undaria pinnatifida 
Induces Apoptosis in A549 Human Lung Carcinoma Cells. Phytotherapy Research. 
2011;25(7):1082-6. 
172. Costa LS, Telles CB, Oliveira RM, Nobre LT, Dantas-Santos N, Camara RB, et al. 
Heterofucan from Sargassum filipendula induces apoptosis in HeLa cells. Marine drugs. 
2011;9(4):603-14. 
173. Yang L, Wang P, Wang H, Li Q, Teng H, Liu Z, et al. Fucoidan derived from Undaria 
pinnatifida induces apoptosis in human hepatocellular carcinoma SMMC-7721 cells via the 
ROS-mediated mitochondrial pathway. Marine drugs. 2013;11(6):1961-76. 
  
Page 200 
 
174. Zhang Z, Teruya K, Eto H, Shirahata S. Induction of apoptosis by low-molecular-
weight fucoidan through calcium- and caspase-dependent mitochondrial pathways in MDA-
MB-231 breast cancer cells. Bioscience, biotechnology, and biochemistry. 2013;77(2):235-42. 
175. Koyanagi S, Tanigawa N, Nakagawa H, Soeda S, Shimeno H. Oversulfation of 
fucoidan enhances its anti-angiogenic and antitumor activities. Biochemical pharmacology. 
2003;65(2):173-9. 
176. Xue M, Ge Y, Zhang J, Wang Q, Hou L, Liu Y, et al. Anticancer properties and 
mechanisms of fucoidan on mouse breast cancer in vitro and in vivo. PloS one. 2012;7:e43483. 
177. Coombe DR, Parish CR, Ramshaw IA, Snowden JM. Analysis of the inhibition of 
tumour metastasis by sulphated polysaccharides. International journal of cancer Journal 
international du cancer. 1987;39(1):82-8. 
178. Soeda S, Ishida S, Shimeno H, Nagamatsu A. Inhibitory effect of oversulfated fucoidan 
on invasion through reconstituted basement membrane by murine Lewis lung carcinoma. 
Japanese journal of cancer research : Gann. 1994;85(11):1144-50. 
179. Liu JM, Bignon J, Haroun-Bouhedja F, Bittoun P, Vassy J, Fermandjian S, et al. 
Inhibitory effect of fucoidan on the adhesion of adenocarcinoma cells to fibronectin. 
Anticancer research. 2005;25(3b):2129-33. 
180. Lee H, Kim JS, Kim E. Fucoidan from seaweed Fucus vesiculosus inhibits migration 
and invasion of human lung cancer cell via PI3K-Akt-mTOR pathways. PloS one. 
2012;7(11):e50624. 
181. Cumashi A, Ushakova NA, Preobrazhenskaya ME, D'Incecco A, Piccoli A, Totani L, 
et al. A comparative study of the anti-inflammatory, anticoagulant, antiangiogenic, and 
antiadhesive activities of nine different fucoidans from brown seaweeds. Glycobiology. 
2007;17(5):541-52. 
182. Patel MK, Mulloy B, Gallagher KL, O'Brien L, Hughes AD. The antimitogenic action 
of the sulphated polysaccharide fucoidan differs from heparin in human vascular smooth 
muscle cells. Thrombosis and haemostasis. 2002;87(1):149-54. 
183. Ale MT, Maruyama H, Tamauchi H, Mikkelsen JD, Meyer AS. Fucoidan from 
Sargassum sp. and Fucus vesiculosus reduces cell viability of lung carcinoma and melanoma 
cells in vitro and activates natural killer cells in mice in vivo. International journal of biological 
macromolecules. 2011;49(3):331-6. 
184. Azuma K, Ishihara T, Nakamoto H, Amaha T, Osaki T, Tsuka T, et al. Effects of oral 
administration of fucoidan extracted from Cladosiphon okamuranus on tumor growth and 
survival time in a tumor-bearing mouse model. Marine drugs. 2012;10(10):2337-48. 
185. Shimizu J, Wada-Funada1 U, Mano1 M, Matahira Y, Kawaguchi M, Wada M. 
Proportion of Murine Cytotoxic T Cells is Increased by High Molecular-Weight Fucoidan 
Extracted from Okinawa mozuku (Cladosiphon okamuranus). Journal of Health Science. 
2005;51:394-7. 
  
Page 201 
 
186. Hu Y, Cheng SC, Chan KT, Ke Y, Xue B, Sin FW, et al. Fucoidin enhances dendritic 
cell-mediated T-cell cytotoxicity against NY-ESO-1 expressing human cancer cells. 
Biochemical and biophysical research communications. 2010;392(3):329-34. 
187. Jin JO, Zhang W, Du JY, Wong KW, Oda T, Yu Q. Fucoidan can function as an 
adjuvant in vivo to enhance dendritic cell maturation and function and promote antigen-specific 
T cell immune responses. PloS one. 2014;9(6):e99396. 
188. Teas J, Harbison ML, Gelman RS. Dietary seaweed (Laminaria) and mammary 
carcinogenesis in rats. Cancer research. 1984;44(7):2758-61. 
189. Wakefield LM, Roberts AB. TGF-beta signaling: positive and negative effects on 
tumorigenesis. Current opinion in genetics & development. 2002;12(1):22-9. 
190. Hsu HY, Lin TY, Hwang PA, Tseng LM, Chen RH, Tsao SM, et al. Fucoidan induces 
changes in the epithelial to mesenchymal transition and decreases metastasis by enhancing 
ubiquitin-dependent TGFbeta receptor degradation in breast cancer. Carcinogenesis. 
2013;34(4):874-84. 
191. Humphrey PA, Wong AJ, Vogelstein B, Zalutsky MR, Fuller GN, Archer GE, et al. 
Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal 
growth factor receptors in human glioblastoma. Proceedings of the National Academy of 
Sciences of the United States of America. 1990;87(11):4207-11. 
192. Lee NY, Ermakova SP, Zvyagintseva TN, Kang KW, Dong Z, Choi HS. Inhibitory 
effects of fucoidan on activation of epidermal growth factor receptor and cell transformation 
in JB6 Cl41 cells. Food Chem Toxicol. 2008;46(5):1793-800. 
193. Ikeguchi M, Yamamoto M, Arai Y, Maeta Y, Ashida K, Katano K, et al. Fucoidan 
reduces the toxicities of chemotherapy for patients with unresectable advanced or recurrent 
colorectal cancer. Oncology letters. 2011;2(2):319-22. 
194. Lv J, Xiao Q, Wang L, Liu X, Wang X, Yang Z, et al. Fucoidan prevents multiple 
myeloma cell escape from chemotherapy-induced drug cytotoxicity. Fitoterapia. 2013;84:257-
63. 
195. Vishchuk OS, Ermakova SP, Zvyagintseva TN. The effect of sulfated (1-->3)-alpha-l-
fucan from the brown alga Saccharina cichorioides Miyabe on resveratrol-induced apoptosis 
in colon carcinoma Cells. Marine drugs. 2013;11(1):194-212. 
196. Zhang Z, Teruya K, Yoshida T, Eto H, Shirahata S. Fucoidan extract enhances the anti-
cancer activity of chemotherapeutic agents in MDA-MB-231 and MCF-7 breast cancer cells. 
Marine drugs. 2013;11(1):81-98. 
197. Oh B, Kim J. Anticancer effect of fucoidan in combination with tyrosine kinase 
inhibitor lapatinib. Evid Based Complement Alternat Med. 2014;2014:865375. 
198. Collins SJ, Gallo RC, Gallagher RE. Continuous growth and differentiation of human 
myeloid leukaemic cells in suspension culture. Nature. 1977;270(5635):347-9. 
  
Page 202 
 
199. Lanotte M, Martin-Thouvenin V, Najman S, Balerini P, Valensi F, Berger R. NB4, a 
maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic 
leukemia (M3). Blood. 1991;77(5):1080-6. 
200. Andersson LC, Nilsson K, Gahmberg CG. K562--a human erythroleukemic cell line. 
International journal of cancer Journal international du cancer. 1979;23(2):143-7. 
201. Koeffler HP, Golde DW. Acute myelogenous leukemia: a human cell line responsive 
to colony-stimulating activity. Science (New York, NY). 1978;200(4346):1153-4. 
202. Asou H, Tashiro S, Hamamoto K, Otsuji A, Kita K, Kamada N. Establishment of a 
human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation. 
Blood. 1991;77(9):2031-6. 
203. Wright SC, Bonavida B. YAC-1 variant clones selected for resistance to natural killer 
cytotoxic factors are also resistant to natural killer cell-mediated cytotoxicity. Proceedings of 
the National Academy of Sciences of the United States of America. 1983;80(6):1688-92. 
204. Castro J, Ribo M, Navarro S, Nogues MV, Vilanova M, Benito A. A human 
ribonuclease induces apoptosis associated with p21WAF1/CIP1 induction and JNK 
inactivation. BMC cancer. 2011;11:9-21. 
205. Kanemura Y, Mori H, Kobayashi S, Islam O, Kodama E, Yamamoto A, et al. 
Evaluation of in vitro proliferative activity of human fetal neural stem/progenitor cells using 
indirect measurements of viable cells based on cellular metabolic activity. Journal of 
neuroscience research. 2002;69(6):869-79. 
206. Schutte B, Nuydens R, Geerts H, Ramaekers F. Annexin V binding assay as a tool to 
measure apoptosis in differentiated neuronal cells. Journal of neuroscience methods. 
1998;86(1):63-9. 
207. Schreiber E, Matthias P, Muller MM, Schaffner W. Rapid detection of octamer binding 
proteins with 'mini-extracts', prepared from a small number of cells. Nucleic acids research. 
1989;17(15):6419. 
208. Bradford MM. A rapid and sensitive method for the quantitation of microgram 
quantities of protein utilizing the principle of protein-dye binding. Analytical biochemistry. 
1976;72:248-54. 
209. DuBois M, Gilles KA, Hamilton JK, Rebers PA, Smith F. Colorimetric Method for 
Determination of Sugars and Related Substances. Analytical Chemistry,. 1956;28(3):350-6. 
210. Dodgson KS. Determination of inorganic sulphate in studies on the enzymic and non-
enzymic hydrolysis of carbohydrate and other sulphate esters. The Biochemical journal. 
1961;78:312-9. 
211. Dodgson KS, Price RG. A note on the determination of the ester sulphate content of 
sulphated polysaccharides. The Biochemical journal. 1962;84:106-10. 
  
Page 203 
 
212. Bruce W, Zoecklein., Kenneth C, Fugelsang., Barry H, Gump., Fred S, Nury. Wine 
analysis and production: Springer Science+Business Media New York 1995. 
213. Jiménez-Escrig A, Jiménez-Jiménez I, Pulido R, Saura-Calixto F. Antioxidant activity 
of fresh and processed edible seaweeds. J Sci Food Agr. 2001;81(5):530-4. 
214. Zhang Q, Zhang J, Shen J, Silva A, Dennis D, A., Barrow C, J. A Simple 96-Well 
Microplate Method for Estimation of Total Polyphenol Content in Seaweeds. J Appl Phycol. 
2006;18(3-5):445-50. 
215. Morvai-Vitányi M, Molnár-Perl I, Knausz D, Sass P. Simultaneous GC derivatization 
and quantification of acids and sugars. Chromatographia. 1993;36(1):204-6. 
216. American Veterinary Medical Association. AVMA guidelines on euthanasia, 2013 
update  [July 2015]. Available from: 
http://www.avma.org/issues/animal_welfare/euthanasia.pdf. 
217. Roth V. Doubling time 2006 [10 Jan 2015]. Available from: http://www.doubling-
time.com/compute.php. 
218. Micallef IN, Rohatiner AZ, Carter M, Boyle M, Slater S, Amess JA, et al. Long-term 
outcome of patients surviving for more than ten years following treatment for acute leukaemia. 
Br J Haematol. 2001;113:443-5. 
219. Senderowicz AM. Flavopiridol: the first cyclin-dependent kinase inhibitor in human 
clinical trials. Investigational new drugs. 1999;17(3):313-20. 
220. Park HS, Kim GY, Nam TJ, Deuk Kim N, Hyun Choi Y. Antiproliferative activity of 
fucoidan was associated with the induction of apoptosis and autophagy in AGS human gastric 
cancer cells. Journal of food science. 2011;76(3):T77-83. 
221. Atashrazm F, Lowenthal RM, Woods GM, Holloway AF, Karpiniec SS, Dickinson JL. 
Fucoidan Suppresses the Growth of Human Acute Promyelocytic Leukemia Cells In Vitro and 
In Vivo. Journal of cellular physiology. 2015. 
222. U.S. Food and Drug Administration. Guidance for Industry: Pyrogen and Endotoxins 
Testing: Questions and Answers 2012 [10 Jan 2015]. Available from: 
http://www.fda.gov/drugs/guidancecomplianceregulatoryinformation/guidances/ucm314718.
htm. 
223. Rabinovitch P. Introduction to cell cycle analysis: Phoenix Flow Systems, Inc.;  [cited 
2015 27.4.15]. Available from: 
http://www.phnxflow.com/Introduction%20to%20Cell%20Cycle%20Analysis.pdf. 
224. Ferreira AK, Meneguelo R, Pereira A, Mendonca Filho O, Chierice GO, Maria DA. 
Anticancer effects of synthetic phosphoethanolamine on Ehrlich ascites tumor: an experimental 
study. Anticancer research. 2012;32(1):95-104. 
  
Page 204 
 
225. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for 
apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells 
using fluorescein labelled Annexin V. Journal of immunological methods. 1995;184(1):39-51. 
226. Hingorani R, Deng J, Elia J, McIntyre C, Mittar D. Detection of Apoptosis Using the 
BD Annexin V FITC Assay on the BD FACSVerse™ System. In: Biosciences. B, editor. BD 
Biosciences2011. p. 2. 
227. Haroun-Bouhedja F, Ellouali M, Sinquin C, Boisson-Vidal C. Relationship between 
sulfate groups and biological activities of fucans. Thrombosis research. 2000;100(5):453-9. 
228. Ale MT, Mikkelsen JD, Meyer AS. Important determinants for fucoidan bioactivity: a 
critical review of structure-function relations and extraction methods for fucose-containing 
sulfated polysaccharides from brown seaweeds. Marine drugs. 2011;9(10):2106-30. 
229. Cho ML, Lee BY, You SG. Relationship between oversulfation and conformation of 
low and high molecular weight fucoidans and evaluation of their in vitro anticancer activity. 
Molecules (Basel, Switzerland). 2010;16(1):291-7. 
230. Codee JD, Christina AE, Walvoort MT, Overkleeft HS, van der Marel GA. Uronic acids 
in oligosaccharide and glycoconjugate synthesis. Topics in current chemistry. 2011;301:253-
89. 
231. Garron ML, Cygler M. Structural and mechanistic classification of uronic acid-
containing polysaccharide lyases. Glycobiology. 2010;20(12):1547-73. 
232. Rosenberg RD, Lam L. Correlation between structure and function of heparin. 
Proceedings of the National Academy of Sciences of the United States of America. 
1979;76(3):1218-22. 
233. Adibekian A, Bindschadler P, Timmer MS, Noti C, Schutzenmeister N, Seeberger PH. 
De novo synthesis of uronic acid building blocks for assembly of heparin oligosaccharides. 
Chemistry (Weinheim an der Bergstrasse, Germany). 2007;13(16):4510-22. 
234. Rosenberg RD, Armand G, Lam L. Structure-function relationships of heparin species. 
Proceedings of the National Academy of Sciences of the United States of America. 
1978;75(7):3065-9. 
235. Giraux JL, Tapon-Bretaudiere J, Matou S, Fischer AM. Fucoidan, as heparin, induces 
tissue factor pathway inhibitor release from cultured human endothelial cells. Thrombosis and 
haemostasis. 1998;80(4):692-5. 
236. Zhuang C, Itoh H, Mizuno T, Ito H. Antitumor active fucoidan from the brown 
seaweed, umitoranoo (Sargassum thunbergii). Bioscience, biotechnology, and biochemistry. 
1995;59(4):563-7. 
237. Vijayabaskar P, Shiyamala V. Antioxidant properties of seaweed polyphenol from 
Turbinaria ornata (Turner) J. Agardh, 1848. Asian Pac J Trop Biomed. 2012;2(1). 
  
Page 205 
 
238. Souza AC, Machado FS, Celes MR, Faria G, Rocha LB, Silva JS, et al. Mitochondrial 
damage as an early event of monensin-induced cell injury in cultured fibroblasts L929. Journal 
of veterinary medicine A, Physiology, pathology, clinical medicine. 2005;52(5):230-7. 
239. Park WH, Lee MS, Park K, Kim ES, Kim BK, Lee YY. Monensin-mediated growth 
inhibition in acute myelogenous leukemia cells via cell cycle arrest and apoptosis. International 
journal of cancer Journal international du cancer. 2002;101(3):235-42. 
240. Lee HE, Choi ES, Shin JA, Lee SO, Park KS, Cho NP, et al. Fucoidan induces caspase-
dependent apoptosis in MC3 human mucoepidermoid carcinoma cells. Experimental and 
therapeutic medicine. 2014;7(1):228-32. 
241. Gillham CM, Reynolds J, Hollywood D. Predicting the response of localised 
oesophageal cancer to neo-adjuvant chemoradiation. World journal of surgical oncology. 
2007;5:97. 
242. Hyun JH, Kim SC, Kang JI, Kim MK, Boo HJ, Kwon JM, et al. Apoptosis inducing 
activity of fucoidan in HCT-15 colon carcinoma cells. Biol Pharm Bull. 2009;32(10):1760-4. 
243. Osaki M, Oshimura M, Ito H. PI3K-Akt pathway: its functions and alterations in human 
cancer. Apoptosis : an international journal on programmed cell death. 2004;9:667-76. 
244. Gallay N, Dos Santos C, Cuzin L, Bousquet M, Simmonet Gouy V, Chaussade C, et al. 
The level of AKT phosphorylation on threonine 308 but not on serine 473 is associated with 
high-risk cytogenetics and predicts poor overall survival in acute myeloid leukaemia. 
Leukemia. 2009;23(6):1029-38. 
245. Zhuang S, Schnellmann RG. A death-promoting role for extracellular signal-regulated 
kinase. The Journal of pharmacology and experimental therapeutics. 2006;319(3):991-7. 
246. Xiao Y, Zou P, Wang J, Song H, Zou J, Liu L. Lower phosphorylation of p38 MAPK 
blocks the oxidative stress-induced senescence in myeloid leukemic CD34(+)CD38 (-) cells. J 
Huazhong Univ Sci Technolog Med Sci. 2012;32(3):328-33. 
247. Park HS, Hwang HJ, Kim GY, Cha HJ, Kim WJ, Kim ND, et al. Induction of apoptosis 
by fucoidan in human leukemia U937 cells through activation of p38 MAPK and modulation 
of Bcl-2 family. Marine drugs. 2013;11(7):2347-64. 
248. Namvar F, Mohamad R, Baharara J, Zafar-Balanejad S, Fargahi F, Rahman HS. 
Antioxidant, antiproliferative, and antiangiogenesis effects of polyphenol-rich seaweed 
(Sargassum muticum). BioMed research international. 2013;2013:604787. 
249. Mak W, Wang SK, Liu T, Hamid N, Li Y, Lu J, et al. Anti-Proliferation Potential and 
Content of Fucoidan Extracted from Sporophyll of New Zealand Undaria pinnatifida. Frontiers 
in nutrition. 2014;1:9. 
250. Miao HQ, Elkin M, Aingorn E, Ishai-Michaeli R, Stein CA, Vlodavsky I. Inhibition of 
heparanase activity and tumor metastasis by laminarin sulfate and synthetic phosphorothioate 
  
Page 206 
 
oligodeoxynucleotides. International journal of cancer Journal international du cancer. 
1999;83(3):424-31. 
251. Kotake-Nara E, Sugawara T, Nagao A. Antiproliferative effect of neoxanthin and 
fucoxanthin on cultured cells. Fisheries Science. 2005;71(2):459-61. 
252. Reddy BS, Cohen LA, McCoy GD, Hill P, Weisburger JH, Wynder EL. Nutrition and 
its relationship to cancer. Advances in cancer research. 1980;32:237-345. 
253. Teas J, Vena S, Cone DL, Irhimeh M. The consumption of seaweed as a protective 
factor in the etiology of breast cancer: proof of principle. Journal of applied phycology. 
2013;25(3):771-9. 
254. Kotzsch M, Bernt K, Friedrich K, Luther E, Albrecht S, Gatzweiler A, et al. Prognostic 
relevance of tumour cell-associated uPAR expression in invasive ductal breast carcinoma. 
Histopathology. 2010;57(3):461-71. 
255. Furusawa E, Furusawa S, Chou SC. Antileukemic activity of Viva-Natural, a dietary 
seaweed extract, on Rauscher murine leukemia in comparison with anti-HIV agents, 
azidothymidine, dextran sulfate and pentosan polysulfate. Cancer letters. 1991;56(3):197-205. 
256. Harada H, Kamei Y. Selective cytotoxicity of marine algae extracts to several human 
leukemic cell lines. Cytotechnology. 1997;25(1-3):213-9. 
257. Goldstein BD, Witz G. Free radicals and carcinogenesis. Free radical research 
communications. 1990;11(1-3):3-10. 
258. Ahmed S, Othman NH. Honey as a potential natural anticancer agent: a review of its 
mechanisms. Evidence-based complementary and alternative medicine : eCAM. 
2013;2013:829070. 
259. Rocha de Souza MC, Marques CT, Guerra Dore CM, Ferreira da Silva FR, Oliveira 
Rocha HA, Leite EL. Antioxidant activities of sulfated polysaccharides from brown and red 
seaweeds. Journal of applied phycology. 2007;19(2):153-60. 
260. Omar HM, Saadeldin HM, Badary MS, Al-khatib BY, Abdelgaffar SK. The 
immunomodulating and antioxidant activity of fucoidan on the splenic tissue of rats treated 
with cyclosporine A. The Journal of Basic & Applied Zoology. 2013;66(5):243-54. 
261. Maruyama H, Tamauchi H, Iizuka M, Nakano T. The role of NK cells in antitumor 
activity of dietary fucoidan from Undaria pinnatifida sporophylls (Mekabu). Planta medica. 
2006;72(15):1415-7. 
262. Furusawa E, Furusawa S. Anticancer activity of a natural product, viva-natural, 
extracted from Undaria pinnantifida on intraperitoneally implanted Lewis lung carcinoma. 
Oncology. 1985;42(6):364-9. 
  
Page 207 
 
263. Yang M, Ma C, Sun J, Shao Q, Gao W, Zhang Y, et al. Fucoidan stimulation induces a 
functional maturation of human monocyte-derived dendritic cells. International 
immunopharmacology. 2008;8(13-14):1754-60. 
264. Zhang W, Oda T, Yu Q, Jin JO. Fucoidan from Macrocystis pyrifera has powerful 
immune-modulatory effects compared to three other fucoidans. Marine drugs. 
2015;13(3):1084-104. 
265. Michikawa T, Inoue M, Shimazu T, Sawada N, Iwasaki M, Sasazuki S, et al. Seaweed 
consumption and the risk of thyroid cancer in women: the Japan Public Health Center-based 
Prospective Study. European journal of cancer prevention : the official journal of the European 
Cancer Prevention Organisation (ECP). 2012;21(3):254-60. 
266. Huang TH, Chiu YH, Chan YL, Chiu YH, Wang H, Huang KC, et al. Prophylactic 
administration of fucoidan represses cancer metastasis by inhibiting vascular endothelial 
growth factor (VEGF) and matrix metalloproteinases (MMPs) in Lewis tumor-bearing mice. 
Marine drugs. 2015;13(4):1882-900. 
267. An JJ, Shi KJ, Wei W, Hua FY, Ci YL, Jiang Q, et al. The ROS/JNK/ATF2 pathway 
mediates selenite-induced leukemia NB4 cell cycle arrest and apoptosis in vitro and in vivo. 
Cell death & disease. 2013;4:e973. 
268. Hampson P, Wang K, Ersvaer E, McCormack E, Schuler J, Fiebig HH, et al. Up-
regulation of anti-apoptotic genes confers resistance to the novel anti-leukaemic compound 
PEP005 in primary AML cells. Oncoscience. 2014;1(8):529-39. 
269. Zhang SY, Zhu J, Chen GQ, Du XX, Lu LJ, Zhang Z, et al. Establishment of a human 
acute promyelocytic leukemia-ascites model in SCID mice. Blood. 1996;87(8):3404-9. 
270. Zuo T, Li X, Chang Y, Duan G, Yu L, Zheng R, et al. Dietary fucoidan of Acaudina 
molpadioides and its enzymatically degraded fragments could prevent intestinal mucositis 
induced by chemotherapy in mice. Food & function. 2015;6(2):415-22. 
271. Maruyama H, Tamauchi H, Hashimoto M, Nakano T. Antitumor activity and immune 
response of Mekabu fucoidan extracted from Sporophyll of Undaria pinnatifida. In Vivo. 
2003;17(3):245-9. 
272. Tallman MS, Altman JK. How I treat acute promyelocytic leukemia. Blood. 
2009;114(25):5126-35. 
273. Patatanian E, Thompson DF. Retinoic acid syndrome: a review. Journal of clinical 
pharmacy and therapeutics. 2008;33(4):331-8. 
274. Specchia G, Lo Coco F, Vignetti M, Avvisati G, Fazi P, Albano F, et al. Extramedullary 
involvement at relapse in acute promyelocytic leukemia patients treated or not with all-trans 
retinoic acid: a report by the Gruppo Italiano Malattie Ematologiche dell'Adulto. Journal of 
clinical oncology : official journal of the American Society of Clinical Oncology. 
2001;19(20):4023-8. 
  
Page 208 
 
275. Lobe I, Rigal-Huguet F, Vekhoff A, Desablens B, Bordessoule D, Mounier C, et al. 
Myelodysplastic syndrome after acute promyelocytic leukemia: the European APL group 
experience. Leukemia. 2003;17(8):1600-4. 
276. Thomas X, Le QH, Fiere D. Anthracycline-related toxicity requiring cardiac 
transplantation in long-term disease-free survivors with acute promyelocytic leukemia. Annals 
of hematology. 2002;81(9):504-7. 
277. Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, et al. Use of arsenic trioxide 
(As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and 
pharmacokinetics in relapsed patients. Blood. 1997;89(9):3354-60. 
278. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, et al. Complete 
remission after treatment of acute promyelocytic leukemia with arsenic trioxide. The New 
England journal of medicine. 1998;339(19):1341-8. 
279. Miller WH, Jr., Schipper HM, Lee JS, Singer J, Waxman S. Mechanisms of action of 
arsenic trioxide. Cancer research. 2002;62(14):3893-903. 
280. Zhang TD, Chen GQ, Wang ZG, Wang ZY, Chen SJ, Chen Z. Arsenic trioxide, a 
therapeutic agent for APL. Oncogene. 2001;20(49):7146-53. 
281. Calleja EM, Warrell RP, Jr. Differentiating agents in pediatric malignancies: all-trans-
retinoic acid and arsenic in acute promyelocytic leukemia. Current oncology reports. 
2000;2(6):519-23. 
282. Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS, et al. Studies on treatment of acute 
promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular 
monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. 
Blood. 1999;94(10):3315-24. 
283. Zhou GB, Zhang J, Wang ZY, Chen SJ, Chen Z. Treatment of acute promyelocytic 
leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular 
targeting therapy. Philos Trans R Soc Lond B Biol Sci. 2007;362(1482):959-71. 
284. Alekseyenko TV, Zhanayeva SY, Venediktova AA, Zvyagintseva TN, Kuznetsova TA, 
Besednova NN, et al. Antitumor and antimetastatic activity of fucoidan, a sulfated 
polysaccharide isolated from the Okhotsk Sea Fucus evanescens brown alga. Bulletin of 
experimental biology and medicine. 2007;143(6):730-2. 
285. Kang YH, Yi MJ, Kim MJ, Park MT, Bae S, Kang CM, et al. Caspase-independent cell 
death by arsenic trioxide in human cervical cancer cells: reactive oxygen species-mediated 
poly(ADP-ribose) polymerase-1 activation signals apoptosis-inducing factor release from 
mitochondria. Cancer research. 2004;64(24):8960-7. 
286. Petrie K, Zelent A, Waxman S. Differentiation therapy of acute myeloid leukemia: past, 
present and future. Curr Opin Hematol. 2009;16(2):84-91. 
  
Page 209 
 
287. Lu KH, Lee HJ, Huang ML, Lai SC, Ho YL, Chang YS, et al. Synergistic Apoptosis-
Inducing Antileukemic Effects of Arsenic Trioxide and Mucuna macrocarpa Stem Extract in 
Human Leukemic Cells via a Reactive Oxygen Species-Dependent Mechanism. Evidence-
based complementary and alternative medicine : eCAM. 2012;2012:921430-44. 
288. Fan Y, Chen M, Meng J, Yu L, Tu Y, Wan L, et al. Arsenic trioxide and resveratrol 
show synergistic anti-leukemia activity and neutralized cardiotoxicity. PloS one. 
2014;9(8):e105890. 
289. Wang Z, Zhang H, Dai L, Song T, Li P, Liu Y, et al. Arsenic Trioxide and Icariin Show 
Synergistic Anti-leukemic Activity. Cell biochemistry and biophysics. 2015. 
290. Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. 
Oncogene. 2005;24(50):7455-64. 
291. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA: a cancer journal 
for clinicians. 2002;52(1):23-47. 
292. Mann KK, Colombo M, Miller WH, Jr. Arsenic trioxide decreases AKT protein in a 
caspase-dependent manner. Molecular cancer therapeutics. 2008;7(6):1680-7. 
293. Scholz C, Wieder T, Starck L, Essmann F, Schulze-Osthoff K, Dorken B, et al. Arsenic 
trioxide triggers a regulated form of caspase-independent necrotic cell death via the 
mitochondrial death pathway. Oncogene. 2005;24(11):1904-13. 
294. Xie J, Zhang M, Song YP, Hu K, Ren JJ, Zhang YJ. [Caspase-independent apoptosis 
induced by arsenic trioxide in human multiple myeloma cell RPMI8226]. Zhongguo shi yan 
xue ye xue za zhi / Zhongguo bing li sheng li xue hui = Journal of experimental hematology / 
Chinese Association of Pathophysiology. 2012;20(1):107-11. 
295. Chaitanya GV, Steven AJ, Babu PP. PARP-1 cleavage fragments: signatures of cell-
death proteases in neurodegeneration. Cell communication and signaling : CCS. 2010;8:31. 
296. Lee J, Kim J, Moon C, Kim SH, Hyun JW, Park JW, et al. Radioprotective effects of 
fucoidan in mice treated with total body irradiation. Phytotherapy research : PTR. 
2008;22(12):1677-81. 
297. Prebet T, Gore SD. Treatment of acute promyelocytic leukemia for older patients. 
Journal of the National Comprehensive Cancer Network : JNCCN. 2011;9(3):337-42. 
298. de The H, Le Bras M, Lallemand-Breitenbach V. The cell biology of disease: Acute 
promyelocytic leukemia, arsenic, and PML bodies. The Journal of cell biology. 
2012;198(1):11-21. 
299. Martin SJ, Bradley JG, Cotter TG. HL-60 cells induced to differentiate towards 
neutrophils subsequently die via apoptosis. Clin Exp Immunol. 1990;79(3):448-53. 
300. Yoshida H, Kitamura K, Tanaka K, Omura S, Miyazaki T, Hachiya T, et al. Accelerated 
degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-
  
Page 210 
 
retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway. Cancer 
research. 1996;56(13):2945-8. 
301. Spencer TE, Jenster G, Burcin MM, Allis CD, Zhou J, Mizzen CA, et al. Steroid 
receptor coactivator-1 is a histone acetyltransferase. Nature. 1997;389(6647):194-8. 
302. Guidez F, Ivins S, Zhu J, Soderstrom M, Waxman S, Zelent A. Reduced retinoic acid-
sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARalpha underlie 
molecular pathogenesis and treatment of acute promyelocytic leukemia. Blood. 
1998;91(8):2634-42. 
303. Zhong S, Muller S, Ronchetti S, Freemont PS, Dejean A, Pandolfi PP. Role of SUMO-
1-modified PML in nuclear body formation. Blood. 2000;95(9):2748-52. 
304. Zhu J, Lallemand-Breitenbach V, de The H. Pathways of retinoic acid- or arsenic 
trioxide-induced PML/RARalpha catabolism, role of oncogene degradation in disease 
remission. Oncogene. 2001;20(49):7257-65. 
305. Ying M, Zhou X, Zhong L, Lin N, Jing H, Luo P, et al. Bortezomib sensitizes human 
acute myeloid leukemia cells to all-trans-retinoic acid-induced differentiation by modifying the 
RARalpha/STAT1 axis. Molecular cancer therapeutics. 2013;12(2):195-206. 
306. Adamson PC. All-Trans-Retinoic Acid Pharmacology and Its Impact on the Treatment 
of Acute Promyelocytic Leukemia. The oncologist. 1996;1(5):305-14. 
307. Prudovsky I, Popov K, Akimov S, Serov S, Zelenin A, Meinhardt G, et al. Antisense 
CD11b integrin inhibits the development of a differentiated monocyte/macrophage phenotype 
in human leukemia cells. European journal of cell biology. 2002;81(1):36-42. 
308. Estey E, Garcia-Manero G, Ferrajoli A, Faderl S, Verstovsek S, Jones D, et al. Use of 
all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute 
promyelocytic leukemia. Blood. 2006;107(9):3469-73. 
309. Camacho LH, Soignet SL, Chanel S, Ho R, Heller G, Scheinberg DA, et al. 
Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia 
treated with arsenic trioxide. Journal of clinical oncology : official journal of the American 
Society of Clinical Oncology. 2000;18(13):2620-5. 
310. Guo XH, Yasen H, Jiang M, Hao JP, Abulaiti D, Chen R. [Retinoic acid in treating 
acute promyelocytic leukemia with hyperleukocytosis and its therapeutic strategy]. Zhongguo 
shi yan xue ye xue za zhi / Zhongguo bing li sheng li xue hui = Journal of experimental 
hematology / Chinese Association of Pathophysiology. 2008;16(2):439-41. 
311. Chen GQ, Shi XG, Tang W, Xiong SM, Zhu J, Cai X, et al. Use of arsenic trioxide 
(As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-
dependent dual effects on APL cells. Blood. 1997;89(9):3345-53. 
312. Solovjov DA, Pluskota E, Plow EF. Distinct roles for the alpha and beta subunits in the 
functions of integrin alphaMbeta2. The Journal of biological chemistry. 2005;280(2):1336-45. 
  
Page 211 
 
313. Spangrude GJ, Heimfeld S, Weissman IL. Purification and characterization of mouse 
hematopoietic stem cells. Science (New York, NY). 1988;241(4861):58-62. 
314. Yang L, Zhao H, Li SW, Ahrens K, Collins C, Eckenrode S, et al. Gene expression 
profiling during all-trans retinoic acid-induced cell differentiation of acute promyelocytic 
leukemia cells. The Journal of molecular diagnostics : JMD. 2003;5(4):212-21. 
315. Kinjo K, Kizaki M, Muto A, Fukuchi Y, Umezawa A, Yamato K, et al. Arsenic trioxide 
(As2O3)-induced apoptosis and differentiation in retinoic acid-resistant acute promyelocytic 
leukemia model in hGM-CSF-producing transgenic SCID mice. Leukemia. 2000;14(3):431-8. 
316. Kolly C, Suter MM, Muller EJ. Proliferation, cell cycle exit, and onset of terminal 
differentiation in cultured keratinocytes: pre-programmed pathways in control of C-Myc and 
Notch1 prevail over extracellular calcium signals. The Journal of investigative dermatology. 
2005;124(5):1014-25. 
317. Dos Santos GA, Kats L, Pandolfi PP. Synergy against PML-RARa: targeting 
transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia. 
The Journal of experimental medicine. 2013;210(13):2793-802. 
318. Kim BS, Kang HJ, Park JY, Lee J. Fucoidan promotes osteoblast differentiation via 
JNK- and ERK-dependent BMP2-Smad 1/5/8 signaling in human mesenchymal stem cells. 
Experimental & molecular medicine. 2015;47:e128. 
319. Coffer PJ, Koenderman L, de Groot RP. The role of STATs in myeloid differentiation 
and leukemia. Oncogene. 2000;19(21):2511-22. 
320. Byon YY, Kim MH, Yoo ES, Hwang KK, Jee Y, Shin T, et al. Radioprotective effects 
of fucoidan on bone marrow cells: improvement of the cell survival and immunoreactivity. 
Journal of veterinary science. 2008;9(4):359-65. 
321. Irhimeh MR, Fitton JH, Lowenthal RM. Fucoidan ingestion increases the expression of 
CXCR4 on human CD34+ cells. Experimental hematology. 2007;35(6):989-94. 
322. Nakajima H, Ihle JN. Granulocyte colony-stimulating factor regulates myeloid 
differentiation through CCAAT/enhancer-binding protein epsilon. Blood. 2001;98(4):897-905. 
323. Liu J, Bi G, Wen P, Yang W, Ren X, Tang T, et al. Down-regulation of CD44 
contributes to the differentiation of HL-60 cells induced by ATRA or HMBA. Cellular & 
molecular immunology. 2007;4(1):59-63. 
324. Elliott VA, Rychahou P, Zaytseva YY, Evers BM. Activation of c-Met and 
upregulation of CD44 expression are associated with the metastatic phenotype in the colorectal 
cancer liver metastasis model. PloS one. 2014;9(5):e97432. 
325. Rego EM, De Santis GC. Differentiation syndrome in promyelocytic leukemia: clinical 
presentation, pathogenesis and treatment. Mediterranean journal of hematology and infectious 
diseases. 2011;3(1):e2011048. 
  
Page 212 
 
326. Crawford S. Is it time for a new paradigm for systemic cancer treatment? Lessons from 
a century of cancer chemotherapy. Frontiers in pharmacology. 2013;4:68. 
327. Burger JA. Nurture versus nature: the microenvironment in chronic lymphocytic 
leukemia. Hematology / the Education Program of the American Society of Hematology 
American Society of Hematology Education Program. 2011;2011:96-103. 
328. Lucas DM, Still PC, Perez LB, Grever MR, Kinghorn AD. Potential of plant-derived 
natural products in the treatment of leukemia and lymphoma. Current drug targets. 
2010;11(7):812-22. 
329. Donoghue M, Lemery SJ, Yuan W, He K, Sridhara R, Shord S, et al. Eribulin mesylate 
for the treatment of patients with refractory metastatic breast cancer: use of a "physician's 
choice" control arm in a randomized approval trial. Clinical cancer research : an official journal 
of the American Association for Cancer Research. 2012;18(6):1496-505. 
330. Wang P, Liu Z, Liu X, Teng H, Zhang C, Hou L, et al. Anti-metastasis effect of fucoidan 
from Undaria pinnatifida sporophylls in mouse hepatocarcinoma Hca-F cells. PloS one. 
2014;9(8):e106071. 
331. Choosawad D, Leggat U, Dechsukhum C, Phongdara A, Chotigeat W. Antitumour 
activities of fucoidan from the aquatic plant Utricularia aurea lour. J Sci Technol. 2005;27 
(Suppl. 3):799-807. 
332. Yang H, Zeng M, Dong S, Liu Z, Li R. Anti-proliferative activity of phlorotannin 
extracts from brown algae Laminaria japonica Aresch. Chinese Journal of Oceanology and 
Limnology. 2010;28(1):122-30. 
333. Cooper R, Dragar C, Elliot K, Fitton JH, Godwin J, Thompson K. GFS, a preparation 
of Tasmanian Undaria pinnatifida is associated with healing and inhibition of reactivation of 
Herpes. BMC complementary and alternative medicine. 2002;2:11. 
334. Chun YJ, Park IC, Park MJ, Woo SH, Hong SI, Chung HY, et al. Enhancement of 
radiation response in human cervical cancer cells in vitro and in vivo by arsenic trioxide 
(As2O3). FEBS letters. 2002;519(1-3):195-200. 
335. Du Y, Wang K, Fang H, Li J, Xiao D, Zheng P, et al. Coordination of intrinsic, extrinsic, 
and endoplasmic reticulum-mediated apoptosis by imatinib mesylate combined with arsenic 
trioxide in chronic myeloid leukemia. Blood. 2006;107(4):1582-90. 
 
 
 
  
Page 213 
 
Appendix A- Reagents 
 
Reagent Preparation 
1M NaCl 5.84 gr NaCl powder was dissolved in 100 mL Milli-Q water and stored at 2-8°C.  
1 M Tris 12.114 gr Tris powder was dissolved in 100 mL Milli-Q water and stored at 2-8°C. 
1 M MgCl2 9.52 gr MgCl2 powder was dissolved in 100 mL Milli-Q water and stored at 2-8°C.  
0.5 M EDTA 1.46 gr EDTA powder was dissolved in 10 mL Milli-Q water and stored at 2-8°C.  
0.5 M Tris 
HCl, pH 6.8 
12.1 gr of Tris base was dissolved in 150 mL of Milli-Q water water. pH was 
adjusted to 6.8 using concentrated HCl and the total volume to 200 mL was made 
up with Milli-Q water. The solution was stored at 2-8 °C. 
1.65 M NaOH 66 mg NaOH powder was dissolved in 1 mL Milli-Q water.  
protease 
inhibitor 
cocktail 
Complete protease inhibitor cocktail tablets were purchased from Roche Co. (Cat. 
No. 04693116001). Each tablet was dissolved in 2 mL Milli-Q water and aliquots 
were stored in -20 °C freezer. 
10% Igepal The Igepal solution was purchased from Sigma-Aldrich, U.S.A. To make the 10% 
Igepal, 2 mL of the stock solution was diluted in 18 mL Milli-Q water and was 
stored at 2-8 °C. 
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Primary and secondary antibodies utilised for Western blot 
Affinity MW (KD) Host Dilution* Supplier (Cat. No.) 
     
Anti-Pro Caspase 3 32 Rabbit 1:100 Abcam (ab136812) 
Anti-Caspase 3 17 Rabbit 1:100 Abcam (ab136812) 
Anti-PARP 89 Rabbit 1:100 Abcam (ab136812) 
Anti-Pro Caspase 8 55 Goat 1:200 Santa Cruz (sc-6134) 
Anti- Caspase 8 18 Goat 1:200 Santa Cruz (sc-6134) 
Anti-Pro Caspase 9 46 Rabbit 1:200 Santa Cruz (sc-8355) 
Anti- Caspase 9 35 Rabbit 1:200 Santa Cruz (sc-8355) 
Anti-ERK 42,44 Rabbit 1:1000 Cell Signalling (4695P) 
Anti-p-ERK 42,44 Rabbit 1:2000 Cell Signalling (4370P) 
Anti-AKT 60 Rabbit 1:1000 Cell Signalling (4691P) 
Anti-p-AKT(Ser) 60 Rabbit 1:2000 Cell Signalling (4060P) 
Anti-p-AKT(Thr) 60 Rabbit 1:1000 Cell Signalling (2965P) 
Anti-Bcl-xl 26,30 Rabbit 1:1000 Cell Signalling (2764P) 
Anti-DR5 40,48 Rabbit 1:1000 Cell Signalling (8074P) 
Anti-Fas 40-50 Rabbit 1:1000 Cell Signalling (4233S) 
Anti-Bax 21 Rabbit 1:1000 Cell Signalling (5023P) 
Anti-Cyclin D1 36 Mouse 1:2000 Cell Signalling (2926P) 
Anti-Waf1/Cip1 21 Mouse 1:2000 Cell Signalling (2946P) 
Anti-Actin 42 Rabbit 1:1000 Abcam (ab184111) 
Anti-GAPDH 36 Mouse 1:5000 Millipore (MAB374) 
Anti-SP1 90 Rabbit 1:1000 Santa Cruz (sc-59) 
Secondary Antibodies Labelled with HRP 
Anti-
Rabbit/Mouse** 
 
Goat 1:250 Abcam (ab136812) 
Anti-Rabbit  Goat 1:1000 Dako (P0448) 
Anti-Goat  Rabbit 1:1000 Dako (P0160) 
Anti-Mouse  Rabbit 1:1000 Dako (P0260) 
* Various antibody dilutions were diluted in 10 mL of 1X TNT with 1% 10X blocking reagent. 
**: Cocktail secondary antibody for anti-caspase 3 and anti-PARP was provided by the supplier 
in the kit 
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Appendix B- Methods 
Quantitation of Protein by Bradford Assay 
Bradford dye reagent was purchased from Bio-Rad, U.S.A and stored in the fridge. To measure 
the proteins concentrations, the dye reagent was diluted 1:5 with Milli-Q water. The extracts 
were diluted 1:10 with Milli-Q water and serial dilutions of bovine serum albumin (BSA) were 
used to further standard curve construction (i.e. 0.1 mg/mL, 0.15 mg/mL, 0.2 mg/mL, 0.25 
mg/mL, 0.5 mg/mL and 1.0 mg/mL samples of BSA were prepared from 10 mg/mL, BSA; 
Invitrogen™, U.S.A). 990 µL of the diluted Bradford dye reagent was added in 10 µL of each 
extract and each diluted BSA standard. Absorbance was measured at 595 nm using the 
SpectraMax® Plus384 Absorbance Reader (Molecular Devices, U.S.A). The results were 
entered in Microsoft Excel 2010 and BSA standard curve was created. Sample protein 
concentrations were determined in comparison to the BSA standard curve. 
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Appendix C –Monitoring Sheets 
Animal monitoring sheet after tumour cells injection 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Project code: A13940 
Aim 
……. 
Mouse Ear tag- ID 
…………………….. 
Cage 
……. 
Tumour injection date 
…………………… 
Treatment start 
…………………….. 
Termination date 
……………………… 
Tumour Appearance Monitoring 
Day Date Weight Condition/comment 
1    
2    
3    
4    
5    
6    
7    
8    
9    
10    
11    
12    
13    
14    
15    
16    
17    
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Animal monitoring sheets during Treatment 
 
Tumour Development 
Day Date Weight Tumour measurement Width  x  
Length (Volume) 
Condition/comment 
1                   ×              (               )  
2                   ×              (               )  
3                   ×              (               )  
4                   ×              (               )  
5                   ×              (               )  
6                   ×              (               )  
7                   ×              (               )  
8                   ×              (               )  
9                   ×              (               )  
10                   ×              (               )  
11                   ×              (               )  
12                   ×              (               )  
13                   ×              (               )  
14                   ×              (               )  
15                   ×              (               )  
16                   ×              (               )  
17                   ×              (               )  
20                   ×              (               )  
21                   ×              (               )  
22                   ×              (               )  
23                   ×              (               )  
24                   ×              (               )  
25                   ×              (               )  
26                   ×              (               )  
27                   ×              (               )  
28                   ×              (               )  
 
Project code: A13940 
Aim 
……. 
Mouse Ear tag- ID 
…………………….. 
Cage 
……. 
Tumour injection date 
…………………… 
Treatment start 
…………………….. 
Termination date 
……………………… 
  
Page 218 
 
Appendix D-Results 
Chapter 4. Daily body weight in mice fed with peanut butter and vehicle (control group) 
Day before tumour injection Control 1 Control 2 Control 3 Control 4 Control 5 Control 6 Control 7 
1 12 12.1 21.52 18.75 22.45 12.3 23.6 
2 12.78 12 21.3 18.83 22.36 12.81 23.84 
3 13.36 12.25 21.88 18.73 23.07 12.95 24.44 
4 13.5 12.48 21.93 19.13 23.11 13.25 24.6 
5 13.7 12.26 21.88 19.66 23.23 12.99 24.7 
6 13.75 12.2 21.54 19.55 23.04 12.99 23.84 
7 13.84 12.6 21.6 19.5 23.5 13.25 24.23 
8 14.01 12.95 21.8 19.91 23.1 13.6 24.65 
9 13.48 12.6 21.71 19.23 22.9 13.32 24.14 
10 13.57 12.8 21.64 19.31 22.6 13.7 23.85 
11 14.15 13.22 21.33 19.73 22.81 14.12 23.06 
12 14.54 13.49 21.47 19.81 22.9 14.61 23.19 
13 14.73 13.45 21.56 19.8 22.76 14.43 23.32 
14 15.04 13.2 21.8 19.72 22.83 14.8 23.6 
Day after tumour injection               
1 15.3 13.33 21.64 19.73 22.6 14.81 24.21 
2 15.68 13.71 21.61 20.06 22.81 14.94 24.26 
3 15.66 13.6 21.35 20.22 22.7 14.9 24.57 
4 15.8 13.9 21.88 20.34 23.28 15.54 24.48 
5 16.1 14.01 21.84 20.68 23.7 15.03 24.17 
6 16.3 14.15 22.36 21.4 24.02 15.42 24.64 
7 15.91 14.32 22.13 21.28 23.31 15.46 24.4 
8 16.5 14.2 22.4 21.1 23.71 15.14 24.81 
9 16.23 14.8 22.14 21.65 23.73 15.6 24.54 
10 16.3 14.65 23.61 21.74 24.86 16.16 25.45 
11 15.98 14.8 22.6 21.29 24.5 16.35 25.4 
12 16.5 15 22.5 20.85 24.7 16.38 25.8 
13 16.14 15.32 22.36 20.82 24.07 16.92 24.49 
14 16.26 15.1 22.4 20.73 24.5 17.41 25 
15 16.62 15.26 22.91 21.55 24.61 17.78 25.25 
16 16.58 15.41 23.11 21.68 End Point 17.86 25.29 
17 17.11 15.48 22.97 21.2   End Point 24.42 
18 17.47 15.61 End Point End Point  
 
25.8 
19 End Point End Point  
   
24.9 
20  
     
24.69 
21  
     
25.25 
22  
     
25.8 
23  
     
25.4 
24  
     
End Point 
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Chapter 4. Daily body weight in mice fed with peanut butter and fucoidan (fucoidan group) 
Day before tumour injection Fucoidan 1 Fucoidan 2 Fucoidan 3 Fucoidan 4 Fucoidan 5 Fucoidan 6 Fucoidan 7 
1 11.87 14.9 23.13 13 23.74 11.8 21.99 
2 12.1 15.45 23.52 13.28 24.18 12.2 21.95 
3 12.6 15.7 23.4 13.6 14.32 12.44 22.68 
4 12.71 16 23.5 13.9 24.51 12.7 22.69 
5 13 16.2 23.4 14.01 24.75 13.03 22.85 
6 13.4 16.35 23.99 14.27 24 13.29 22.4 
7 13.5 16.09 23.6 14 24.32 13.09 22.76 
8 13.67 15.9 24.13 13.98 24.65 13.35 23 
9 13.31 15.8 24.03 13.73 24.01 12.86 23.08 
10 13.34 16.04 24.11 13.74 23.29 12.9 23.14 
11 13.7 16.23 24.2 14.2 23.9 13.4 23.39 
12 14.01 16.56 24.15 14.56 23.47 13.63 23 
13 14.01 16.03 24.23 14.3 23.5 13.23 23.1 
14 14.12 16.46 24.1 14.65 23.81 14.57 22.8 
Day after tumour injection               
1 14.1 16.31 24.4 14.01 24.41 14.3 23.4 
2 14 16.13 24.8 14.27 24.42 13.5 23.62 
3 14.25 16.44 24.93 14 23.81 13.7 23.4 
4 14.38 16.47 24.31 13.98 24.34 13.66 23.6 
5 14.72 16.93 24.47 13.73 24.1 14.28 23.6 
6 14.33 16.98 24.36 13.74 24.68 14.67 23.9 
7 14.36 17.23 23.83 14.2 25.05 14.8 23.81 
8 14.69 17.56 23.87 14.56 24.78 14.96 23.91 
9 14.7 17.48 23.96 14.46 24.79 14.9 24.11 
10 15.12 17.45 24.26 14.53 24.26 15.23 23.91 
11 15.33 17.8 23.7 14.78 25 15.22 24.21 
12 14.89 18.1 23.69 14.6 25.4 15.54 23.96 
13 15.26 18 23.5 14.9 25.2 15.36 24.48 
14 15.6 18.32 23.17 14.52 25.3 15.72 23.97 
15 15.88 18.4 23.59 14.31 24.75 15.78 24.43 
16 15.81 18.68 23.02 14.5 25.07 15.73 24.15 
17 16.38 19.1 23.91 14.52 25.01 15.78 24.1 
18 16.11 20.1 End Point 14.95 25.1 15.91 23.92 
19 16.42 20.36  15.2 24.72 15.9 23.75 
20 16.12 20.8  15.73 25.16 15.54 23.58 
21 16.98 End Point  15.68 25.72 16.14 23.53 
22 17.47  
 
16.4 26.51 16.4 24.39 
23 17.6  
 
16.8 26.5 16.52 24.06 
24 17.47  
 
16.65 25.15 16.83 23.69 
25 17.25  
 
16.08 25.28 16.86 23.6 
26 17.73  
 
17.01 26.3 16.7 23.47 
27 17.27  
 
17.08 26.24 17.1 24.18 
28 17.2  
 
17.52 25.98 16.88 23.9 
29 17.39  
 
17.6 26.25 17 23.93 
30 End Point  
 
17.91 25.8 17.23 23.59 
31  
  
End Point 26.24 17.17 23.78 
32  
   
25.57 End Point 23.5 
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Continue from last page 
Day after tumour injection     Fucoidan 6  Fucoidan 1 
33  
   
26.23  23.36 
38  
   
25.99  23.65 
43  
   
26.12  23.91 
48  
   
End Point  23.5 
53  
     
23.46 
58  
     
23.97 
63  
     
23.8 
68  
     
23.5 
73  
     
24.98 
78  
     
24.6 
83  
     
24.83 
87  
     
End Point 
 
 
